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The process of translation, which refers to decoding genetic information from mRNA to protein,
is vital for all cellular function. Translational fidelity starts at the level of aminoacylation of
transfer RNAs (tRNA). This reaction is catalyzed by aminoacyl tRNA synthetases where each
amino acid is transferred to its corresponding cognate tRNA. Because tRNAs harbor the
anticodon sequence to decodes a particular mRNA codon, the specific aminoacylation of the
tRNA with a cognate amino acid establishes the rules of decoding genetic code into proteins.
Aminoacylated tRNAs are then delivered to ribosomes, where ribosomes in a highly organized
manner need to accurately translate the mRNA into protein.
Because of the complexity of translation, errors may occur during translation and pathways have
evolved to mitigate errors and the production of potentially toxic byproducts during translation.
However, little is known about the in vivo defects that arise in the absence of these quality
control pathways. The outlined studies in this dissertation utilize mouse genetics to identity and
interrogate quality control pathways that regulate translational fidelity in the nervous system.
These studies reveal that defects in translation through impairment of quality control pathways
are deleterious for neuronal homeostasis but seemingly act in a cell-type specific manner and/or

are critical either during or post neurodevelopment. Importantly, the apparent selectivity of
defects in translation is influenced by cellular context, changes in the translational landscape and
additional pathways that function linear or in parallel.
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CHAPTER 1
TRANSLATION AND MECHANISMS THAT REGULATE TRANSLATIONAL
FIDELITY
1.1. Aminoacylation and editing by tRNA synthetases
Translational fidelity, the process of accurately deciphering the genetic code, is essential for
proper protein production, proteostasis and cellular function. Numerous factors ensure
translational fidelity including the aminoacyl tRNA synthetases (aaRS). This family of enzymes
catalyzes the formation of aminoacylated transfer RNAs (aa-tRNA), which in turn are used by
the ribosome to decode the messenger RNA (mRNA) into protein during translation. Typically,
cells have 20 aaRSs and each synthetase is responsible for transferring one specific amino acid
onto the cognate tRNA (Szymański et al., 2001). With the exception of the glycyl- (GlyRS) and
lysyl- (LysRS) tRNA synthetases, which have dual cellular localization, two separate sets of
aaRSs are used for cytosolic and mitochondrial translation in mammalian cells (Diodato et al.,
2014).
The aaRSs are divided into two classes based on structural features in the catalytic site and tRNA
binding site (Eriani et al., 1990; Zhang et al., 2006). However, regardless of their classification,
aaRS mediate the aminoacylation of tRNAs is mediated in two steps. First, an aaRS binds the
amino acid and together with ATP generates a reactivate aminoacyl adenylate (aa-AMP) (Arnez
and Moras, 1997; Mascarenhas et al., 2008). Next, the activated amino acid is transferred from
the reactive aminoacyl adenylate onto its cognate tRNA to generate the aminoacylated tRNA and
AMP (Arnez and Moras, 1997; Mascarenhas et al., 2008).
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Both the correct amino acid and tRNA need to be faithfully recognized by each aaRS. Otherwise,
misacylation of tRNAs may result in the incorporation of the incorrect amino acid into proteins
during translation. In general, amino acid selection is more challenging for aaRSs than tRNA
selection, since amino acids, as small molecules, have fewer distinct identifying features (Nagy
et al., 2020). Activation of the incorrect amino acid is usually prevented by size-exclusion and
steric-hindrance between the aaRS and the non-cognate amino acid.
However, this mechanism may fail to reject amino acids that are smaller or structurally similar to
the cognate amino acid. Thus, about half of aaRSs utilize additional proofreading mechanisms
that involve the catalytic site of the aaRS (pre-transfer editing), separate editing domains (posttransfer editing), and autonomous free standing proteins (trans editing factors) to correct
misactivation and mischarging of non-cognate amino acids onto tRNAs (Gomez and Ibba, 2020;
Ling et al., 2009a; Martinis and Boniecki, 2010; Nagy et al., 2020). Both class I and II aaRSs
possess editing ability either via pre-transfer editing through hydrolysis of the misactivated
aminoacyl adenylate before it is transferred onto tRNA and/or via post-transfer editing that
involves deacylation of the already mischarged tRNA at a separate editing site. In addition,
various aaRSs (class II) rely on trans editing factors that in some cases are homologous to the
editing domain of these enzymes and thereby, deacetylate mischarged tRNAs in cases where preor post-transfer editing mechanisms have failed. The evolution of multiple editing mechanisms
suggests a significant need to avoid and to correct potential defects in translational fidelity.
Indeed, impaired proofreading or editing may cause protein misfolding that impedes cell growth
and survival across different species (Beebe et al., 2003; Lee et al., 2006; Y. Liu et al., 2014; Lu
et al., 2014; Nangle et al., 2006; Schimmel, 2008).
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Although aaRSs have been extensively studied for their roles in tRNA charging and translational
fidelity, it has become apparent that multiple cytoplasmic aaRSs have acquired additional
functions beyond their primary role in translation. Coinciding with the increasing organismal
complexity of eukaryotes, one or more domains (structural elements) that are not connected to
aminoacylation and/or editing have been added to eukaryotic aaRSs. In humans, all aaRS except
for the alanyl- (AlaRS) tRNA synthetase acquired an appended domain (M. Guo et al., 2010).
While some of these domains may be shared among different aaRSs (e.g. the WHEP domain is
shared between 4 aaRSs), many aaRSs have acquired unique domains (e.g. UNE domain).
Intriguingly, novel functions for aaRSs that depend on these additional elements have been
identified including specific roles in angiogenesis, inflammation, immune response and
tumorgenesis (Brown et al., 2009; Joy Pang et al., 2014).

1.2. Translation elongation and translation-dependent quality control pathways
In addition to the formation of correctly aminoacylated tRNAs, the process of protein synthesis
is equally important for translational fidelity. Upon release from aaRSs, aminoacylated tRNAs
are delivered to the ribosome where the mRNA is translated into protein. As tRNAs harbor the
anticodon sequence, which recognizes and decodes a particular mRNA codon, the specific
aminoacylation of the tRNA with a cognate amino acid establishes the rules of decoding genetic
information into proteins. Translation is a cyclic process of initiation, elongation and termination
that is mediated by ribosomes.
During translation initiation, the small 40S ribosomal subunit is recruited to the mRNA together
with the initiator methionyl-tRNA (iMet-tRNA) and multiple eukaryotic initiation factors to
3

form the 48S preinitiation complex (PIC). Upon recognition of the start codon, the large 60S
ribosomal subunit joins the PIC to form the 80S ribosome (Jackson et al., 2010; Kapur et al.,
2017). After initiation, the 80S ribosome containing three tRNA binding sites (A, the acceptor
site; P, the peptidyl site; and E, the exit site), pairs the iMet-tRNA with the AUG start codon in
the P-site. The second codon of the mRNA is in the A-site and awaits the delivery of the cognate
aminoacylated tRNA. Recognition of the cognate codon by the tRNA triggers the peptide bond
formation (Jackson et al., 2010; Kapur et al., 2017). The polypeptide is transferred from the
iMet-tRNA in the P-site to the newly delivered aminoacyl tRNA in the A-site, extending the
nascent chain by one amino acid. Afterwards, the ribosome rearranges, allowing the deacylated
iMet-tRNA to be released from the ribosome at the E-site, with the new peptidyl-tRNA now
located in the P-site, and an empty A-site awaiting the delivery of the next aminoacylated tRNA
(Dever and Green, 2012). This cycle is repeated until the elongating ribosome encounters a stop
codon in the A-site, leading to the termination of translation. Translation termination is initiated
by the release factors (eRF1:eRF3) triggering the release of the polypeptide and dissociation of
the large 60S and small 40S ribosomal subunit, which can then engage in another cycle of
translation (Buskirk and Green, 2017; Dever and Green, 2012).
Translational accuracy and efficiency are defined by the processivity of translation elongation.
Thus, translation elongation and the ribosome have emerged as core regulators not only to avoid
decoding errors, but also to facilitate proper co-translational folding of the nascent peptide chain
and co-translational mRNA decay of problematic mRNAs to ultimately generate correct and
functional proteins.
Because of its complexity, translation is prone to errors and translation may be perturbed by
poly-adenosine tracts (Dimitrova et al., 2009), rare codons (Chen et al., 2010; Doma and Parker,
4

2006; Letzring et al., 2013), inhibitory di-codons (Gamble et al., 2016), oxidized and damaged
mRNAs (Simms et al., 2014; Yan et al., 2019), secondary mRNA structures (Doma and Parker,
2006; Tsuboi et al., 2012), amino acid starvation (Darnell et al., 2018; Guydosh and Green,
2014), tRNA deficiency (Ishimura et al., 2014) and genetic mutations in ribosomal RNAs
(rRNA) (LaRiviere et al., 2006). Thus, quality control pathways that recognize changes in
elongation (e.g. premature translation termination or ribosome stalling) have evolved to mitigate
errors, eliminate aberrant mRNAs and prevent the production of faulty proteins (Collart and
Weiss, 2019; Ikeuchi et al., 2019; Inada, 2020).

1.2.1. Nonsense-mediated decay
Nonsense-mediated decay (NMD) was initially conceived as a quality control pathway that
specifically degrades aberrant mRNAs containing a premature termination codon (PTC), which
may occur due to transcriptional errors, splicing errors or genetic mutations (Lykke-Andersen
and Bennett, 2014; Raimondeau et al., 2018). Since the original discovery of NMD, additional
mRNAs have been identified whose stability is also regulated by NMD, even in the absence of
PTCs (He et al., 2003; Jaffrey and Wilkinson, 2018; Lelivelt and Culbertson, 1999; Mendell et
al., 2004; Smith and Baker, 2015). In addition to the three core components including UPF1 (Up
frameshift 1), UPF2 and UPF3, several SMG (Suppressor with morphogenetic effect on genitalia
1, 5, 6, 7, 8, and 9) proteins are required to recognize and target NMD-substrates for degradation
(Behm Ansmant et al., 2007).
Although, the exact mechanism by which NMD is able to distinguish between the ‘canonical’
and ‘premature’ termination codon is still under investigation (Raimondeau et al., 2018),
5

evidence suggests that translation termination by eRF1:eRF3 at the PTC may be delayed as the
3’UTR, which usually contains termination-promoting factors such as the poly(A)-binding
protein (PABP), is further away and the delay in translation termination may trigger the NMD
pathway (Amrani et al., 2004; Behm-Ansmant et al., 2007; Eberle et al., 2008; Ivanov et al.,
2008). Upon recognition of PTC-containing mRNAs, degradation of these NMD substrates is
initiated by an endonucleolytic cleavage that occurs in the vicinity of the PTC via SMG6 (Eberle
et al., 2009; Gatfield and Izaurralde, 2004). Subsequently, the resulting 5’NMD and 3’NMD
RNA intermediates may be degraded by the exosome complex and exoribonuclease 1 (XRN1),
respectively (Gatfield and Izaurralde, 2004; Lejeune et al., 2003; Mühlemann and LykkeAndersen, 2010). In addition to the endonucleolysis via SMG6 that is conserved in metazoans,
degradation of NMD substrates may also occur via exonucleolysis from one or both RNA
termini, suggesting that perhaps multiple mechanisms exist to eliminate nonsense substrates in
mammals (Eberle et al., 2009; Lejeune et al., 2003). Furthermore, the nascent polypeptide
produced from PTC-containing mRNAs may be subject to ubiquitination and proteolysis
(Kuroha et al., 2013, 2009; Park et al., 2020; Raimondeau et al., 2018; Verma et al., 2013).
Degradation of truncated protein products derived from NMD substrates involves UBR1
(Ubiquitin protein ligase E3 component N-recognin 1), UBF1 (Ubiquitin fusion protein 1) and
VCP (Valosin-containing protein), an ATPase known to extract nascent peptide chains from the
large 60S ribosomal subunit (Verma et al., 2013).
Interestingly, early studies in human cells revealed that the levels of UPF1 are ~10 times higher
compared to other NMD proteins such as UPF2 and UPF3B, suggesting that in contrast to other
UPF proteins, UPF1 may engage in additional pathways (Maquat and Serin, 2001). Indeed,
UPF1 has been shown to function in at least five additional RNA decay pathways including
6

staufen-mediated mRNA decay (SMD), replication-dependent histone mRNA decay (HMD),
glucocorticoid receptor-mediated mRNA decay (GMD), regnase 1-mediated mRNA decay
(RMD), and tudor-staphylococcal/micrococcal-like nuclease-mediated microRNA decay
(TumiD) (Kim and Maquat, 2019).

1.2.2. No-go decay
A second mRNA quality control pathway is no-go mRNA decay pathway (NGD) and occurs
when ribosomes fail to elongate (‘ribosome stalling’). Recent studies have shown that ribosome
stalling may lead to the collision of the ‘stalled’ and the following ‘trailing’ ribosomes
(‘disome’) that in turn may trigger mRNA cleavage (Arpat et al., 2020; Diament et al., 2018; Han
et al., 2020; Meydan and Guydosh, 2020). The endonucleolytic cleavage of the mRNA is
mediated by CUE2 (Coupling of ubiquitin conjugation to ER degradation) and occurs in
between the two ribosomes leading to the formation of 5’NGD and 3’NGD RNA intermediates,
in which each RNA intermediate may be occupied by a ribosome (D’Orazio et al., 2019; Glover
et al., 2020; Pelechano et al., 2015). For the 3’NGD RNA intermediate, the initially ‘stalled’
ribosome may be dissociated or engaged in a restart of translation to allow RNA degradation via
XRN1 (Ikeuchi et al., 2019; Tesina et al., 2019). On the other hand, the exosome together with
SKI (Superkiller) complex mediates decay of the 5’NGD intermediate after ribosomal subunit
dissociation (Doma and Parker, 2006; Glover et al., 2020; Schaeffer and van Hoof, 2011; Tsuboi
et al., 2012; Van Hoof et al., 2002). Unlike eRF1:eRF3 that mediate ribosome dissociation in the
presence of a termination codon, the highly homologous factors PELO:HBS1L (Pelota and
Hsp70 subfamily B suppressor 1-like) promote subunit dissociation of ribosomes that now stall
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on these truncated 5’NGD intermediates since these RNAs lack a termination codon (Guydosh
and Green, 2014; Ikeuchi et al., 2019; Pisareva et al., 2011; Shoemaker and Green, 2011).
Furthermore, ribosome collision may also trigger quality control mechanisms through the ASC
complex (activating signal co-integrator complex, ASCC) leading to ribosome subunit
dissociation and proteasomal degradation of the faulty nascent peptide chain (Hashimoto et al.,
2020; Ikeuchi et al., 2019). Recent experiments have shown that the ASCC stimulates
dissociation of the ‘stalled’ ribosome and allows the ‘trailing’ ribosome that initially collided
with the ‘stalled’ ribosome to resume translation elongation (Juszkiewicz et al., 2020a). The
observation that colliding ribosomes may be able to trigger different quality control pathways is
intriguing. Perhaps, defects in elongation that are mediated by aberrant mRNA may activate cotranslational mRNA decay and the release of stalled ribosomes via PELO:HBS1L, while
elongation defects that are influenced by alterations other than aberrant mRNAs (e.g. aminoacyltRNA deficiency (Juszkiewicz et al., 2020a)) may instead trigger quality control pathways via
ASCC that resolve stalled ribosomes, avoiding the co-translational degradation of these ‘normal’
mRNAs and allowing translation to resume. However, it is unclear what dictates the choice
between these two pathways for the resolution of elongation defects and whether such putative
distinctions depend merely on the severity of ribosome stalling and collision, the nature of the
mRNA or other factors.
In addition to PELO:HBS1L and ASCC that are conserved from yeast to human (Inada, 2020),
further ribosome rescue factors have been found in higher eukaryotes. Ribosome stalling and
collision induced by a tRNA-deficiency in mice requires resolution by the ribosome rescue factor
GTPBP2 (GTP-binding protein 2) (Ishimura et al., 2014; Wu et al., 2020). Whether resolution of
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stalled ribosomes through GTPBP2 is mechanistically similar to one of the other quality control
pathways is still unknown.
Following the dissociation of the ribosome into the large 60S and small 40S ribosomal subunit,
the nascent peptidyl-tRNA species is extracted from the large 60S ribosomal subunit to target the
peptide chain for degradation mediated by an array of proteins referred to as the RQC
(Ribosome-associated protein quality control) (Ikeuchi et al., 2019). NEMF (Nuclear export
mediator factor) elongates the stalled nascent peptide chain by adding multiple C-terminal
alanyl- and threonyl-residues (CAT tailing) in the absence of a mRNA template (Lyumkis et al.,
2014; Shao et al., 2015; Shen et al., 2015). This template-free elongation of the nascent peptide
chain is thought to function as a fail-safe to allow it to efficiently exit the ribosomal exit tunnel
and be accessible for ubiquitination (Kostova et al., 2017). In contrast to the ubiquitin ligase
UBR1 that is utilized during NMD, during RQC the nascent peptide chain is ubiquitinated by
Listerin (Defenouillère et al., 2016; Shen et al., 2015; Verma et al., 2013). Eventually, ANKZF1
(Ankyrin repeat and zinc finger peptidyl tRNA hydrolase 1) releases the tRNA from the peptidyltRNA species and allows VCP to extract the nascent peptide chain from the 60S ribosomal
subunit for subsequent proteasomal degradation (Brandman et al., 2012; Defenouillère et al.,
2016, 2013; Kuroha et al., 2018; Verma et al., 2018, 2013; Zurita Rendón et al., 2018).

1.2.3. Non-stop decay
Initially considered to be distinct from NGD, non-stop decay (NSD) occurs when ribosomes stall
at the 3’end of mRNAs without encountering a termination codon and ribosomes are liberated
from mRNAs through PELO:HBS1L (Inada, 2020; Lykke-Andersen and Bennett, 2014). Non9

stop mRNA substrates were thought to primarily arise upon mRNA processing defects, e.g. when
polyadenylation occurred prematurely within the coding sequence (D’Orazio et al., 2019;
Frischmeyer et al., 2002; Guydosh and Green, 2017, 2014; Van Hoof et al., 2002). However,
additional NSD substrates may result from endonucleolytic cleavage within the protein-coding
region and generate 5’RNA intermediates that lack a termination codon (Matsuda et al., 2014;
Tsuboi et al., 2012). Indeed, 5’RNA intermediates that may merge into NSD have been observed
during NGD, NMD and RNA interference (RNAi) pathways (Arribere and Fire, 2018; D’Orazio
et al., 2019; Doma and Parker, 2006; Glover et al., 2020; Hashimoto et al., 2017).
Together, what emerges is a network of control pathways where multiple pathways with different
specificities vigorously aim to avoid defects and errors that may occur during translation. With
that in mind, it is perhaps not surprising that mutation in genes that regulate translational fidelity
are associated with numerous human diseases. Neurological disorders (neurodevelopmental
defects and neurodegeneration), immune system defects and multisystemic disorders have been
linked to various components of the translation machinery including ribosomal genes (FarleyBarnes et al., 2019; Kampen et al., 2020; Mills and Green, 2017), components of the NMD
machinery (e.g. UPF3B and UPF2 (Jaffrey and Wilkinson, 2018; Nguyen et al., 2013; Pawlicka
et al., 2020; Tarpey et al., 2007)), the RQC machinery (e.g. NEMF, ANKZF1 and VCP
(González-Pérez et al., 2012; Johnson et al., 2010; Martin et al., 2020; Rohrer et al., 2011; Van
Haaften-Visser et al., 2017)), ASCC1 (Knierim et al., 2016; Oliveira et al., 2017), HBS1L
(O’Connell et al., 2019; Sankaran et al., 2013), GTPBP2 (Bertoli-Avella et al., 2018; Carter et
al., 2019; Jaberi et al., 2016) and aaRSs (González-Serrano et al., 2019; Meyer-Schuman and
Antonellis, 2017; Sissler et al., 2017; Yao and Fox, 2013).
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However, it still remains unclear how genes that regulate translational fidelity give rise to such a
wide range of disorders. Particularly puzzling is how defects in these ubiquitously expressed
genes often lead to tissue and cell-type specific clinical manifestations. Although, various
components of the translational machinery have roles beyond their canonical function in
translation, the translational activity, energy demand and the crosstalk of translation with other
cellular programs may also influence tissue specificity. Thus, forward and reverse mouse
genetics are utilized to identity and interrogate pathways that regulate translational fidelity in the
nervous system (Chapter 2 to 4). In the last chapter, I discuss how defects in translation may lead
to cell-type specific pathologies.
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CHAPTER 2
ANKRD16 PREVENTS NEURON LOSS CAUSED BY AN EDITING-DEFECTIVE
TRNA SYNTHETASE
2.1. Abstract
Editing domains of aminoacyl tRNA synthetases correct tRNA charging errors to maintain
translational fidelity. A mutation in the editing domain of alanyl tRNA synthetase (AlaRS) in
Aarssti mutant mice resulted in a mild increase in production of serine-mischarged tRNAAla and
degeneration of cerebellar Purkinje cells. By positional cloning, we identified Ankrd16, which
acts epistatically with the Aarssti mutation to attenuate neurodegeneration. ANKRD16, a
vertebrate-specific, ankyrin repeat-containing protein, binds directly to the catalytic domain of
AlaRS. Serine misactivated by AlaRS is captured by lysine side chains of ANKRD16,
preventing the charging of serine adenylates to tRNAAla and precluding serine misincorporation
in nascent peptides. Deletion of Ankrd16 in the Aarssti/sti brain causes widespread protein
aggregation and neuron loss. These results identify a novel amino acid-accepting co-regulator of
tRNA synthetase editing as a new layer of the machinery essential for preventing severe
pathologies that arise from defects in editing.

2.2. Introduction
Accurate aminoacylation of tRNAs by tRNA synthetases establishes the universal genetic code
and occurs in two steps: first, activation of the selected amino acid with ATP to form a firmly
bound aminoacyl adenylate; second, transfer of the aminoacyl group of the adenylate to the 2’or 3’-OH of the cognate tRNA. However, structural similarities between some amino acids allow
misactivation of non-cognate amino acids and subsequent misacylation of tRNA. These errors
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can be corrected by the hydrolytic editing functions found in many tRNA synthetases, thus
preventing incorporation of non-cognate amino acids into nascent proteins (Guo et al., 2009;
Schimmel, 2011). ‘Editing’ can occur after amino acid misactivation, but prior to aminoacyl
transfer, or after aminoacylation of tRNA, known as pre-transfer and post-transfer editing,
respectively. Pre-transfer editing occurs in either the aminoacylation active site or in a distinct
editing site, whereas post-transfer editing occurs only in the editing site of these enzymes (Dulic
et al., 2010; Ling et al., 2009a; Martinis and Boniecki, 2010).
The physiological importance of tRNA synthetase editing including editing by the alanyl tRNA
synthetase (Aars; AlaRS) has been shown in E. coli, yeast, and mammals (Beebe et al., 2003;
Lee et al., 2006; Y. Liu et al., 2014; Lu et al., 2014; Nangle et al., 2006; Schimmel, 2008).
Although AlaRS misactivates both glycine and serine to form Gly-AMP and Ser-AMP,
respectively, misactivation of serine appears to have more serious consequences, perhaps due to
the presence of D-aminoacyl-tRNA deacylases which act on Gly-tRNAAla (Calendar, 2017;
Calendar and Berg, 1967; Pawar et al., 2017). We previously showed that sticky (sti) mutant
mice that have a point mutation (Ala734Glu) in the editing domain of AlaRS have ubiquitinated
protein aggregates in cerebellar Purkinje cells and subsequent degeneration of these neurons (Lee
et al., 2006). The sti mutation results in only a 2-fold increase in the generation of Ser-tRNAAla,
demonstrating that Purkinje cells are particularly sensitive to loss of AlaRS editing (Lee et al.,
2006).
Here we identified a novel vertebrate-specific gene Ankrd16 that greatly attenuates misfolded
aggregate formation and Purkinje cell degeneration in Aarssti/sti mice. Deletion of Ankrd16 in
other Aarssti/sti neurons also caused formation of ubiquitinated protein aggregates and neuron
death. ANKRD16 binds to AlaRS and prevents misincorporation of serine at alanine codons in
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nascent peptides by stimulating serine-dependent ATP hydrolysis prior to tRNA aminoacylation
via acceptance of misactivated serines. Our data collectively reveal ANKRD16 as a co-regulator
of AlaRS that protects against assaults on translation fidelity and proteostasis in mammalian
neurons.

2.3. Results
2.3.1. Ankrd16 suppresses Aarssti-mediated Purkinje cell degeneration. Aarssti/sti mice on the
inbred C57BL/6J (B6) genetic background are ataxic with cerebellar Purkinje cell degeneration
beginning at 3 weeks of age (Lee et al., 2006). However, neither ataxia nor Purkinje cell
degeneration was apparent in 9/10 F2 Aarssti/sti mice from a B6.Aarssti/+ and CAST/Ei (CAST)
mating that were aged to 12-16 months, suggesting that CAST-derived alleles could suppress
neuron loss. In agreement, two phenotypically distinct classes of N1 Aarssti/sti offspring
(generated from a backcross of F1 B6/CAST Aarssti/sti mice to B6.Aarssti/sti mice) were observed
at equal frequencies at 3 to 4 months of age: mice with ataxia and extensive Purkinje cell loss
that was indistinguishable from that of B6.Aarssti/sti mice (22 of 46), and mice without ataxia and
little Purkinje cell loss (24 of 46) (Figure S1A). Suppression of the neurodegenerative phenotype
was observed in 50% of backcross mice from crosses to CASA/RkJ (CASA; a strain closely
related to CAST/Ei), but not in other crosses, suggesting that a single dominant allele from the
CAST or CASA strains can suppress sti-mediated neurodegeneration (Figure S1A).
Genome scans on affected and unaffected N1 Aarssti/sti mice revealed that the Purkinje cell
degeneration was suppressed in mice that were heterozygous for CAST alleles on proximal
chromosome 2 (Figure S1B). This locus (~3.3 Mbp) also segregated with the Aarssti/sti modifier
gene from CASA, suggesting these strains share the same suppressor gene. To confirm that
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CAST alleles at the Modifier of sticky (Msti) locus can protect against Aarssti/sti-mediated cell
death we transferred this region from the CAST genome onto the B6.Aarssti/sti genetic
background by repeated backcrossing. The latency to fall in a rotorod test of 3-month-old
B6.MstiCAST/B6; Aarssti/sti mice was indistinguishable from that of B6 mice, whereas this
measurement was significantly decreased in B6.Aarssti/sti mice (Figure 1A). Aarssti/sti-mediated
Purkinje cell death was also dramatically reduced in B6.MstiCAST/B6; Aarssti/sti mice, although
some neurons in the rostral cerebellum of these mice still degenerated (Figure 1B). Furthermore,
heterozygosity and homozygosity for CAST alleles in the Msti region similarly attenuated
Purkinje cell loss, demonstrating that Msti acts dominantly to protect against Purkinje cell death
in B6.Aarssti/sti mice (Figure 1B).
Ubiquitin punctae characteristic of protein inclusions were observed in many Purkinje cells in 4week-old B6.Aarssti/sti, but not in B6 or CAST, mice (Figure 1C). As expected, due to progressive
Purkinje cell loss observed in sti mutant mice, the number of Purkinje cells containing inclusions
decreased by 6 and 12 weeks of age. However, very few Purkinje cells in B6.MstiCAST/B6;
Aarssti/sti mice contained inclusions, even at later ages, confirming long-term protection of
Purkinje cells (Figure 1C).
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Figure 1: Modifier of sticky (Msti) suppresses Aarssti-mediated neurodegeneration. (A)
Rotorod analysis of 3-month-old mice (mean ± SD, ** p ≤ 0.01, *** p ≤ 0.001). (B) Calbindin
D-28 immunohistochemistry. Sections were counterstained with hematoxylin. (C) Aggregatepositive cells (mean ± SD, ** p = 0.00148 (6 weeks), p = 0.00498 (12 weeks), **** p =
2.819x10-6). Scale bars: 500 μm (D). Two-way ANOVA was corrected for multiple comparisons
using Tukey correction (A); t-tests were corrected for multiple comparisons using Holm-Sidak
method (C).

We further localized Msti to a 0.63 Mbp region and the coding regions of the protein-coding
genes in this interval were amplified by RT-PCR from B6 and CAST cerebellar RNA and
sequenced (Figure 2A, Figure S1B). Non-synonymous SNPs were observed in Il2ra, Fbxo18,
and Ankrd16 (Figure 2A). However, with the exception of Il2ra, these SNPs were either not
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present in CASA, an Aarssti/sti modifying strain (Fbxo18), or were also present in MOLF
(Ankrd16), a strain in which neurodegeneration is not rescued (Figures S1A and S1C).
A strain-specific Ankrd16 transcript that contained a 138 bp cryptic exon (exon 5’) was also
observed in B6 (with or without the Aarssti/sti mutation) and other non-rescuing strains but was
absent in CAST or CASA (Figure 2B, Figures S1D and S1E). Sequence analysis of intron 5
suggested that inclusion of this exon was due to a SNP that generated a novel alternative splice
site (Figure 2C, Figure S1F). Transcript levels of the correctly spliced Ankrd16 isoform (lacking
exon 5’) were 3.3 and 5.3-fold higher in the cerebellum of congenic MstiCAST/B6 or CAST,
respectively, relative to B6 (Figure 2D). Protein levels were 2.8 ± 0.2 and 3.9 ± 0.22 fold higher
in the B6.MstiCAST/B6 and CAST cerebellum, respectively, and the Aarssti/sti mutation did not alter
Ankrd16 splicing or protein levels (Figure 2E, Figures S1E and S1G). Increased ANKRD16
levels were also observed in other tissues from MstiCAST/B6 mice (Figure S1H). The Ankrd16
transcript with exon 5’ contains a premature stop codon and is predicted to undergo nonsensemediated decay and in agreement, truncated forms of ANKRD16, predicted to be ~34 kDa, were
not observed (Figure 2E, Figure S1G).
Neurodegeneration in Aarssti/sti mice was modified neither by transgenic expression of the CAST
Il2ra cDNA nor deletion of Il2ra. However, suppression of Aarssti/sti-mediated Purkinje cell loss
was observed in mutant mice that carried a CAST BAC transgene containing the 3’ portion of
the Il15ra gene, and the Fbxo18 and Ankrd16 genes (Figure 2F). Surprisingly, another
transgenic line (Tg25L9-19) generated with this BAC was not able to suppress Purkinje cell
degeneration. However, genomic PCR analysis using markers that differentiate between CAST
and B6 alleles demonstrated that Ankrd16 was deleted in this latter line (Figure 2F, Figure S1I).
Indeed, transgenic expression of the Ankrd16CAST coding sequence using the Purkinje cell17

specific promoter Pcp2 (L7) in B6.Aarssti/sti mice suppressed the death of these neurons (Figure
2G).

Figure 2: Ankrd16 is the modifier of Aarssti/sti. (A) Amino acid polymorphisms between
C57BL/6J and CAST/Ei in Msti region. (B) Alternative splicing of Ankrd16 in the cerebellum.
(C) An intronic SNP (red) introduces a cryptic exon (exon 5’) in Ankrd6 in non-Msti containing
strains. (D) Expression of correctly spliced Ankrd16 in the cerebellum (mean ± SEM). (E)
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immunohistochemistry. Scale bars: 500 μm. One-way ANOVA was corrected for multiple
comparisons using Tukey correction (D). * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.

2.3.2. ANKRD16 binds AlaRS to reduce misincorporation of serine. ANKRD16 encodes a 39
kDa protein of unknown function that is composed of nine repeats of the ankyrin protein-protein
interaction domain and is found only in vertebrates (Figures S1J and S2A). To identify proteins
that interact with ANKRD16, we transgenically expressed Ankrd16-myc under the control of the
chicken beta-actin promoter and cytomegalovirus enhancer, known to drive expression of target
genes in mice (Hitoshi et al., 1991; Okabe et al., 1997). Co-immunoprecipitation (Co-IP) of
ANKRD16 was performed using liver tissue (which highly expressed the transgene) of
transgenic and non-transgenic mice, and the immunoprecipitates were analyzed via tandem mass
spectrometry (LC-MS/MS). Surprisingly, AlaRS was the most abundant protein after the
ANKRD16 bait protein (Figure S2A). Interaction of ANKRD16 with wild type or mutant AlaRS
in the liver and brain was confirmed by Co-IP/western blotting (Figure 3A). Interactions between
ANKRD16 and AlaRS were independent of both the epitope tag and bait protein (Figures S2B
and S2C).
Co-IP experiments demonstrated that the AlaRS aminoacylation domain was efficiently coimmunoprecipitated by ANKRD16, and little interaction was observed in the absence of this
domain (Figure 3B, Figure S2B). Affinity-capture experiments using purified AlaRS protein
further defined that the AlaRS catalytic domain was sufficient for ANKRD16 interaction and
that this interaction was direct (Figure 3C, Figure S2E). Furthermore, AlaRS did not Co-IP
ANKRD29, a protein comprised of 8 ankyrin repeats (Figure S2D), nor did ANKRD16 interact
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with tyrosyl-tRNA synthetase or tryptophanyl-tRNA synthetase (Figure 3C), suggesting a
specific ANKRD16-AlaRS interaction with similar binding dynamics between wild type AlaRS
and AlaRSA734E (Figure S2F).
The AlaRSA734E mutation leads to increased death of Aarssti/sti embryonic fibroblasts when
cultured with increasing concentrations of serine (Lee et al., 2006). MstiCAST/B6; Aarssti/sti
fibroblasts were more resistant than B6.Aarssti/sti fibroblasts to high serine concentrations, and at
the highest concentrations (40 mM), less cell death was observed in these cells than in MstiB6/B6
fibroblasts (Figure 3D) demonstrating that Ankrd16 suppresses serine-mediated cell death in
Aarssti/sti cells.
Although ANKRD16 is a vertebrate-specific protein, mammalian and E. coli AlaRS are highly
conserved with ~67% similarity in the catalytic domain. Indeed, mouse ANKRD16 was able to
affinity-capture E. coli AlaRS (Figure 3C), and reduced death of E. coli with a severe editing
domain mutation (C666A/Q584H) in AlaRS when grown on a serine gradient (Figure 3E). This
result demonstrated that even though an obvious ortholog of ANKRD16 is only present in
vertebrates, the mechanism of action of ANKRD16 is conserved between mammals and bacteria.
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Figure 3: ANKRD16 interacts with AlaRS and prevents serine-mediated cell death. (A)
Co-IP experiments and western blotting reveal the AlaRS-ANKRD16 interaction in the brain.
(B) Co-IP experiments in HEK293T cells using mouse Myc-AlaRS domain constructs. (C)
Purified AlaRS, TyrRS, or TrpRS proteins were incubated with GST-ANKRD16. (D) Cell death
of embryonic fibroblasts (mean ± SD). (E) AarsC666A/Q584H E.coli expressing mouse Ankrd16 or
mouse Ankrd29. Two-way ANOVA was corrected for multiple comparisons suing Tukey
correction. *** p ≤ 0.001; **** p ≤ 0.0001.

To better understand how ANKRD16 inhibits serine misincorporation, we used dipeptide
formation on defined ribosome complexes as a read-out of charging and decoding fidelity. These
experiments sufficiently detected serine mistranslation and AlaRS-mediated editing of SertRNAAla (Figures S3A and S3B). When reactions using Ser-tRNAAla and AlaRS were
Supplemented with alanine, loss of fMet-Ser coincided with gain of fMet-Ala (Figure 4A),
consistent with reported post-transfer editing by AlaRS (Beebe et al., 2003). However, no
obvious differences were observed between reactions using AlaRSWT or AlaRSA734E, and
ANKRD16 had no effect on either reaction in these experiments using mischarged tRNA (Figure
4A).
In contrast, when deacyl tRNAAla, serine, and ATP were used, AlaRSA734E generated more fMetSer than AlaRSWT and unlike in reactions with misacylated tRNAAla, ANKRD16 reduced the
amount of this aberrant dipeptide in reactions with either AlaRSA734E or AlaRSWT (Figure S3C).
Although ANKRD16 interacts with AlaRS1-455 (Figure S2F), no reduction in the amount of
aberrant dipeptide was observed (Figure S3C); implying the editing and/or C-terminal domains
of AlaRS may contribute to ANKRD16 function. Furthermore, in the presence of ATP and a
mixture of Ser and Ala, ANKRD16 specifically decreased fMet-Ser formation, thereby
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increasing AlaRSA734E fidelity (i.e., fMet-Ala/fMet-Ser) by a factor of ~20 (Figure 4B).
Collectively, these data suggest that ANKRD16 acts prior to formation of mischarged tRNA to
enhance translational fidelity.
In agreement, ANKRD16 had no effect on subsequent steps of tRNA mischarging including
deacylation of mischarged Ser-tRNAAla, transfer of the mischarged tRNA to EF-Tu, or
activation/aminoacylation of the cognate amino acid alanine (Figures S3D to S3G). In addition to
the well-characterized post-transfer editing activity of AlaRS, pre-transfer editing has been
observed with E. coli AlaRS (Tsui and Fersht, 1981). Serine-dependent ATPase activity was also
observed with wild type mouse AlaRS in the absence of tRNA (Figure S4A). However, this
activity was decreased with both AlaRSA734E and AlaRS1-455 (Figure 4C, Figure S4B).
ANKRD16 was able to restore that activity for AlaRSA734E, but not for AlaRS1-455, further
suggesting that the editing domain contributes to the serine-dependent ATPase activity and/or the
modulation of this activity by ANKRD16 (Figure 4C, Figure S4B and S4C).
Unexpectedly, in the classical assay for aminoacylation, in which tRNA-dependent acid
precipitation of radiolabeled amino acid is measured, ANKRD16 appeared to stimulate tRNAdependent precipitation of 3H-serine but not of 3H-alanine (Figures S4D to S4F). Misactivated
3

H-serine was precipitated in reactions with ANKRD16 and AlaRS in the absence of tRNAAla,

with approximately three linked-serine adducts per ANKRD16 (Figure S4G). In contrast,
alanine-adduct formation per ANKRD16 with AlaRS in the absence of tRNAAla was much lower
(Figure S4H). Furthermore, in the presence of tRNA and AlaRS, the amount of alanine linked to
ANKRD16 was negligible relative to that coupled to tRNAAla (Figure 4D).
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These results suggest that ANKRD16 functions as an alternative to water or tRNAAla, accepting
misactivated serine. Previous studies have demonstrated that reactive aminoacyl adenylates may
react with cysteine or lysine residues (He et al., 2018; Jakubowski, 2011, 1999; Yanagisawa et
al., 2010). However, the levels of precipitated serine were only slightly diminished after
prolonged exposure to alkaline pH, which hydrolyzes thiol esters (e.g. cysteine), suggesting the
ANKRD16 serine adduct is likely an amide (e.g. lysine) (Figure S4I).
To identify residues of ANKRD16 that accept misactivated serine, we utilized mass
spectrometry. In support of our above experiments, no spectral shift with Cys-containing
peptides was observed. While not all Lys-containing peptides of ANKRD16 could be resolved,
three highly conserved lysines - K102, K135, and K165 - shifted by 87 Da (the mass of serine)
(Figures S1J, S5A to S5D). To prevent the formation of isopeptide bonds with serine we mutated
lysine 102, 135, and 165 codons to arginine (ANKRD163xArg) (Figure S4G). Circular dichroism
spectroscopy and thermal shift assays suggested that both wild type and ANKRD163xArg have
similar secondary structures and stabilities (Figures S5E and S5F), and only a slight reduction
(~2 fold) in the binding affinity with AlaRSA734E (Figures S2F and S5G). In stark contrast to wild
type ANKRD16, ANKRD163xArg had no effect on AlaRSA734E pre-transfer editing, demonstrating
serinylation may be critical to restore editing activity (Figure 4E, Figure S4B). Unlike wild type
ANKRD16, which rescued AlaRSC666A/Q584H E. coli growth in high levels of serine,
ANKRD163xArg did not rescue growth of mutant bacteria under these conditions (Figure 4F).
Similarly, serine-induced death of B6.Aarssti/sti embryonic fibroblasts was prevented by
expression of wild type Ankrd16, but not Ankrd163xArg, suggesting that transfer of misactivated
serines to ANKRD16 may also be necessary to prevent cell death of these AlaRS editingdeficient cells (Figure 4G, Figure S6).
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Based on these results, we generated a model for the ANKRD16-AlaRS complex (Figure 4H).
Modified lysine side chains of ANKRD16 project out from the helix-loop-helix motifs, with each
being in close proximity to the active site of AlaRS, where serine is misactivated. Together these
data support the concept that ANKRD16 prevents mistranslation by stimulating tRNAindependent ATPase activity and functions as an alternative acceptor for misactivated serine.
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Figure 4. ANKRD16 enhances tRNA-independent editing and accepts serine adenylates
from AlaRS. (A) Mouse AlaRS (±ANKRD16) was added to reactions containing Ser-tRNAAla
and alanine. (B) Mouse AlaRS (±ANKRD16) was added to reactions containing deacylated
tRNAAla, alanine and serine (* oxidized fMet). (C) Ser-AMP hydrolysis at 10 min (mean ± SD).
(D) Ratio of alanine- or serine-linked ANKRD16/aminoacylated tRNAAla (mean ± SD, ** p =
0.0011). (E) Ser-AMP hydrolysis at 10 min (mean ± SD). Control reactions from panel c (†). (F)
AarsC666A/Q584H E. coli expressing mouse Ankrd16 or Ankrd163xArg. (G) Cell death of embryonic
fibroblasts (mean ± SEM). (H) Structural model of ANKRD16 and the aminoacylation domain
(AAD) of AlaRS, modified lysines (purple), active site residues (orange), and Ala-AMS (AlaAMP analog, green). One-way ANOVA was corrected for multiple comparisons using Tukey
correction (C, E, G); Student’s t-test (D). *** p ≤ 0.001; **** p ≤ 0.0001.

2.3.3. Complete loss of Ankrd16 in Aarssti/sti mice leads to extensive neurodegeneration. To
determine if the specificity of neuron death in Aarssti/sti mice is correlated with the ANKRD16
levels, we performed immunofluorescence with ANKRD16 antibodies in B6.MstiCAST/CAST
brains. ANKRD16 was widely expressed in the brain and was detected in the nucleus as well as
the cytoplasm (Figure 5A, Figures S7A and S7B). Intriguingly, ANKRD16 levels were lower in
Purkinje cells relative to cerebellar granule cells, cells of the cerebellar molecular layer,
hippocampal neurons, and cells in the cortex (Figure 5A).
To test if the levels of Ankrd16 influence the sensitivity of cells to the Aarssti/sti mutation, we
generated an Ankrd16 null allele (Figures S7C and S7D). Ankrd16-/- mutant mice had no obvious
pathologies in the brain or other organs, even when aged to 12 months. However, loss of
Ankrd16 in Aarssti/sti mice resulted in early embryonic lethality (Figure S7E). These results
demonstrate a strong genetic interaction between the Aarssti/sti mutation and Ankrd16, and also
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show that the low levels of ANKRD16 present in B6 mice are sufficient to resolve sti-mediated
editing defects induced during embryonic development.
To determine the impact of decreasing ANKRD16 levels on neuronal cell survival we first
conditionally deleted Ankrd16 in postnatal Purkinje cells in Aarssti/sti mice. Purkinje cell loss in
B6.Pcp2-Cre; Ankrd16fl/-; Aarssti/sti mice began at about 3 weeks of age; by 4 weeks of age, the
majority of Purkinje cells were absent and in contrast to Aarssti/sti mice, all Purkinje cells had
degenerated by 7 months of age (Figures S8A and S9A). In agreement, formation of ubiquitinand p62-positive aggregates was accelerated in Purkinje cells of 3-week-old mice. Aggregates
were observed in 12.3% of Purkinje cells compared to 2.5% of these neurons in Aarssti/sti mice
(Figure S9A).
To determine if loss of Ankrd16 can induce death in neuron types that do not degenerate in
Aarssti/sti mice, we deleted Ankrd16 in the embryonic cerebellar primordium using En1-Cre
(Kimmel et al., 2000). Protein aggregates and neuron death were no longer restricted to Purkinje
cells but were also observed for interneurons in the molecular layer and neurons in the granule
cell layer (Figures S8B, S8C and S9B). Furthermore, loss of Ankrd16 in postnatal cortical and
hippocampal neurons also caused their degeneration (Figure 5C and 5D). Ubiquitin- and p62positive aggregates were observed both hippocampal pyramidal cells (2.80% ± 0.22%) and
cortical neurons in 2-month-old B6.CaMKIIa-Cre; Ankrd16fl/-; Aarssti/sti mice (Figure 5B, Figure
S9C). Together, these data demonstrate that neurons other than Purkinje cells are also sensitive
to the effects of mistranslation and further suggest that ANKRD16 protects against
mistranslation in a dose-dependent fashion.
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Figure 5: Loss of Ankrd16 in Aarssti/sti mice causes protein aggregation and
neurodegeneration. (A and B) Immunofluorescence with antibodies to ANKRD16 (green) and
calbindin D-28 (red) or ubiquitin (red) and p62 (green). (C and D) Cresyl violet staining of
hippocampus (C) and cortex (D). Scale bars: 50 μm (A, low magnification), 10 μm (A, higher
magnification), 50 μm (B, low magnification), 10 μm (B, higher magnification), 500 μm (C, low
magnification), 50 μm (C, higher magnification), 100 μm (D). Postnatal day (P), Cornu ammonis
(CA), Dentate gyrus (DG).

2.4. Discussion
Aminoacyl tRNA synthetases utilize the aminoacylation and editing domains to prevent
misincorporation of non-cognate amino acids. In contrast to known editing mechanisms of tRNA
synthetases or free-standing homologs of editing domains (Beebe et al., 2008; Chong et al.,
2008) that act autonomously, tRNA-independent hydrolysis of misactivated serine by AlaRS is
enhanced through binding of ANKRD16 which captures misactivated serine and removes it from
the pool for protein synthesis. Unlike most tRNA synthetases, AlaRS not only misactivates
smaller (glycine) but also larger (serine) amino acids than alanine due to structural properties that
make it difficult for AlaRS to exclude misactivated serine (Chong et al., 2008; Fersht, 1977; Ibba
and Söll, 1999; Jakubowski and Goldman, 1992; Schimmel, 2011). Thus, serine misactivation by
AlaRS, and the toxic effects of Ser-for-Ala replacements in vertebrates, may present a special
situation in which an editing co-factor is necessary for proofreading.
In addition to providing direct mechanistic insights into editing functions of aminoacyl tRNA
synthetases, highlighting the importance of studying basic processes such as mRNA translation
in higher organisms, the discovery of Ankrd16 may provide understanding for the cell-type
sensitivity of phenotypes associated with the Aarssti mutation. More broadly, cell-type selectivity
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resulting from “monogenic” mutations in ubiquitous genes has been difficult to resolve. Only a
few modifier genes of disease mutations have been identified in an unbiased approach and these
suggest that modifier genes may function in independent, parallel pathways (Chen and
Burgoyne, 2012; Lenz et al., 2013; Van Ham et al., 2009). Our identification of Ankrd16 as a
modifier of the Aarssti mutation demonstrates that this possibility may be an oversimplification
and that restricted pathologies may be due to the expression levels of genes that modify the
function of the gene harboring the primary mutation. A modifier-based mechanism for
understanding the underlying pathology of diseases associated with mutations in ubiquitous
genes may be a promising route to clarify the causes of the specificity of pathogenesis.
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CHAPTER 3
GTPBP1 RESOLVES PAUSED RIBOSOMES TO MAINTAIN NEURONAL
HOMEOSTASIS
3.1. Abstract
Ribosome-associated quality control pathways respond to defects in translational elongation to
recycle arrested ribosomes and degrade aberrant polypeptides and mRNAs. Loss of an individual
tRNA gene leads to ribosomal pausing that is resolved by the translational GTPase GTPBP2, and
in its absence causes neuron death. Here, we show that loss of the homologous protein GTPBP1
during tRNA deficiency in the mouse brain also leads to codon-specific ribosome pausing and
neurodegeneration, suggesting that these non-redundant translational GTPases function in the
same pathway to mitigate ribosome pausing. As we previously observed in Gtpbp2-/- mice
(Ishimura et al., 2016), GCN2-mediated activation of the integrated stress response (ISR) was
also apparent in the Gtpbp1-/- brain. In addition, we observed decreased mTORC1 signaling
which increased neuronal death, whereas ISR activation was neuroprotective. Our data
demonstrate that GTPBP1 functions as an important quality control mechanism during
translation elongation and suggest that translational signaling pathways intricately interact to
regulate neuronal homeostasis during defective translation elongation.

3.2. Introduction
Translation of mRNA into protein utilizes four principle cycles: translation initiation, elongation,
termination and ribosome recycling (Schuller and Green, 2019). During translation initiation,
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eukaryotic translation initiation factors (eIFs) mediate assembly of an 80S ribosome and an
initiator methionyl-tRNA at the start codon. Subsequently, the elongating 80S ribosome moves
along the mRNA decoding mRNA triplets until the termination codon is reached where
eukaryotic peptide chain release factors (eRFs) stimulate the release of the nascent protein.
Lastly, to permit engagement of ribosomes in new rounds of translation, the terminated 80S
ribosome complex is separated into the 40S and 60S subunits and released from the mRNA by
ATP-binding cassette sub-family E member 1 (ABCE1).
Although much attention has been dedicated to the regulation of protein synthesis through
translation initiation, collective evidence highlights the effect of translation elongation and its
kinetics on protein synthesis (Stein and Frydman, 2019). Elongation rates not only vary between
mRNAs generated from different genes but rates also fluctuate across a given transcript (Chaney
and Clark, 2015; Kaiser and Liu, 2018; Rodnina, 2016). Multiple factors including secondary
structure of mRNAs, availability of tRNAs, interactions of the nascent peptide with the ribosome
and codon identity influence elongation rates, and variations in these rates affect co-translational
protein folding, translational fidelity, and gene expression through mRNA decay (Brule and
Grayhack, 2017; Buhr et al., 2016; Chaney and Clark, 2015; Drummond and Wilke, 2008;
Rodnina, 2016; Spencer et al., 2012; Thommen et al., 2017; Wolf and Grayhack, 2015; Yu et al.,
2015).
With growing evidence suggesting translation elongation is regulated, elaborate mRNA
surveillance mechanisms that resolve translation elongation defects have been identified
(Brandman and Hegde, 2016; Joazeiro, 2019). We previously reported that an ENU-induced null
mutation (nmf205) in the translational GTPase (trGTPase) GTPBP2 causes early, widespread
neurodegeneration when present on the common inbred mouse strain C57BL/6J (B6J) (Ishimura
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et al., 2014). Neuron death in B6J-Gtpbp2nmf205/nmf205 (B6J-Gtpbp2-/-) mice is a result of the
epistatic interaction between the loss-of-function mutation in Gtpbp2 and a hypomorphic
mutation present in the B6J strain that disrupts processing of the brain-specific, nuclear encoded
tRNA, n-Tr20. n-Tr20 is widely expressed in neurons and is the most highly expressed member
of the five tRNAArgUCU genes in brain, and the B6J-associated mutation reduces the pool of
available tRNAArgUCU (Ishimura et al., 2014; Kapur et al., 2020). In the absence of Gtpbp2,
translating ribosomes in the cerebellum exhibit prolonged pauses at AGA codons, suggesting
GTPBP2 acts as a ribosome rescue factor to resolve codon-specific ribosome pausing that occurs
when the available pool of cognate tRNAs is limited. The essential role of Gtpbp2 in neuronal
homeostasis was further revealed by the identification of mutations in Gtpbp2 causing
neurological defects and intellectual disabilities in humans (Bertoli-Avella et al., 2018; Carter et
al., 2019; Jaberi et al., 2016).
Defects in translation elongation may feedback to regulate translation initiation, supporting the
emerging link between translation elongation and initiation to control global translation (Chu et
al., 2014; Inglis et al., 2019; Liakath-Ali et al., 2018a; Sanchez et al., 2019). Translation is highly
regulated by two signaling pathways: the mTOR signaling pathway and the integrated stress
response (ISR). mTOR complex 1 (mTORC1) phosphorylates the ribosomal protein S6 kinase
(S6K1) and the eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) to
positively regulate translation initiation and elongation (Nandagopal and Roux, 2015). The ISR
reprograms the translatome by inhibiting translation initiation to suppress global translation via
phosphorylation of the translation initiation factor eIF2α (p-eIF2αS51) which inhibits formation of
the ternary complex, while allowing translation of stress-responsive genes such as ATF4
(Harding et al., 2003; Wortel et al., 2017). In the B6J-Gtpbp2-/- cerebellum, ribosome stalling is
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accompanied by induction of the integrated stress response (ISR) (Ishimura et al., 2014).
Phosphorylation of eIF2α in the B6J-Gtpbp2-/- cerebellum is mediated by GCN2, one of four
known kinases in mammals (Dalton et al., 2012), which are activated during distinct cellular or
environmental stressors. Deletion of Gcn2 in B6J-Gtpbp2-/- mice led to increased
neurodegeneration, demonstrating GCN2-dependent activation of the ISR acts to partially restore
cellular homeostasis (Chesnokova et al., 2017; Dalton et al., 2012; Ishimura et al., 2016).
In addition to Gtpbp2, the genome of many eukaryotes contains a related gene, Gtpbp1
(Atkinson, 2015). A previous report demonstrated that loss of Gtpbp1 in mice did not lead to
overt defects, suggesting functional redundancy between Gtpbp1 and Gtpbp2 (Senju et al.,
2000). However, here we demonstrate that loss of Gtpbp1 in mice with the B6J-associated
mutation in n-Tr20 have neurodegeneration identical to that observed in B6J-Gtpbp2-/- mice.
Furthermore, ribosome footprint profiling analysis suggests GTPBP1 functions as a novel
ribosome rescue factor to resolve ribosome pausing defects during tRNA deficiency. As
observed in B6J-Gtpbp2-/- mice, the ISR is also induced in the Gtpbp1-/- brain and protects
neurons from ribosome-pausing induced neurodegeneration. Finally, we show that deficiencies
in ribosome pause resolution alter mTOR signaling in a cell type-specific manner, suggesting
that differences in the modulation of translational signaling pathways may contribute to the
selective neurodegeneration observed with defects in translation elongation.

3.3. Results
3.3.1. Loss of Gtpbp1 leads to widespread neurodegeneration when tRNA is deficient.
Previously, we demonstrated that loss of the trGTPase GTPBP2 causes progressive
neurodegeneration in mice (Ishimura et al., 2014). However, mice homozygous for a null
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mutation in Gtpbp1, which encodes a structurally related trGTPase (Figure 6A), were reported to
have no apparent phenotypes on a mixed genetic background (Senju et al., 2000). Both GTPBP2
and GTPBP1 are expressed in many tissues, and in situ hybridization revealed that transcripts of
these genes were widely expressed throughout the brain (Ishimura et al., 2014; Senju et al.,
2000) (Figures 6B to 6D, Figures S10A and S10B). Interestingly, expression of Gtpbp1 and
Gtpbp2 occurred both in neurons that degenerate in Gtpbp2-/- mice (e.g., cerebellar granule cells,
dentate gyrus granule cells, neurons in cortical layer IV) and those that do not (e.g., hippocampal
pyramidal cells and non-layer IV cortical neurons) suggesting possible functional redundancy
between these genes in some cell types.
To investigate if phenotypes in Gtpbp1-/- mice are dependent on genetic background as observed
for B6J-Gtpbp2-/- mice, we generated congenic B6J.Gtpbp1-/- mice. Like B6J-Gtpbp2-/- mice,
B6J.Gtpbp1-/- mice were indistinguishable from littermate controls at 3 weeks of age, developed
overt ataxia by 6 weeks, and died by 8 weeks of age. Cerebellar degeneration was also similar to
that observed in B6J-Gtpbp2-/- mice (Ishimura et al., 2014) (Figure 6E). Apoptotic granule cells
were observed in caudal lobes of the cerebellum just prior to 4 weeks of age and these neurons
progressively died in a posterior to anterior manner. As previously observed in B6J-Gtpbp2-/mice, granule cells in the dentate gyrus (DG), layer IV cortical neurons and multiple neurons in
the retina degenerated in B6J.Gtpbp1-/- mice, but cell death was not observed for other neurons
such as hippocampal pyramidal cells or neurons in the other layers of the cortex (Figures S11A
to S11E). Consistent with the dependency of cerebellar granule cell degeneration on levels of nTr20, a tRNAArgUCU gene with a processing mutation in the B6J strain, transgenic expression of
wild type n-Tr20 greatly attenuated degeneration of these neurons as has previously been
observed for B6J-Gtpbp2-/- mice (Figure 6E).
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To genetically test for compensation between Gtpbp1 and Gtpbp2, we analyzed mice that had
mutations in both genes. Neurodegeneration was not observed in mice heterozygous for
mutations in both Gtpbp1 and Gtpbp2 (Figure 6F). Furthermore, the onset, progression and
specificity of neurodegeneration were similar between B6J.Gtpbp1-/-; Gtpbp2-/-, B6J.Gtpbp1-/and B6J-Gtpbp2-/- mice (Figures 6G and 6H). These results suggest that Gtpbp1 and Gtpbp2 are
functionally distinct and act in a common pathway to mediate cellular homeostasis that is
necessary for neuron survival.
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Figure 6. tRNA deficiency induces neurodegeneration in B6J.Gtpbp1-/- mice. (A) Domain
structure of mouse GTPBP2 and GTPBP1. The percent of identical amino acids for each domain
is shown. (B-D) In situ hybridization demonstrating ubiquitous expression of Gtpbp1 (yellow)
and Gtpbp2 (red) in the P28 wild type (B6J) cerebellum (B), and CA1 region of the hippocampus
(C), dentate gyrus (DG) (D). Images of individual probes from areas defined by rectangles in C
and D are shown above merged images. (E, F) Hematoxylin and eosin staining of sagittal
sections of the cerebellum. Higher magnification images of lobule IX are shown below each
genotype. Cerebellar lobes are indicated by Roman numerals. (G, H) Number of cerebellar
granule cells in lobule VI (G) and lobule IX (H) of 3-, 4-, and 6-week-old BP1 (B6J.Gtpbp1-/-);
BP2 (B6J-Gtpbp2-/-); and BP1, BP2 (B6J.Gtpbp1-/-; Gtpbp2-/-) mice. Data represent mean + SD.
ML, molecular cell layer; PL, Purkinje cell layer; GCL, granule cell layer. Scale bars: 20μm (B,
C, D); 500μm and 50μm (higher magnification) (E, F). One-way ANOVA was corrected for
multiple comparisons using Tukey method (G, H). *** P ≤ 0.001; **** P ≤ 0.0001.

3.3.2. GTPBP1 is a novel ribosome rescue factor. The genetic interaction between the B6Jderived n-Tr20 mutation and the loss of Gtpbp1 suggested that like GTPBP2, GTPBP1 might act
as a rescue factor for ribosomes paused at AGA codons. To investigate this possibility, we
performed ribosome profiling on cerebella from 3-week-old B6J.Gtpbp1-/- and B6J mice. As
previously observed in the B6J-Gtpbp2-/- cerebellum, ribosome occupancy dramatically
increased in the B6J-Gtpbp1-/- cerebellum when AGA codons were in the A site of the ribosome
(Figures 7A and 7B, Figure S12A). Comparison of genes with AGA pauses revealed that
approximately 50% of pausing genes were shared between libraries generated from individual
B6J.Gtpbp1-/- mice, and this was also true for B6J-Gtpbp2-/- mice, supporting that AGA pausing
is likely stochastic (Figure 7C). Similarly, about 50% of genes with AGA pausing intersected
between B6J.Gtpbp1-/- and B6J-Gtpbp2

-/-

mice (Figure S12B). Consistent with stochastic

pausing at AGA codons, gene ontology (GO) analysis of genes with pauses revealed enrichment
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in numerous biological processes and the majority of these processes were enriched in both
Gtpbp1 and Gtpbp2 (Figure S12C). Thus, our data suggest that both GTPBP1 and GTPBP2
rescue stochastic ribosome pausing events when the tRNAArgUCU pool is reduced.
To determine if transcriptional changes are shared upon loss of Gtpbp1 and Gtpbp2, we
performed RNA-Sequencing analysis. Comparison of data from the cerebellum of 3-week-old
B6J.Gtpbp1-/- and B6J mice revealed significant (q-value ≤ 0.05) differential expression (DE) of
approximately 12% of the detected genes, with 46% upregulated and 54% downregulated (DE
Gtpbp1). Similarly, loss of Gtpbp2 altered expression of about 10% of the detected genes with
45% and 55% upregulated and downregulated, respectively, when compared to B6J (DE
Gtpbp2). Interestingly, only 27 genes (mostly non-coding genes) were differentially expressed
between Gtpbp1-/- and Gtpbp2-/- cerebella, revealing that loss of either gene similarly altered the
transcriptome (Figure 7D).
The high similarity of gene expression changes in Gtpbp1 and Gtpbp2 mutant mice, combined
with our observation that ribosome pausing defects are likely stochastic, suggested that
transcriptional alterations might reflect a common cellular response to ribosome pausing rather
than changes in levels of the specific genes that harbor paused ribosomes. In agreement,
transcriptional changes were only weakly correlated with genes showing increased ribosomal
occupancy (Spearman correlation coefficient of 0.0405, p-value = 0.0083). Significant (q-value ≤
0.05) changes in expression were only observed in 33% or 26% of the genes with AGA pauses
(that were detected in at least 2 replicates) in the Gtpbp1-/- and Gtpbp2-/- cerebellum, respectively
(Figure 7E).
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Figure 7. GTPBP1 resolves ribosome pausing induced by tRNA deficiency. (A) Ribosome
occupancy was calculated by dividing the number of genome-wide reads at codons by the
expected reads in the ribosomal A-site. Data represent mean + SEM. Note that ribosome
occupancy increased only at AGA codons in P21 B6J.Gtpbp1-/- mice. (B) Ribosome occupancy
at AGA codons was calculated by dividing genome-wide reads at AGA codons by expected
reads. Data represent mean + SEM from ribosome profiling from cerebella of P21 B6J and
B6J.Gtpbp1-/- mice. (C) Venn diagram of genes with increased ribosome occupancy at AGA
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codons (z-score ≥ 10) between libraries prepared from individual B6J.Gtpbp1-/- (red) or B6JGtpbp2-/- (blue) mice. (D) Significant (q-value ≤ 0.05, q-value refers to the corrected p-value
using Benjamini-Hochberg correction) transcriptional changes in gene expression between P21
B6J and B6J.Gtpbp1-/- cerebellum (x-axis, DE Gtpbp1) are plotted against those between P21
B6J and B6J-Gtpbp2-/- cerebellum (y-axis, DE Gtpbp2). Significant (q-value ≤ 0.05) Gtpbp1dependent expression changes are colored in pink and Gtpbp2-dependent expression changes in
blue. Significant (q-value ≤ 0.05) transcriptional changes in gene expression between
B6J.Gtpbp1-/- and B6J-Gtpbp2-/- are shown in red (27 genes). The beta effect size is analogous to
the natural log fold change in expression. (E) Analysis of differential gene expression between
P21 B6J and B6J.Gtpbp1-/- mice (DE Gtpbp1). Significant (q-value ≤ 0.05) transcriptional
changes in gene expression are shown in grey, and genes with increased AGA ribosome
occupancy (z-score ≥ 10, detected in at least 2 biological replicates) that are differentially
expressed are highlighted in red (260 genes). The beta effect size is analogous to the natural log
fold change in expression and 1.5-fold changes in gene expression are indicated by the red
dashed lines. Multiple t tests were corrected for multiple comparisons using Holm-Sidak method
(B). ** P ≤ 0.01.

3.3.3. Loss of GTPBP1 activates the integrated stress response. In order to identify molecular
pathways that might respond to ribosome pausing, we performed upstream regulator analysis
(Ingenuity Pathway Analysis) of genes differentially expressed between B6J and B6J.Gtpbp1-/mice (DE Gtpbp1). This analysis revealed significant enrichment for activation of the
transcription factor ATF4, an effector of the integrated stress response (ISR) (Figure 8A, inset).
The ISR is induced by the coupling of stress signals to the phosphorylation of serine 51 of the
translation initiation factor eIF2a to decrease translation initiation. While the ISR reduces
translation of many mRNAs, translation of ATF4 is enhanced, which results in the upregulation
of genes to restore cellular homeostasis. We previously observed induction of the ISR in the
B6J-Gtpbp2-/- cerebellum suggesting that activation of this pathway may be a common cellular
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response to ribosome stalling (Ishimura et al., 2016). In agreement, Atf4 and 141 of the 153
differentially expressed ATF4 target genes (Han et al., 2013) were upregulated in the cerebellum
of 3-week-old B6J.Gtpbp1-/- mice (DE Gtpbp1, Figure 8A). Furthermore, levels of
phosphorylated eIF2a (p-eIF2aS51) were increased in the cerebellum and hippocampus of
B6J.Gtpbp1-/- mice (Figures 8B and 8C). In agreement, in situ hybridization of the B6J.Gtpbp1-/hippocampus with probes to ATF4 targets induced in the cerebellum of these mice demonstrated
that these ATF4 targets were also induced in hippocampal neurons of 3-week-old mutant mice
(Figure 8D). Interestingly, induction of ATF4 targets varied in different types of neurons. Sesn2,
Slc7a1, and Chac1 were upregulated in both CA1 and DG neurons, whereas Ddr2 was only
upregulated in CA1 neurons (Figure 8D).
In B6J-Gtpbp2-/- mice, the ISR is activated by the eIF2a kinase GCN2 (EIF2AK4). Inhibition of
ISR activation via Gcn2 deletion in these mice accelerated cerebellar granule cell death and
induced neurodegeneration of hippocampal pyramidal cells (Ishimura et al., 2016). GCN2 was
enriched in upstream regulator analysis of differentially expressed genes in the B6J.Gtpbp1-/cerebellum (DE Gtpbp1), suggesting that this kinase may also mediate activation of the ISR in
Gtpbp1-deficient mice (Figure 8A, inset). In agreement, Gcn2 deletion in B6J.Gtpbp1-/- mice
accelerated degeneration of cerebellar granule cells. In 5-week-old B6J.Gtpbp1-/-; Gcn2-/- mice,
65% of these neurons had degenerated compared to 37% in B6J.Gtpbp1-/- mice (Figure 8E and
8F). Furthermore, the dentate gyrus of B6J.Gtpbp1-/-; Gcn2-/- mice had twice the number of
granule cells with pyknotic nuclei compared to B6J.Gtpbp1-/- mice (Figure 8G, Figure S13).
Finally, although CA1 pyramidal neurons do not normally degenerate in B6J.Gtpbp1-/- mice,
10.3% of these neurons were undergoing apoptosis in the hippocampus of 5-week-old

44

B6J.Gtpbp1-/-; Gcn2-/- mice (Figure 8G and 8H). As previously reported (Ishimura et al., 2016;
Zhang et al., 2002), neurodegeneration was not observed in the B6J.Gcn2-/- brain.
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Figure 8. Ribosome pausing activates the integrated stress response (ISR) to ameliorate
neurodegeneration in Gtpbp1-/- mice. (A) Analysis of transcriptional changes in gene
expression between P21 B6J and B6J.Gtpbp1-/- mice (DE Gtpbp1). Significant (q-value ≤ 0.05,
q-value refers to the corrected p-value using Benjamini-Hochberg correction) changes in
expression are shown in grey and differentially expressed ATF4 targets are highlighted in green.
The beta effect size is analogous to the natural log fold change in expression and 1.5-fold
changes in gene expression are indicated (red dashed lines). (Inset) Identification of upstream
regulators using Ingenuity Pathway Analysis (IPA) of differentially expressed genes between
B6J and B6J.Gtpbp1-/- mice (DE Gtpbp1). Top ten transcription factors and kinases (italics) are
shown. (B) Western blot analysis of tissue lysates from P21 mice. Vinculin was used as an input
control. (C) Relative abundance of p-eIF2aS51 and p-S6S240/244 in the hippocampus and
cerebellum of BP1 (B6J.Gtpbp1-/-), BP2 (B6J-Gtpbp2-/-), and control (B6J) mice. Levels of peIF2aS51 or p-S6S240/244 were normalized to total level of eIF2a or S6, and phosphorylation levels
are relative to those of B6J. Data represent mean + SD. (D) In situ hybridization of ATF4 targets
in the hippocampal CA1 and dentate gyrus (DG) at P21. (E) Sagittal cerebellar sections stained
with hematoxylin and eosin. Higher magnification images of lobule IX are shown below each
genotype. Cerebellar lobes are indicated by Roman numerals. (F) Quantification of cerebellar
granule cells of lobule VI and lobule IX of control (B6J), BP1 (B6J.Gtpbp1-/-), and Gcn2; BP1
(B6J.Gcn2-/-; Gtpbp1-/-) mice at P35. Data represent mean + SD. (G) Percent of dentate gyrus
(DG) and CA1 neurons that are pyknotic in control (B6J), BP1 (B6J.Gtpbp1-/-), and Gcn2; BP1
(B6J.Gcn2-/-; Gtpbp1-/-) mice at P35. Data represent mean + SD. (H) Sagittal sections of the CA1
area of the hippocampus stained with hematoxylin and eosin. Arrowheads indicate pyknotic
cells. Scale bars: 50μm (D); 500μm and 50μm (higher magnification) (E); 20μm (H). One-way

46

ANOVA was corrected for multiple comparisons using Tukey method (C, F, G). ** P ≤ 0.01,
*** P ≤ 0.001, **** P ≤ 0.0001.

3.3.4. Ribosome stalling induces neuron-specific changes in mTOR signaling. Our data
suggest that defects in translation elongation activate the ISR, which regulates translation
initiation and influences neurodegeneration. Thus, we wondered if ribosome pausing in Gtpbp1
or Gtpbp2 mutant mice could alter additional translational control pathways. Upstream regulator
analysis of differentially expressed genes in the cerebellum of B6J.Gtpbp1-/- mice (DE Gtpbp1)
revealed enrichment, although lower than that observed for ATF4, of the mammalian target of
rapamycin kinase (mTOR) (Figure 8A, inset). mTOR functions in two distinct protein complexes
known as mTOR complex 1 (mTORC1) and complex 2 (mTORC2). Although association with
membrane bound ribosomes (i.e., the endoplasmic reticulum) has been observed for mTORC2,
the central role of mTOR in protein translation is largely attributed to mTORC1 through
phosphorylation of specific effector proteins and translation of particular genes that contain 5’
terminal oligopyrimidine (TOP) tracts (Dai and Lu, 2009; Laplante and Sabatini, 2013, 2009; Ma
and Blenis, 2009a, 2009b; Nandagopal and Roux, 2015; Zinzalla et al., 2011). To determine if
mTOR activity is altered by loss of Gtpbp1 or Gtpbp2, we analyzed the translational efficiency
(TE) of genes regulated by mTORC1 via their TOP motifs by normalizing the number of
ribosome footprint reads to that of RNA sequencing reads. In addition, we assessed the
phosphorylation status of the ribosomal protein S6 (p-S6240/244), a known downstream target of
mTORC1 (Saxton and Sabatini, 2017; Thoreen et al., 2012). Only one (Rps29) of the 53 detected
5’TOP genes had an altered TE in the B6J.Gtpbp1-/- cerebellum compared to the B6J cerebellum
(TE Gtpbp1) and none of the 5’TOP genes displayed TE alterations in the B6J-Gtpbp2-/47

cerebellum relative to the B6J cerebellum (TE Gtpbp2) (Figure S14A). In addition, levels of pS6240/244 were unchanged at 3 weeks of age in the cerebellum of both mutant strains, suggesting
that mTOR signaling is not altered by ribosome pausing in granule cells, which comprise the vast
majority of cells in the cerebellum (Figure 8B and 8C).
In contrast to the cerebellum, p-S6240/244 levels were decreased by about 90% in the hippocampus
of 3-week-old B6J.Gtpbp1-/- and B6J-Gtpbp2-/- mice relative to wild type (Figure 8B and 8C).
Interestingly, immunofluorescence using antibodies to p-S6240/244 revealed that the reduction of
p-S6240/244 in the mutant hippocampus was more pronounced in specific neuron populations. In
the control hippocampus, p-S6240/244 signal was most intense in CA3 pyramidal cells and lower in
CA1 pyramidal cells and dentate gyrus granule cells (Figure 9A). In Gtpbp1-/- and Gtpbp2-/mutant hippocampi, p-S6240/244 levels were dramatically reduced in the granule cells of the
dentate gyrus and some scattered CA1 neurons (Figure 9A). However, levels of p-S6240/244 were
not affected in CA3 or cortical neurons (i.e. layer IV cortical neurons) of 3-week-old
B6J.Gtpbp1-/- and B6J-Gtpbp2-/- mice (Figures S14B and S14C). Together, these results
demonstrate that changes in mTOR signaling may occur in a cell-type specific manner in the
brains of B6J.Gtpbp1-/- and B6J-Gtpbp2-/- mice.
The decrease in translation initiation by inhibition of the mTOR pathway has been suggested to
reduce ribosome pausing during amino acid deprivation (Darnell et al., 2018) suggesting that like
the ISR, this pathway may also be protective in the Gtpbp1 and Gtpbp2 mutant brain. However,
changes in levels of p-S6240/244 in the mutant hippocampus suggested that decreases in mTOR
activity were most profound in hippocampal neurons that ultimately degenerate (i.e. the granule
cells of the dentate gyrus). Thus, to determine the role of mTOR signaling on neuron survival
during ribosome pausing, we pharmacologically inhibited mTOR by treating B6J, B6J.Gtpbp1-/48

and B6J-Gtpbp2-/- mice with rapamycin daily for two weeks beginning at P14. Similar to the
dramatic decrease in p-S6240/244 in 3-week-old hippocampi in B6J.Gtpbp1-/- and B6J-Gtpbp2-/mice, cerebellar levels of p-S6240/244 were decreased by approximately 85% by P21 in
rapamycin-treated mice (Figure S14D to S14F). Examination of the cerebellum from P28
B6J.Gtpbp1-/- and B6J-Gtpbp2-/- cerebellum revealed that rapamycin treatment increased granule
cell loss by 30% (lobule VI) and 40% (lobule IX) compared to mutant mice treated with vehicle
(Figures 9B and 9C). No neuron loss was observed in rapamycin-treated control (B6J) mice
(Figure 9B and 9C). Although it has been reported that mTOR inhibition may cause repression of
Atf4 transcripts and some of its target genes (Park et al., 2017), no significant reduction of Atf4 or
its targets was observed in rapamycin-treated mutant mice, suggesting that the ISR and mTOR
pathways function independently upon loss of Gtpbp1 and Gtpbp2 in the B6J cerebellum (Figure
S14G).
Rapamycin treatment also increased apoptosis of layer IV cortical neurons by about 3-fold in
P28 B6J.Gtpbp1-/- and B6J-Gtpbp2-/- mice but did not cause death of other cortical neurons
(Figures S15A and S15B). In addition, death of granule cells in the dentate gyrus was accelerated
upon rapamycin treatment. Pyknotic nuclei were observed in 22% of these neurons in P28
rapamycin-treated B6J.Gtpbp1-/- or B6J-Gtpbp2-/- mice, whereas only 3.4% of these neurons had
pyknotic nuclei in vehicle-treated mutant mice (Figures S15C and S15D). In addition, the
number of granule cells was decreased by 35% in the dentate gyrus of rapamycin-treated mice,
indicating that apoptosis in this region of the brain began earlier (Figure S15E). Finally,
apoptosis of CA1 neurons was not observed in rapamycin-treated B6J.Gtpbp1-/- and B6J-Gtpbp2/-

mice at P28 when treatment began at P14. However, pyknotic nuclei were observed when mice

were treated from P28-P42, suggesting that while these neurons are sensitive to mTOR
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suppression, the timing of this sensitivity differs from that of other neurons (Figure S15F). Taken
together, our data demonstrate that unlike the ISR, which acts to prevent loss of neurons with
ribosome stalling, inhibition of mTOR increases the vulnerability of multiple neuronal
populations.
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Figure 9. Decreased mTOR signaling enhances neurodegeneration in trGTPase-deficient
mice. (A) Immunofluorescence of P21 hippocampal sections with antibodies against p-S6S240/244
(orange) and S6 (green). Sections were counterstained with DAPI (blue). Higher magnifications
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of CA1 and dentate gyrus (DG) are shown. (B) Sagittal cerebellar sections of P28 mice injected
with vehicle or rapamycin for 14 days stained with hematoxylin and eosin. Higher magnification
images of lobule IX are shown below each genotype. Cerebellar lobes are indicated by Roman
numerals. (C) Quantification of cerebellar granule cells in lobule VI and lobule IX of either
vehicle (V) or rapamycin (R) treated control (B6J), BP1 (B6J.Gtpbp1-/-), and BP2 (B6J-Gtpbp2-/) mice. Data represent mean + SD. Scale bars: 100μm and 50μm (higher magnification) (A);
500μm and 50μm (higher magnification) (B). Two-way ANOVA was corrected for multiple
comparisons using Tukey method (C). ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001.

3.4. Discussion
Ribosome speed during translation is regulated to allow proper folding of the nascent peptide and
functional protein production. However, prolonged pausing or stalling of translating ribosomes
can be detrimental to cells. Thus cells have evolved multiple quality control mechanisms that
mediate steps from recognition of stalled ribosomes to the resolution of these complexes
(Brandman and Hegde, 2016; Joazeiro, 2019). We previously identified GTPBP2 as a ribosome
rescue factor essential for neuronal survival during tRNA deficiency (Ishimura et al., 2014). The
high homology of GTPBP1 and GTPBP2, their broad expression patterns, and the lack of overt
phenotypes of Gtpbp1-deficient mice on a mixed genetic background had suggested functional
redundancy of these translational GTPases (Senju et al., 2000). However, we show here that loss
of Gtpbp1 leads to widespread neurodegeneration in B6J mice. As observed in Gtpbp2-/- mice,
neuron loss in Gtpbp1-/- mice is dependent on a mutation in the B6J strain that disrupts n-Tr20
tRNAArgUCU processing (Ishimura et al., 2014). Ribosome profiling of the Gtpbp1-/- cerebellum
revealed increased ribosome occupancy at AGA codons as we previously observed for Gtpbp2-/mice (Ishimura et al., 2014). These data suggest that both GTPBP1 and GTPBP2 function as
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ribosome rescue factors and are essential genes in many neurons when n-Tr20 levels are
diminished. In addition, the lack of neurodegeneration in mice heterozygous for mutations in
both Gtpbp1 and Gtpbp2 and the lack of an additive phenotype in the brains of mice lacking both
genes suggest that these trGTPases function in the same pathway to mitigate ribosome stalling,
perhaps mediating different steps in this pathway.
GTPBP1 and GTPBP2 share domain homology with other trGTPases including the yeast protein
Hbs1 (HBS1L in mammals) (Atkinson, 2015). Hbs1 and its interacting partner Dom34 recognize
paused ribosomes at the 3’end of truncated mRNAs and in the 3’UTR of mRNAs, and the
resolution of paused ribosomes is in part gated by the GTPase activity of Hbs1 (Becker et al.,
2012; Guydosh et al., 2017; Guydosh and Green, 2014; Juszkiewicz et al., 2020a; Pisareva et al.,
2011; Shoemaker and Green, 2011). The mechanism by which GTPBP1 and GTBP2 mitigate
defects in ribosome elongation is unknown. Recent biochemical studies revealed that the GTPase
activity of GTPBP1 and GTPBP2 is not stimulated in the presence of 80S ribosomes (Zinoviev
et al., 2018), suggesting that these two trGTPases likely function differently than Hbs1. In
agreement, Dom34/Hbs1 did not mediate pause resolution in a codon-specific manner when
pausing was induced at His codons upon inhibition of histidine biosynthesis (Guydosh and
Green, 2014).
During the process of pause resolution, multiple factors are recruited to mediate ribosome
recycling and degradation of the nascent peptide chains or mRNAs associated with stalled
ribosomes (Collart and Weiss, 2019; D’Orazio et al., 2019; Ibrahim et al., 2018; Pelechano et al.,
2015). Interestingly, GTPBP1 can stimulate exosomal degradation of mRNAs (Woo et al.,
2011), unlike GTPBP2 (Zinoviev et al., 2018), and thus may provide a link between elongation
defects and mRNA degradation. Although we did not observe a strong correlation between
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mRNA abundance and ribosome pausing in the Gtpbp1-/- cerebellum, the stochastic nature of
ribosome stalling could make it difficult to observe the corresponding, and similarly stochastic,
changes in mRNA decay. RNA sequencing techniques that are specifically designed to capture
degradation intermediates may be more effective in investigating mRNA degradation in vivo
(Ibrahim et al., 2018).
As we previously observed in the B6J-Gtpbp2-/- cerebellum (Ishimura et al., 2016), loss of
Gtpbp1 induced the ISR via activation of GCN2, and deletion of GCN2 in B6J.Gtpbp1-/- mice
resulted in accelerated, and more widespread, neurodegeneration. GCN2 can be activated by
uncharged tRNA that accumulates during amino acid deprivation (Masson, 2019). However,
increases in uncharged tRNA were not observed in the B6J-Gtpbp2-/- cerebellum, suggesting
other mechanisms underlie GCN2 activation (Ishimura et al., 2016). Indeed, recent biochemical
and genetic studies revealed that the P-stalk, a pentameric complex located near the A-site of the
ribosome, interacts with GCN2 and activates it, suggesting that translation elongation defects
may be sensed directly by GCN2 (Harding et al., 2019; Inglis et al., 2019). Activation of the ISR
and its accompanying protective function were observed across multiple neuronal populations in
Gtpbp1-/- and Gtpbp2-/- mice. Interestingly, expression of some ATF4 target genes varied
between types of neurons, suggesting that additional cell type-specific mechanisms, such as
those controlling formation of ATF4 heterodimers, post-translational modifications of ATF4, or
epigenetic regulation of target genes may modulate expression of these genes (Wortel et al.,
2017).
We also show that defects in ribosome pause resolution in the B6J.Gtpbp1-/- and B6J-Gtpbp2-/brain are associated with decreased mTORC1 signaling. In contrast to ISR activation, which
prolonged neuronal survival, inhibition of mTOR signaling negatively affected neuronal survival
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in mutant mice, despite the fact that the observed changes in both of these pathways are
associated with decreased translation initiation. Previous studies showed that during amino acid
starvation of HEK293T cells, reduction of mTOR activity and translation correlated with a
reduction in ribosome pausing (Darnell et al., 2018). While inhibition of mTORC1 may be
beneficial at the level of translation in some instances of ribosome stress, the negative impact we
observe on neuronal survival may reside in the severity or the duration of the stressor and/or the
influence of mTORC1 on other cellular processes including ribosomal RNA processing, gene
transcription, protein degradation, and ribosomal and mitochondrial biogenesis (Laplante and
Sabatini, 2013, 2009; López et al., 2019; Mayer and Grummt, 2006; Puertollano, 2014).
The dramatic downregulation of mTORC1 activity in granule cells of the B6J.Gtpbp1-/- and B6JGtpbp2-/- dentate gyrus relative to other neurons suggests that the cellular context plays a role in
modulating this signaling pathway upon ribosomal stress. A previous study observed increased
mTOR activity in epidermal stem cells upon loss of the ribosome recycling factor Pelo, and
suppression of mTOR signaling partially restored cellular defects in vivo (Liakath-Ali et al.,
2018a). We recently observed that the relatively low levels of ribosome pausing that occur upon
tRNA deficiency (with normal levels of GTPBP1 and GTPBP2) can lead to mTORC1 inhibition
and alter neuronal physiology (Kapur et al., 2020). Together, these data demonstrate that
elongation defects may lead to hyper- or hypoactivity of mTOR signaling and these changes in
mTORC1 appear to negatively modulate cellular homeostasis and survival.
Whether mTORC1 responds directly to translational stress or alterations in this signaling
pathway are due to changes in cellular homeostasis (e.g. amino acid metabolism, energy levels,
or neuronal activity) is unknown, as is the mechanism underlying its cell type-specific response.
Proteomic experiments have revealed mTOR-dependent phosphorylation of translation initiation
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factors and ribosomal proteins. Interestingly, multiple phosphorylation sites were observed on
the surface of the 80S ribosome, suggesting that mTOR or mTOR-associated kinases can access
the ribosome (Jiang et al., 2016). The interaction of mTOR and/or its downstream kinases with
the ribosome may provide a mechanism for mTOR to simultaneously monitor and regulate
translation. Because protein synthesis varies between cell types and changes during development
(Blair et al., 2017; Buszczak et al., 2014; Castelo-Szekely et al., 2017; Gonzalez et al., 2014;
Sudmant et al., 2018), the rate of translation may differentially impact elongation defects and
thus the signaling pathways which control translation.
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CHAPTER 4
MUTATIONS IN DISTINCT TRANSLATION-DEPENDENT QUALITY CONTROL
PATHWAYS LEAD TO CONVERGENT MOLECULAR PATHOGENESIS AND
NEURODEVELOPMENTAL DEFECTS
4.1. Abstract
Translation-dependent quality control pathways such as no-go decay (NGD), non-stop decay
(NSD) and nonsense-mediated decay (NMD) govern protein synthesis and proteostasis by
resolving non-translating ribosomes and preventing the production of potentially toxic peptides
derived from faulty and aberrant mRNAs. However, how translation is altered and the in vivo
defects that arise in the absence of these pathways are poorly understood. Here, we show that the
NGD/NSD factors Pelo and Hbs1l are critical for cerebellar neurogenesis but expendable for
survival of these neurons after development. Analysis of mutant embryonic fibroblasts revealed
translational pauses, alteration of signaling pathways, and translational reprogramming. Similar
effects on signaling pathways, the translatome and cerebellar development were observed upon
deletion of the NMD factor Upf2. These data reveal that these quality control pathways that
function to mitigate errors at distinct steps in translation can evoke similar cellular responses.

4.2. Introduction
Regulation of gene expression is essential for cell growth and development. Although epigenetic
mechanisms and transcriptional regulation are essential steps in gene expression, translation and
its regulation have emerged as major hubs to control the production of functional proteins. In
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fact, translation is intricately coordinated with the degradation of faulty mRNAs and their
resulting peptide products to balance gene expression and proteostasis (Collart and Weiss, 2019).
Numerous studies have revealed that mRNA levels show limited correlation with protein levels,
particularly when cells undergo dynamic transitions (Abreua et al., 2009; Kristensen et al., 2013;
Yansheng Liu et al., 2016; Maier et al., 2009). Indeed, post-transcriptional mechanisms, such as
translation, play vital roles in rapidly altering gene expression and the signaling pathways that
mediate cell identity and cell fate changes necessary for mammalian development (Blair et al.,
2017; Blanco et al., 2016; Fujii et al., 2017; Gabut et al., 2020; Kong and Lasko, 2012;
Rodrigues et al., 2020; Signer et al., 2014; Tahmasebi et al., 2019a).
The process of translation is highly organized, and ribosomes need to accurately perform the
steps of translation initiation, elongation and termination. However, multiple factors can perturb
translation including secondary structures of mRNAs, amino acid limitations, tRNA deficiencies,
rare codons, interactions of nascent peptides with the ribosome, chemically damaged mRNAs,
and cleaved or aberrant mRNAs (Brandman and Hegde, 2016; Brule and Grayhack, 2017; Buhr
et al., 2016; Drummond and Wilke, 2008; Hu et al., 2009; Simms et al., 2014; Spencer et al.,
2012; Thommen et al., 2017; Wolf and Grayhack, 2015; Yu et al., 2015). In turn, these defects
may trigger translation-dependent quality control pathways including non-stop decay (NSD), nogo decay (NGD) or nonsense-mediated mRNA decay (NMD) to release ribosomes, eliminate
potentially toxic or faulty peptide products, and co-translationally decay problematic or aberrant
mRNAs (Collart and Weiss, 2019).
Defects in translation and their translation-dependent quality control pathways impair cellular
homeostasis and have been linked to proteotoxicity, changes in synaptic function, and
neurodegeneration (Choe et al., 2016; Chu et al., 2009; Huang et al., 2017; Ishimura et al., 2014;
59

Johnson et al., 2019; Kapur et al., 2020; Martin et al., 2020; Notaras et al., 2019; Terrey et al.,
2020; Yonashiro et al., 2016). Here, we demonstrate that the ribosome rescue factors Pelo and
Hbs1l, which are implicated in NSD and NGD, are critical for embryonic and brain
development, but dispensable for neuronal survival in the adult brain. Our analysis of Pelo- and
Hbs1l-deficient fibroblasts reveal translational reprogramming of multiple pathways. Inhibition
of NMD via deletion of Upf2 resulted in strikingly similar effects on the translatome, signaling
pathways, and neurogenesis. Our data reveal that defects in translation-dependent quality control
pathways, which mitigate errors in translation to prevent the production of defective peptide
products from aberrant mRNAs, can trigger similar cellular responses and neurodevelopmental
abnormalities.

4.3. Results
4.3.1. Hbs1l is required for embryogenesis. Multiple neurological abnormalities, including
defects in motor control, were recently described in a patient with biallelic mutations in Hbs1l
(O’Connell et al., 2019). Alternative splicing of Hbs1l produces transcripts that encode two
distinct proteins (Figure 10A). Levels of full length Hbs1l (Hbs1l-V1 and Hbs1 in human and
yeast, respectively) were dramatically decreased in Hbs1l patient fibroblasts (O’Connell et al.,
2019). The levels of the shorter isoform II (Hbs1l-V3 in human), which is encoded by the first 4
exons of full length Hbs1l and a unique last exon (‘exon 5a’) located between exon 4 and exon 5
of the Hbs1l locus, were relatively unaffected in the Hbs1l patient fibroblasts (O’Connell et al.,
2019). In contrast to the translation-dependent quality control function of Hbs1l, previous studies
suggested that isoform II of Hbs1l is likely an ortholog of the Saccharomyces cerevisiae protein
SKI7 (Brunkard and Baker, 2018; Kalisiak et al., 2017; Marshall et al., 2018), which is involved
60

in global mRNA turnover (Kalisiak et al., 2017). Although an additional splice variant (Hbs1lV2 in human) which lacks the third coding exon is annotated in the human transcriptome (Mills
et al., 2016; O’Connell et al., 2019), this splice variant is not annotated in mice, and we were
unable to detect it by RT-PCR.
To study the neurological function of Hbs1l in mice, we first examined an Hbs1l allele
(Hbs1ltm1a) with a gene trap cassette inserted between ‘exon 5a’ and exon 5 (Figure 10B). As
previously reported, homozygous Hbs1ltm1a/tm1a mice were viable, but male mice were infertile
(O’Connell et al., 2019). Histological analysis of the Hbs1ltm1a/tm1a testis at postnatal day P45
revealed a dramatic loss of mitotically active (PCNA+) spermatogonia, as well as spermatocytes
and spermatids that normally differentiate from these cells (Figure 10C). However, no overt
defects were observed in the Hbs1ltm1a/tm1a brain (Figure 10D).
Residual levels of Hbs1l were still present in various tissues from Hbs1ltm1a/tm1a mice (O’Connell
et al., 2019). In agreement, Hbs1l transcripts spliced into the gene trap cassette in all tested
tissues; however, correctly spliced Hbs1l transcripts were still detected in several tissues (Figure
10E). Thus, to completely eliminate expression of Hbs1l, we ubiquitously deleted exon 5 in
Hbs1ltm1a mice to generate Hbs1l-/- mice (Figure 10B). In contrast to embryonic day (E) 8.5
Hbs1ltm1a/tm1a embryos, which still expressed 9% of the wild type levels of Hbs1l mRNA,
expression of Hbs1l was not detected in E8.5 Hbs1l-/- embryos (Figure 10F). Expression of
Hbsl1 isoform II was not significantly changed in homozygous embryos of either allele, as
predicted (Figure 10F). In contrast to hypomorphic Hbs1ltm1a/tm1a mice, Hbs1l-/- embryos failed to
develop after E8.5 and could not be recovered at E11.5 (Figure 10G). These results demonstrate
that Hbs1l is necessary for embryonic development, however embryos lacking Hbs1l develop
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longer than embryos deficient for Pelo, the binding partner of HBS1L, which die by E7.5
(Adham et al., 2003) (Figure 10G).
To determine if isoform II of Hbs1l is also necessary for embryonic viability, we utilized an
additional allele (Hbs1lGTC) with a gene trap cassette located in intron 2 (Figure 10B).
Expression of Hbs1l and isoform II transcripts in E8.5 heterozygous Hbs1lGTC/+ embryos was
reduced by 51% and 41%, respectively (Figure 10F). Homozygous Hbs1lGTC/GTC embryos were
not recovered at E6.5 demonstrating that they died even before Pelo-/- or Hbs1l-/- embryos. The
early embryonic lethality of Hbs1lGTC/GTC embryos suggests that the Hbs1l isoforms are likely
functionally distinct, and that their loss causes additive or synergistic defects during
embryogenesis.
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Figure 10. Hbs1l is required for embryogenesis. (A) Domain structure of HBS1L and Isoform
II and the exons encoding the two splice variants. (B) Design of Hbs1l loss-of-function alleles
that target Hbs1l and Isoform II. Hbs1ltm1a allele, Hbs1l specific gene trap (hypomorph);
Hbs1ldelta allele, Hbs1l specific deletion of exon 5 (knock out); and Hbs1lGTC allele, Hbs1l gene
trap to target Hbs1l and isoform II (knock out). (C) Cresyl violet-stained cross-sections of testis
from P45 control (Hbs1ltm1a/+) and Hbs1ltm1a/tm1a mice. Immunofluorescence was performed with
antibodies to proliferating cell nuclear antigen (PCNA, red) and sections were counterstained
with DAPI. (D) Cresyl violet-stained sagittal brain section from 4-month-old control (Hbs1l+/+)
and Hbs1ltm1a/tm1a mice. (E) Splicing analysis of correctly spliced Hbs1l and trapped Hbs1l
transcripts in various tissues from 4-month-old control (Hbs1l+/+) and Hbs1ltm1a/tm1a mice. b-actin
was used as an input control. (F) Quantitative RT-PCR analysis of Hbs1l and isoform II using
cDNA from E8.5 embryos. Data were normalized to Gapdh and the fold change in gene
expression is relative to that of controls (Hbs1l+/+) from each cross. Data represent mean + SEM.
(G) Bright field images of control (Hbs1l+/+ and Pelo+/+), Hbs1l-/- and Pelo-/- embryos at E7.5,
E8.5

and

E10.5.

Scale

bars:

500μm

and

200μm

(higher

magnification),

50μm

(immunofluorescence image) (C); 500μm (D); 100μm (E7.5), 200μm (E8.5), and 2mm (E10.5)
(G). PTC, premature termination codon; Frt, flippase-mediated recombination site; loxP, Cre
recombinase-mediated recombination site; En2(SA), splice acceptor of mouse Engrailed-2 exon
2; SC, spermatocytes; SG, spermatogonia; St, spermatids; LC, Leydig cells. t-tests were
corrected for multiple comparisons using Holm-Sidak method (E). ns, not significant; ** P ≤
0.01; *** P ≤ 0.001.

4.3.2. Hbs1l is required for cerebellar development. Consistent with transcriptome data from a
brain RNA sequencing database (Zhang et al., 2014), we observed expression of Hbs1l in
multiple cell types of the brain (Figure 11A). Expression of HBS1L and its binding partner
PELO was observed throughout and after cerebellar development (Figures 11A to 11C).
However, levels of HBS1L and PELO decreased in the postnatal (P)14 cerebellum after the
completion of development, which was similar to the levels observed in the whole brain (Figures
64

11B, 11C and S16A). To begin to investigate the role of Hbs1l in the brain, we deleted this gene
in the developing cerebellum and midbrain by crossing the floxed allele to En1-Cre (En1cre/+)
mice (Kimmel et al., 2000). Differences in cerebellar size between mutant and control embryos
were already apparent by E13.5 (Figure 11D). Although the trilaminar structure of the
cerebellum appeared normal in En1-Cre; Hbs1lcKO mice at postnatal day P21, cerebellar foliation
was delayed in P0 mutant mice, and secondary fissures failed to form compared to control mice
(Figure 11D) and consistent with previous studies no cerebellar abnormalities were observed in
En1-Cre mice (Dong and Kwan, 2020; Q. Guo et al., 2010; Li et al., 2002; Sgaier et al., 2007;
Tripathi et al., 2008).
Lineage-restricted GABAergic precursors are generated beginning at ~E10.5 from progenitors in
the ventricular zone (VZ) of the developing cerebellum (Ju et al., 2016; Leto et al., 2012). The
pool of progenitors declines as progenitors either exit the cell cycle to generate precursors or
retract from the VZ to form a secondary germinal zone in the prospective white matter to
transition from neurogenesis to gliogenesis (Leto et al., 2012; Vong et al., 2015; Wizeman et al.,
2019). Immunofluorescence with antibodies to the cell cycle-associated protein Ki67
demonstrated a loss of progenitors between E12.5 to E16.5 in both the control and En1-Cre;
Hbs1lcKO cerebella. However, the number of progenitors remained higher in En1-Cre; Hbs1lcKO
compared to control cerebella (Figures 11E and 11F), suggesting that Hbs1l-deficient progenitors
may aberrantly proliferate. In agreement, we observed a higher fraction of VZ-progenitors in Sphase in the E12.5 and E13.5 mutant cerebella by pulse labeling with BrdU for 30 minutes and
performing co-immunofluorescence with BrdU and Ki67 antibodies (Figures S16B and S16C).
Immunofluorescence with antibodies to the M-Phase marker phospho-histone 3 (pH3) and the
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general cell cycle marker PCNA demonstrated an increase of VZ-progenitors also in M-phase in
the mutant cerebellum (Figure S16D).
To test if Hbs1l-deficient progenitors are able to exit the cell cycle, which is necessary to
generate lineage-restricted precursors, we labeled control and mutant embryos at E12.5 or E13.5
with BrdU and then determined the fraction of BrdU+ cells that had left the cell cycle (do not
express Ki67) twenty-four hours after labeling. Fewer VZ-progenitors exited the cell cycle in
En1-Cre; Hbs1lcKO relative to control cerebella (Figures 11G and 11H). Concordantly, the
number of VZ-derived Lhx1/5+ Purkinje cells and Pax2+ interneuron precursors was reduced to
~32% and ~34% in En1-Cre; Hbs1lcKO between E12.5 to E16.5 compared to control cerebella
(Figures 11I, 11J, S16E and S16F), suggesting that Hbs1l deficient VZ-progenitors remain
proliferative at the expense of differentiation.
Cerebellar glutamatergic precursors are generated beginning at ~E10.5 from the rhombic lip
(RL), a germinal zone located in the caudal region of the cerebellar primordia. Between E10.512.5 the RL gives rise to Tbr1+ cells that migrate subpially to take up residence in the nuclear
transitory zone and will develop into deep cerebellar neurons (Fink et al., 2006). Following
Tbr1+ cell production, proliferating granule cell precursors emerge from the RL and form the
external granule cell layer (EGL) (Chung et al., 2010). As observed for VZ-derived neuronal
precursors,

deletion

of

Hbs1l

also

decreased

progeny

generated

from

the

RL.

Immunofluorescence with antibodies to Tbr1, revealed fewer Tbr1+ cells in the E14.5 mutant
cerebella compared to controls (Figure S16G). In addition, the EGL of En1-Cre; Hbs1lcKO at
E13.5 to E16.5 contained only ~45% of the granule cell precursors compared to controls (Figures
S16H and S16I).
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Granule cell precursors that derive from the RL continue to proliferate in the EGL to generate
additional precursors that exit the cell cycle postnatally prior to migrating to the IGL. To
determine if the decrease in granule cell precursors was due to a failure of progenitors in the RL
to generate sufficient numbers of granule cell precursors, or a failure of granule cell precursors to
proliferate, we labeled E12.5 and E13.5 wild type and mutant embryos with BrdU and then
determined the number of BrdU+ cells in the EGL twenty-four hours after labeling. Fewer BrdU+
cells were present in the En1-Cre; Hbs1lcKO EGL compared to that of controls indicating that the
mutant rhombic lip generates fewer granule cell precursors (Figures S16J and S16K). However,
cell cycle exit of these precursors did not vary between mutant and control cells (Figure S16L).
Furthermore, no difference in proliferation (S- and M-phase) was observed when granule cell
precursors were analyzed at E16.5 or P5 (Figures S16M and S16N). Together, these data suggest
that while Hbs1l is required for the initial production of granule cell precursors, it is dispensable
for the subsequent cell cycle progression of these precursors in the EGL. In agreement, genetic
ablation of Hbs1l by Atoh1-Cre which specifically deletes in cerebellar granule cell precursors in
the EGL beginning at ~E16.5 (Lorenz et al., 2011; Pan et al., 2009; Qiu et al., 2010; Wojcinski et
al., 2019), did not impair development of these cells (Figure S17A).
Hbs1l was also required for gliogenesis in the developing cerebellum. Cerebellar gliogenesis
starts at ~E18 and continues during postnatal development during which time progenitors that
have retracted from the VZ switch from a neurogenic to gliogenic fate and produce
oligodendrocytes

and

astrocytes

(Götz

and

Huttner,

2005;

Vong

et

al.,

2015).

Immunofluorescence with antibodies to Olig2, a marker of oligodendroglial progenitors which
gives rise to oligodendrocytes and astrocytes (Chung et al., 2013; Tatsumi et al., 2018), revealed
the number of these cells was reduced in P5 En1-Cre; Hbs1lcKO cerebella (Figure S16O).
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Together these data indicate that Hbs1l is required for the generation of multiple cell types in the
developing cerebellum.
We have previously identified a mutation in the common C57BL/6J (B6J) strain that partially
disrupts processing of the brain-specific arginine tRNA, n-Tr20 (n-Tr20B6J/B6J). This processing
defect in turn reduces the pool of available tRNAArgUCU, leading to ribosome pausing at the Asite at AGA codons in cerebellar mRNAs (Ishimura et al., 2014). Hbs1lcKO mice were generated
with the B6J-associated mutation in n-Tr20. To test if the n-Tr20 deficiency influenced the
developmental defects observed in the absence of Hbs1l, we either restored n-Tr20 to wild type
levels or completely deleted n-Tr20 in Hbs1lcKO mice. Wild type expression of the tRNA (nTr20B6N/B6N) did not rescue defects in En1-Cre; Hbs1lcKO cerebella, nor did complete loss of nTr20 (n-Tr20-/-) cause developmental defects in Atoh1-Cre; Hbs1lcKO cerebella (Figure S17A). In
addition, neither loss of Hbs1l or Pelo affected cell survival of terminally differentiated granule
cells in 9-month-old mice even in the presence of the n-Tr20 deficiency (Figures S17B to S17E),
indicating that Hbs1l and Pelo do not respond to AGA pausing.
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Figure 11. Hbs1l is required for cerebellar development. (A) In situ hybridization of Hbs1l
mRNA (red) on cerebellar sections from E13.5 and P28 control (B6J) mice. Sections were
counterstained with DAPI. (B) Western blot analysis using cerebellar lysates from B6J mice.
Vinculin was used as an input control. (C) The relative protein levels of HBS1L and PELO were
normalized to levels of vinculin and protein levels are relative to those of E16.5 B6J cerebella.
(D) Parasagittal (E13.5) and sagittal (P0 and P21) cerebellar sections from control (Hbs1lfl/+) and
En1-Cre; Hbs1lcKO mice stained with cresyl violet. Higher magnification images of lobules IV/V
at P21 are shown below each genotype. Cerebellar lobules are indicated by Roman numerals. (E)
Immunofluorescence using antibodies to Ki67 (red) on cerebellar section from E14.5 control
(Hbs1l+/+) and En1-Cre; Hbs1lcKO embryos. Sections were counterstained with DAPI and higher
magnification images of boxed area are shown. (F) Number of cerebellar VZ-progenitors (Ki67+
cells) from control (Hbs1l+/+ or Hbs1lfl/+) and En1-Cre; Hbs1lcKO embryos. Data represent mean
+ SD. (G) Immunofluorescence using antibodies to BrdU (green) and Ki67 (red) on cerebellar
sections from E14.5 control (Hbs1lfl/+) and En1-Cre; Hbs1lcKO embryos to determine the fraction
of cells that exited the cell cycle. Embryos were injected with BrdU 24 hours prior to harvest.
(H) Percentage of cerebellar VZ-progenitors that exited the cell cycle (BrdU+, Ki67- cells). Data
represent mean + SD. (I) Immunofluorescence using antibodies to Lhx1/5 on cerebellar sections
from E13.5 control (Hbs1l+/+) and En1-Cre; Hbs1lcKO embryos. Sections were counterstained
with DAPI and higher magnification images of boxed areas are shown. (J) Number of cerebellar
Purkinje cell precursors (Lhx1/5+ cells). Data represent mean + SD. Scale bars: 100μm and
20μm (higher magnifications) (A); 200μm (E13.5 and P0), 500μm and 50μm (higher
magnification) (P21) (D); 100μm and 20μm (higher magnification) (E); 20μm (G); 100μm and
50μm (higher magnification) (I). VZ, ventricular zone; NTZ, nuclear transitory zone; RL,
rhombic lip; EGL, external granule cell layer; ML, molecular cell layer; PL, Purkinje cell layer;
GCL, granule cell layer; IC, inferior colliculus. t-tests were corrected for multiple comparisons
using Holm-Sidak method (C, F, H, J). ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤
0.001.
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4.3.3. Ribosome pausing correlates with pathology in Hbs1l-deficient mice. To determine if
the developmental defects that occur upon loss of Hbs1l are accompanied by alterations in
translation elongation, we performed ribosome profiling on wild type and Hbs1l-/- embryos at
E8.5. Ribosome protected fragments (RPF) mapped primarily to the protein coding sequence of
genes in both wild type and mutant embryos (Figure 12A). Using the previously described
methodology (Ishimura et al., 2014), we found a total of ~1300 sites with significant (z-score ≥
10) increases in local ribosome occupancy (‘ribosome pauses’) in wild type and mutant embryos
(Figure 12B). About 40% of the ribosome pauses, which mapped to 319 genes, were shared
between genotypes suggesting they occurred independently of the loss of Hbs1l. Ten percent of
ribosome pauses (mapped to 107 genes) were found only in wild type embryos. Differential gene
expression analysis of the translatome using the ribosome protected fragments (DE RPF)
indicated translation of these genes was decreased in mutant embryos (Figure 12C), which may
contribute to the apparent specificity of these pauses to wild type embryos. Strikingly, 50% of
ribosome pauses (mapped to 459 genes) were uniquely observed in Hbs1l-/- embryos and like
other pauses, occurred primarily in protein coding sequences. Similar to the metagene (Figure
12A), we did not observe genotype-dependent differences in the ribosome occupancy in different
gene regions (i.e. untranslated 5’ or 3’ region). Only 9% of genes associated with Hbs1l-/-specific ribosome pauses were differentially translated in Hbs1l-/- embryos (DE RPF Hbs1l-/-)
and translation of 26 genes and 15 genes was decreased and increased, respectively (Figure
S18A).
Loss of Hbs1l did not affect survival of granule cells (Figures S17B and S17C), which constitute
the vast majority of the cellular content of the cerebellum. Thus, to determine if elongation
defects correlate with pathogenesis in Hbs1l mutant tissues, we also performed ribosome
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profiling on the cerebellum of P14 control and Atoh1-Cre; Hbs1lcKO mice. We observed more
ribosome pausing sites (~2700) in the cerebellum than in embryos, likely due to the higher
amount of input RNA and sequencing depth. Consistent with the lack of a genetic interaction
between the Hbs1l and the n-Tr20 mutation, no significant increase in ribosome occupancy on
A-site AGA codons was observed in Hbs1l-/- cerebella. Unlike the high percentage of pauses that
were unique to Hbs1l-/- embryos, only 2% of ribosome pauses (mapped to 69 genes) were unique
to the mutant cerebellum (Figure 12B). In addition, the z-scores (‘pause scores’) for Hbs1lspecific pauses were significantly higher in mutant embryos than the mutant cerebellum (Figure
S18B).
Mutant embryos also exhibited larger changes in the translatome (DE RPF) than the mutant
cerebellum (Figure S18C), indicating that defects in translation also correlate with pathology.
Kyoto Encyclopedia of Genes and Genomes (KEGG) and Ingenuity Pathway Analysis (IPA) of
differentially translated genes (DE RPF Hbs1l-/-, adj. P ≤ 0.05) in Hbs1l-/- embryos revealed that
downregulated genes were significantly enriched for heart/cardiac muscle contraction and
calcium signaling (Figures S18D and S18E). In agreement, upstream regulator analysis predicted
downregulation of multiple transcription factors required for heart development (Cui et al., 2018;
Molkentin et al., 1997; Muñoz-Martín et al., 2019; Steimle and Moskowitz, 2017) (Figure 12D).
Together these data suggest that HBS1L deficiency may cause defects in the embryonic heart,
one of the first organs to begin developing in the mouse embryo.
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Figure 12. Ribosome pausing correlates with pathology in Hbs1l deficient mice. (A)
Metagene profiles of RPFs from E8.5 control (Hbs1l+/+, grey traces) and Hbs1l-/- (red traces)
embryos. (B) Analysis of significantly increased local ribosome occupancy (z-score ≥ 10, pause
site detected in all three replicates) from E8.5 wild type (Hbs1l+/+) and Hbs1l-/- embryos (left) or
P14 control (Atoh1-Cre; Hbs1l+/+) and Atoh1-Cre; Hbs1lcKO cerebella (right). The number of
genes that pause sites map to is shown below for each genotype. (C) All translated genes (DE
RPF Hbs1l-/-) from E8.5 Hbs1l-/- embryos were compared to the translation of genes which
contained pauses specific to either Hbs1l-/- or wild type embryos. Downward direction of arrow
indicates significant reduction in translation of pausing genes in E8.5 Hbs1l-/- embryos relative to
wild type embryos. (D) Identification of upstream regulators using Ingenuity Pathway Analysis
(IPA) of differentially translated genes of E8.5 Hbs1l-/- embryos (DE RPF Hbs1l-/-).
Transcription factors that are involved in heart development are shown in red. Downward
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direction of arrow indicates predicated activity (downregulation) of transcription factors. RPFs,
ribosome-protected fragments; nts, nucleotides. Wilcoxon rank-sum test was used to determine
statistical significance (C).

4.3.4. Loss of Pelo/Hbs1l alters translation regulation and reprograms the translatome. Our
embryonic data suggested that defects in translation modulate the translatome. Because Pelo-/embryos could not be profiled due to their early embryonic lethality, we conditionally deleted
Pelo or Hbs1l in primary mouse embryonic fibroblasts (MEFs) using a tamoxifen-inducible Cre
transgene (CAG-CreER) to compare changes in translation upon loss of Pelo and Hbs1l (Figure
13A). Consistent with previous studies (Juszkiewicz et al., 2020b; O’Connell et al., 2019),
deletion of Hbs1l was accompanied by decreased levels of PELO protein, but not its mRNA
levels (Figures 13B, S19A to S19C). In addition, we found deletion of Pelo also led to the loss of
HBS1L without altering Hbs1l mRNA levels, suggesting protein degradation of PELO or
HBS1L occurs in the absence of either interacting partner (Figures 13B, S19A to S19C).
To analyze defects in translation elongation, we performed ribosome profiling of tamoxifentreated control (CAG-CreER), Pelo-/- (CAG-CreER; PelocKO), and Hbs1l-/- (CAG-CreER; Hbs1lcKO)
cells. Analyzing the ribosome occupancy in Pelo-/- and control cells revealed ~10,000 sites with
significant (z-score ≥ 10) increases in local ribosome occupancy which mapped to 4,693 genes
(Figure 13C). One percent of these ribosome pauses were only observed in control cells
(‘control-pauses’), 57% were shared between control and Pelo-/- cells, and 42% were specific to
Pelo-/- cells (‘Pelo-/--pauses’). In contrast, analysis of Hbs1l-/- and control cells revealed fewer
ribosome pauses (~4,200 - mapping to 1,807 genes) and only 5% were specific to Hbs1l-/- cells
(‘Hbs1l-/--pauses’) (Figures 13C). In addition to the fewer ribosome pause sites, the z-scores
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(‘pause scores’) for Hbs1l-/--pauses were also significantly lower than those of Pelo-/--pauses
(Figure 13D). Approximately 80% of the Hbs1l-/--pausing genes also had pauses in Pelo-/- cells,
however only 30% of the ribosome pauses occurred at the same pause site (Figure 13E).
Together, these data suggest that the loss of Pelo or Hbs1l leads to translation elongation defects,
but particularly severe defects are observed in the absence of Pelo.
The Dom34:Hbs1 complex has been implicated in multiple translation-dependent quality control
pathways including non-stop decay (NSD) (Collart and Weiss, 2019; Simms et al., 2017). This
pathway rescues ribosomes stalled at the ends of truncated mRNAs, ribosomes in polyAsequences on prematurely polyadenylated mRNAs that lack a termination codon, or ribosomes in
the 3’UTR of mRNAs that were not recycled at canonical stop codons (Arribere and Fire, 2018;
D’Orazio et al., 2019; Guydosh and Green, 2014; Mills et al., 2017; Young et al., 2015).
Examination of Pelo-/-- and Hbs1l-/--pauses revealed that ~92% of pauses mapped to the proteincoding region of transcripts. The remaining local increases in ribosome occupancy were
similarly split between the 5’ and 3’UTRs. Although the frequency of pauses in the 3’UTR was
similar for mutant specific, control specific and shared pauses, the frequency of control-specific
pauses that mapped to the 5’UTR was increased and those in the coding region were decreased
(Figure S19D). Thus, consistent with our observation in Hbs1l-/- embryos, these data suggest that
neither loss of Hbs1l nor Pelo in MEFs led to enrichment of ribosomes in the 5’ or 3’UTR.
We also searched for RPFs containing untemplated stretches of adenosines (A) at the 3’end
indicative of ribosomes extending into the poly(A) tail of premature polyadenylated mRNAs.
Ribosomes did not protect more then 15 consecutive A’s (Figure S19E) suggesting that like in
yeast, the poly(A) tract does not extend beyond the P-site of the ribosome (Guydosh and Green,
2014). Interestingly, we observed a significantly higher fraction of these 3’end A reads in Pelo-/75

compared to control cells (Figure S19F), supporting a role for Pelo in rescuing ribosomes in
polyA tails (D’Orazio et al., 2019; Guydosh and Green, 2017, 2014). However, the fraction of
those reads did not significantly increase in Hbs1l-/- MEFs (Figure S19F), Hbs1l-/- embryos
(Student’s t-test, P = 0.4621) or Hbs1l-/- cerebella (Student’s t-test, P = 0.3269).
In addition to NSD, Dom34:Hbs1 is implicated in ribosome rescue during No-Go decay (NGD),
a quality control pathway in which ribosome stalling is evoked due to stretches of rare codons,
secondary mRNA structures, amino acid starvation, or tRNA deficiency. NGD may trigger
endonucleolytic cleavage of mRNAs due to ribosome collision, leading to 5’RNA intermediates
that lack a stop codon and are then targeted by Dom34:Hbs1 via NSD (D’Orazio et al., 2019;
Doma and Parker, 2006; Glover et al., 2020). Studies in Drosophila and C. elegans revealed that
RNA intermediates that converge onto NSD may also be generated through additional
mechanisms including RNA interference (RNAi) and nonsense-mediated decay (NMD)
(Arribere and Fire, 2018; Hashimoto et al., 2017).
To determine if loss of Pelo or Hbs1l alters the frequency of ribosome pauses that are associated
with potential targets such as NMD targets, we mapped pauses to unique coding transcripts,
which is generally difficult due to the short nature of RPFs. Indeed, only a fraction (~30%) of
Pelo-/- and Hbs1l-/--pauses could be assigned to unique coding transcripts (1,518 and 95,
respectively). Of these transcripts, ~8% were classified as NMD transcripts and ~92% were
protein-coding transcripts. A similar percentage of pauses mapping to NMD transcripts (~6.5%)
was observed when we analyzed transcripts, which contained ribosome pauses shared between
either control and Pelo-/- cells, control and Hbs1l-/- cells, or control-specific pausing transcripts
(Figure S19G). In addition, transcriptome analysis of MEFs revealed that NMD transcripts
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represented ~6% of expressed transcripts. These data suggest that loss of Pelo or Hbs1l did not
lead to enrichment of ribosome pauses on transcripts predicted to undergo NMD.
Our observation that ribosome pausing is more dramatic in Pelo-/- than Hbs1l-/- cells correlates
with the earlier lethality of Pelo-/- embryos. To get a broader perspective of whether the loss of
Pelo impacts other aspects of translation more than the Hbs1l deficiency, we analyzed at first the
translational efficiency (TE) of genes by normalizing the abundance of ribosomal footprint reads
to that of the RNA sequencing reads. In Pelo-/- cells about 35% (4,884) of genes displayed
significant (adj. P ≤ 0.05) alterations in TE compared to control cells. The TE of 57% of these
genes was increased and for 43% it was decreased. In contrast, the TE of only 4% of genes (314,
60% up- and 40% downregulated) was significantly changed in Hbs1l-/- cells and genes with
differential translational efficiency only showed a moderate correlation between Hbs1l-/- and
Pelo-/- cells (Pearson’s correlation, r = 0.3739). The TE of Pelo-/--specific pausing genes
increased, but this effect was less for Hbs1l-/--specific pausing genes (Figure S20A), suggesting
that elongation defects maybe more dramatic in Pelo-/- cells as a result of the increase in
translation of these genes.
In addition to its greater impact on the TE of genes, the loss of Pelo also had a stronger impact
on gene translation in general as evidenced by the differential expression of ribosome-protected
fragments (DE RPF) (Figure S20B). While Hbs1l deficiency altered translation of 26% (3,445)
of genes, the loss of Pelo affected translation of 34% (4,965) of genes and led to significantly
greater fold changes in gene expression in Pelo-/- cells (Wilcoxon test, P < 2.2e-16). However,
differentially translated genes between Pelo-/- (DE RPF Pelo-/-) and Hbs1l-/- (DE RPF Hbs1l-/-)
cells were strongly correlated (Figure S20C), indicating that, although loss of Hbs1l may lead to
smaller alterations in translation, most of the changes occur in the same direction.
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In addition, 20% (1,060) and 2% (70) of the differentially translated genes in Pelo-/- and Hbs1l-/cells also contained ribosome pauses specifically found in Pelo-/- and Hbs1l-/- cells, respectively,
and translation of these pausing genes was both increased and decreased (Figure S20B).
However, changes in expression were under 2-fold for the majority of Pelo-/-- and Hbs1l-/-pausing genes (88% of Pelo-/-- and 93% of Hbs1l-/--pausing genes) and these changes were
significantly lower compared to those in genes without mutant-specific pauses (Figures S20B
and S20D). Thus, similar to Hbs1l-/- embryos, these data suggest that most of the translational
changes in gene expression are not due to an increase in the ribosome occupancy but are likely a
response to changes in mRNA expression and/or translation regulation.
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Figure 13. Loss of Pelo induces greater defects in translation elongation then loss of Hbs1l.
(A) Experimental strategy for in vitro studies using tamoxifen (4-OHT) treatment of primary
mouse embryonic fibroblasts (MEFs). (B) Western blot analysis of HBS1L and PELO using
MEF lysates from tamoxifen-treated control (Hbs1lfl/+ or Pelofl/fl), Hbs1l-/- and Pelo-/- cells.
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Vinculin was used as an input control. (C) Analysis of significantly increased local ribosome
occupancy (z-score ≥ 10, pause site detected in all three replicates) from tamoxifen treated
control (CAG-CreER) and Pelo-/- (left), or control and Hbs1l-/- cells (right). The number of genes
that pause sites map to is shown below for each genotype. (D) Comparison of the z-scores
(‘pause score’) for pauses observed in Pelo-/- (blue) and Hbs1l-/- (red) cells. Downward direction
of arrow indicates significant lower pause scores of Hbs1l-/-- compared to Pelo-/--specific pauses.
(E) Examples of mapped footprints (27-34 nucleotides) on genes from tamoxifen treated control
(CAG-CreER, grey) and Pelo-/- (blue), or control and Hbs1l-/- (red) cells. Upward direction of
arrow indicates significant increase in local ribosome occupancy and the dashed line indicates
the pause site. 4-OHT, 4-hydroxytamoxifin; nts, nucleotides; rpm, reads per million. Wilcoxon
rank-sum test was used to determine statistical significance (D).

Interestingly, we observed an opposing relationship between transcriptional expression changes
(DE mRNA) and changes in translational efficiency (TE) of many genes in Pelo-/- and Hbs1l-/cells (Figure 14A). KEGG pathway analysis of genes with this opposing behavior revealed
enrichment of several pathways (ribosome, ribosome biogenesis, RNA transport, spliceosome,
cell cycle and lysosome) that overlapped with those of differently translated genes (DE RPF)
(Figures 14B and S20E), suggesting that expression of genes in these pathways is translationally
regulated, perhaps to restore homeostasis between the transcriptome and translatome.
To identify signaling pathways that might control these changes in translation regulation upon
loss of Pelo/Hbs1l, we performed IPA analysis on differentially transcribed (DE mRNA) genes
and genes with altered translation efficiency (TE). EIF2 and mTOR/p70S6K signaling, both of
which are known to regulate translation, were highly enriched in Pelo-/- cells but less enriched in
Hbs1l-/- cells (Figures 14C and S20F). Phosphorylation of eIF2α decreases translation initiation,
while the activity of mTOR, in particular mTORC1 (mechanistic target of rapamycin complex
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1), increases translation initiation and elongation. About 50% of the differentially regulated
genes identified by IPA overlapped between the two pathways and therefore, we assessed the
phosphorylation status of p-eIF2αS51 and p-p70S6T389, a known target of mTORC1, to determine
if one or both signaling pathways were affected. Levels of p-eIF2αS51 in Pelo-/- cells were
unchanged from those of control cells (Figures 14D and 14E). However, levels of p-p70S6T389
were significantly increased in Pelo-/- cells, indicating activation of mTOR signaling (Figures
14D and 14E). In agreement, the TE of genes that are known to be translationally regulated by
mTORC1 via their 5’terminal oligopyrimidine motifs (5’TOP) (Yamashita et al., 2008) was
significantly increased in Pelo-/- and Hbs1l-/- cells, although this increase was less pronounced in
the latter (Figure 14F). Activation of mTORC1 may underlie some of the observed gene
expression changes (DE RPF) given its role as a positive regulator for ribosome biogenesis and
translation of ribosomal genes and a negative regulator of lysosomal biogenesis and autophagy
(Kim et al., 2011; Mayer and Grummt, 2006; Puertollano, 2014; Rabanal-Ruiz and Korolchuk,
2018; Roczniak-Ferguson et al., 2012), which parallels the directionality of the changes in these
pathways (Figure S20E).

81

Figure 14. Pelo/Hbs1l deficiency alters translation regulation and reprograms the
translatome. (A) Translational efficiency (TE) of genes that are transcriptionally upregulated or
downregulated was compared to the remaining (‘other’) genes from Pelo-/- (blue) and Hbs1l-/(red) MEFs, respectively. Downward direction of arrows indicates significant decrease in
translational efficiency of transcriptionally upregulated genes in Pelo-/- and Hbs1l-/- MEFs.
Upward direction of arrows indicates significant increase in translational efficiency of
transcriptionally downregulated genes in Pelo-/- and Hbs1l-/- MEFs. (B) KEGG pathway analysis
of genes from Pelo-/- MEFs in which the translational efficiency (TE Pelo-/-, adj. P ≤ 0.05) is
opposite to their transcriptional expression (DE mRNA Pelo-/-, q-value ≤ 0.05). Italicized
pathways indicate pathways that overlapped with enriched pathways of differentially translated
genes in Pelo-/- MEFs (DE RPF Pelo-/-, adj. P ≤ 0.05) (Figure S6E). The red dashed line indicates
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the significance threshold (P = 0.05). (C) Ingenuity pathway analysis (IPA) of genes with
differential translational efficiency from Pelo-/- (TE Pelo-/-) and Hbs1l-/- (TE Hbs1l-/-) MEFs.
EIF2 and mTOR/p70S6K signaling are in italics. The red dashed line indicates the significance
threshold (P = 0.05). (D) Western blot analysis of p-eIF2aS51 and p-p70S6KT389 using lysates of
tamoxifen-treated control (Pelofl/fl) and Pelo-/- MEFs at Day 2 (Passage P1). Vinculin was used
as an input control. (E) Levels of p-eIF2aS51 or p-p70S6KT389 were normalized to total level of
eIF2a or p70S6K, and phosphorylation levels are relative to those of control (Pelofl/fl). Data
represent mean + SD. (F) Translational efficiency (TE) of genes with translational regulation by
mTOR via their 5’TOP motif was compared to the remaining (‘other’) genes from Pelo-/- (blue)
and Hbs1l-/- (red) MEFs. Upward direction of arrows indicates significant increase in
translational efficiency of 5’TOP genes. 4-OHT, 4-hydroxytamoxifin; 5’TOP, 5’terminal
oligopyrimidine motif. Student’s t-test (E); Wilcoxon rank-sum test was used to determine
statistical significance (A, F). ns, not significant; ** P ≤ 0.01.

4.3.5. Convergent modulation of the translatome in cells with defects in translationdependent quality control pathways. Our findings suggest that translational reprogramming
occurs upon loss of Pelo/Hbs1l. However, whether these changes are unique to Pelo/Hbs1l or
reflect a more general cellular response upon impairment of translation-dependent quality control
pathways is unclear. To investigate this possibility, we conditionally deleted the core NMD
component, Upf2, in MEFs (Lelivelt and Culbertson, 1999; Serin et al., 2001). In contrast to
NGD and NSD that resolve ribosomes on mRNAs impeding translation elongation, nonsensemediated decay (NMD) targets aberrant mRNAs (e.g. mRNAs containing a premature
termination codon) for degradation during translation (Karousis and Mühlemann, 2019; Schuller
and Green, 2019). Consistent with the function of Upf2 in NMD, about 20% and 13% of
upregulated transcripts (DE mRNA Upf2, q-value ≤ 0.05) were NMD transcripts or transcripts
with retained introns, respectively (Figure S21A). Although the accumulation of these transcripts
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was specific to Upf2

-/-

cells (Figures S21A and S21B), we observed an inverse relationship

between transcriptional gene expression changes (DE mRNA Upf2) and changes in translational
efficiency (TE Upf2) in Upf2-/- cells as we did in Pelo-/- and Hbs1l-/- cells (Figure 15A).
Surprisingly, IPA analysis on differentially transcribed (DE mRNA Upf2-/-) genes and genes with
altered translation efficiency (TE Upf2-/-) revealed enrichment for EIF2 and mTOR signaling in
Upf2-/- as observed in Pelo-/- and Hbs1l-/- cells (Figures 15B and S21C). Western blot analysis
revealed the level of p-eIF2αS51 in Upf2-/- cells was unchanged from that of controls, but pp70S6T389 levels and translation of 5’TOP genes were significantly increased (Figures 15C to
15E), indicating that mTORC1 is activated in Upf2-/- cells. Although translation of ribosomal
genes was increased, transcriptional levels of ribosomal genes were decreased in Upf2-/- similar
to Pelo-/- cells (Figure 15F), further supporting that mTORC1 activation may be a general
response in an attempt to restore cellular homeostasis in Upf2-/- and Pelo-/- cells.
Surprisingly, most of the top upstream regulators including TP53, MYC, TGFB1, ERBB2,
CDKN1A, HRAS and NFKBIA were shared between Upf2-/- and Pelo-/- cells (Figure 15G) and
genes with differential translational efficiency were strongly correlated between Upf2-/- and Pelo/-

cells (Pearson’s correlation, r = 0.6576). Furthermore, differentially translated genes in Upf2-/-

(32% of genes, DE RPF Upf2-/-) and Pelo-/- (34% of genes, DE RPF Pelo-/-) cells also showed a
strong linear correlation (Figure 15H), indicating that defects in these quality control pathways
may not only lead to similar changes in translation regulation (TE) but also in global gene
translation (DE RPF). Consistent with the similar changes in translation, KEGG pathway
analysis of differentially translated genes (DE RPF, adj. P ≤ 0.05) revealed similar enrichment of
multiple pathways in Upf2-/-, Pelo-/- and Hbs1-/- cells (Figure 15I).
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In contrast with the many ribosome pauses we observed specifically in Pelo-/- cells, only 4% of
all ribosome pausing events observed in Upf2-/- and control cells were uniquely found in Upf2-/cells (Figure S21D). Although, only a small fraction (8%) of Pelo- and Hbs1l-specific pausing
transcripts corresponded to NMD transcripts, we considered the possibility that some of the
protein-coding transcripts with ribosome pauses in Pelo-/- and Hbs1l-/- cells may also be NMD
sensitive given that 5-10% of mRNAs even without premature termination codons are thought to
be degraded by the NMD pathway (He et al., 2003; Jaffrey and Wilkinson, 2018; Lelivelt and
Culbertson, 1999; Mendell et al., 2004). However, upregulation of these protein-coding pausing
transcripts was not observed in Upf2-/- cells (Figure S21E), suggesting that these pausing
transcripts are not NMD sensitive. Together, these findings suggest that while Pelo/Hbs1l and
Upf2 largely function in distinct quality control pathways, disruption of either pathway results in
similar translational gene expression changes.
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Figure 15. Defects in different translation-dependent quality control pathways similarly
alter translation regulation and the translatome. (A) Translational efficiency (TE) of genes
that are transcriptionally upregulated or downregulated was compared to the remaining (‘other’)
genes from Upf2-/- (green) MEFs. Downward direction of arrows indicates significant decrease in
translational efficiency of transcriptionally upregulated genes in Upf2-/- MEFs. Upward direction
of arrows indicates significant increase in translational efficiency of transcriptionally
downregulated genes in Upf2-/- MEFs. (B) Ingenuity pathway analysis (IPA) of differentially
transcribed genes from Upf2-/- MEFs (DE mRNA Upf2-/-). EIF2 and mTOR/p70S6K signaling
are in italics. The red dashed line indicates the significance threshold (P = 0.05). (C) Western
blot analysis of p-eIF2aS51 and p-p70S6KT389 of lysates from tamoxifen-treated control (Upf2fl/+)
and Upf2-/- MEFs at Day 2 (Passage P1). Vinculin was used as an input control. (F) Levels of peIF2aS51 or p-p70S6KT389 were normalized to total level of eIF2a or p70S6K, and
phosphorylation levels are relative to those of control (Upf2fl/+) MEFs. Data represent mean +
SD. (E) Translational efficiency (TE) of genes those translation is regulated by mTOR via their
5’TOP motif was compared to the remaining (‘other’) genes from Upf2-/- (green) MEFs. Upward
direction of arrows indicates significant increase in translational efficiency of 5’TOP genes. (F)
Differential transcription (DE mRNA) or translational efficiency (TE) of ribosomal protein genes
(small and large ribosomal subunit) was compared to the remaining (‘other’) genes from Pelo-/(blue), Upf2-/- (green) and Hbs1l-/- (red) MEFs. Up- and downward direction of arrow indicates
significant up- and downregulation of ribosomal protein genes, respectively. The heatmap
indicates the gene expression changes of ribosomal protein genes. (G) Identification of upstream
regulators of genes with differential translational efficiency in Upf2-/- (TE Upf2-/-) and Pelo-/- (TE
Pelo-/-) MEFs. Top ten transcription factors are shown. Those enriched in both Upf2-/- and Pelo-/MEFs and shown in red. Up- or downward direction of arrow indicates predicated up- or
downregulation of transcription factors, respectively. (H) Differentially translated genes in Upf2/-

MEFs (DE RPF Upf2-/-, adj. P ≤ 0.05, x-axis, green) were plotted against genes that are

differentially translated in Pelo-/- MEFs (DE RPF Pelo-/-, adj. P ≤ 0.05, y-axis, blue). Genes those
translation was significantly different in both Upf2-/- and Pelo-/- MEFs are shown in purple. (I)
KEGG pathway analysis of differentially translated (up- and downregulated) genes (DE RPF,
adj. P ≤ 0.05) in Upf2-/- (green), Pelo-/- (blue) and Hbs1l-/- (red) MEFs. Significantly (P ≤ 0.05)
enriched pathways are shown and pathways in bold indicate pathways that are shared between
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any of the mutant MEFs. Pathways known to be positively and negatively regulated by mTORC1
are in red. 4-OHT, 4-hydroxytamoxifin; 5’TOP, 5’terminal oligopyrimidine motif. Student’s ttest (D); Wilcoxon rank-sum test was used to determine statistical significance (A, E, F); Pearson
coefficient (r) was determined to analyze linearity of gene expression changes (H). ns, not
significant; ** P ≤ 0.01.

4.3.6. Deletion of Upf2 or Pelo cause similar cerebellar developmental defects. Intrigued by
the similar changes in translation upon impairment of Upf2 and Pelo/Hbs1l in MEFs, we
conditionally deleted Upf2 during cerebellar development to determine if phenotypic similarities
exist upon loss of these different translation-dependent quality control pathways. Surprisingly,
deletion of Upf2 (En1-Cre; Upf2cKO) or Pelo (En1-Cre; PelocKO) using En1-Cre resulted in
largely indistinguishable defects with a grossly hypoplastic cerebellum and regions of the
midbrain (superior and inferior colliculus) being nearly absent unlike in En1-Cre; Hbs1lcKO mice
(Figures 16A and 11D). Both Upf2 and Pelo mutant pups died shortly after birth, perhaps due to
En1-Cre deletion of these genes in other cell types (Britz et al., 2015; Kimmel et al., 2000; Sapir
et al., 2004; Sgaier et al., 2007; Wurst et al., 1994).
Similar neurogenesis defects were observed in the Upf2 and Pelo mutant cerebellum. The
fraction of ventricular zone (VZ) progenitors that remained in the cell cycle was higher in E13.5
Upf2- or Pelo-deficient cerebella compared to controls (Figures S22A and S22B), indicating that
like Hbs1l, loss of Upf2 or Pelo impairs cell cycle exit of VZ-progenitors. Inversely, the number
of VZ-derived precursors, e.g. Purkinje cells (Lhx1/5+ cells) and Pax2+ interneurons were
reduced by ~83% and ~90% in the En1-Cre; Upf2cKO and En1-Cre; PelocKO cerebellum (Figures
S22C to S22F). Glutamatergic cerebellar neurons (Tbr1+) were nearly absent in the E13.5 En1Cre; Upf2cKO and En1-Cre; PelocKO cerebellum (Figures S22G and S22H). In addition, the EGL
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was missing in En1-Cre; Upf2cKO and En1-Cre; PelocKO cerebella at both E13.5 and P0 (Figures
S22I and 16A), indicating that neurogenesis defects are particularly more severe in the absence
of Upf2 or Pelo relative to those observed upon Hbs1l loss.
Thus, we considered that in addition to cell cycle exit abnormalities, cell death might also
contribute to impaired cerebellar development. Indeed, the number of apoptotic cells (Casp3+
cells) was significantly increased in the En1-Cre; Upf2cKO and En1-Cre; PelocKO cerebellum
compared to that of controls or En1-Cre; Hbs1lcKO embryos, and apoptotic cells were observed in
both the ventricular zone and the prospective white matter where progenitor-derived progeny
reside (Figures S22J and S22K). Together, these data suggest that defects in cell cycle exit and
increased cell death likely impair cerebellar development in Upf2 and Pelo mutant mice. To
determine if loss of Upf2 or Pelo also increased mTORC1 signaling in the developing
cerebellum as it did in MEFs, we analyzed levels p-S6S240/244, a known downstream target of
mTORC1. In agreement, levels of p-S6S240/244 were significantly increased in the En1-Cre;
Upf2cKO and En1-Cre; PelocKO cerebellum, including the VZ (Figure S22L and S22M).
Because loss of Upf2 or Pelo severely impaired early granule cell neurogenesis, we investigated
if these genes are also required later in the development of these cells. Conditional deletion of
either Upf2 or Pelo using Atoh1-Cre resulted in abnormalities of the anterior lobes of the
cerebellum in P21 mice (Figure 16B). These lobes were reduced in length and Purkinje cells
failed to form a monolayer. In contrast, the posterior lobes appeared unaffected, possibly due to
the anterior-to-posterior gradient of Cre expression in granule cell precursors in the developing
cerebellum (Pan et al., 2009; Qiu et al., 2010; Wojcinski et al., 2019).
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During postnatal cerebellar development, granule cell precursors in the outer region of the EGL
(oEGL) exit the cell cycle and transiently reside in the inner EGL (iEGL) before migrating to the
internal granule cell layer (IGL). To determine if granule cell precursors in postnatal Atoh1-Cre;
Upf2cKO or Atoh1-Cre; PelocKO cerebellum properly exited the cell cycle, we labeled granule cell
precursors with BrdU to determine the fraction of precursors that exited the cell cycle twentyfour hours later (BrdU+; Ki67- cells). In P6 control cerebella, BrdU-labeled granule cell
precursors that were negative for Ki67 formed a distinct layer on the ventral surface of the EGL
consistent with the appearance and location of the iEGL (Legué et al., 2016) (Figure 16C).
However, no clear separation between the oEGL and iEGL was observed in the anterior lobes in
Atoh1-Cre; Upf2cKO or Atoh1-Cre; PelocKO cerebella (Figure 16C), and the fraction of granule
cell precursors that exited the cell cycle (BrdU+; Ki67- cells) in these lobes, but not posterior
lobes, was significantly lower compared to control or Atoh1-Cre; Hbs1lcKO cerebella (Figure
16D). Correspondingly, the number of terminally differentiated granule cells in the IGL (NeuN+
cells) of the anterior, but not posterior, lobes was reduced by ~45% in P6 Atoh1-Cre; Upf2cKO
and Atoh1-Cre; PelocKO cerebella (Figure 16E), indicating that both of these genes are necessary
for differentiation of granule cell precursors.
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Figure 16. Loss of Upf2 and Pelo cause similar cerebellar developmental defects. (A)
Parasagittal (E13.5) and sagittal (P0) cerebellar sections of control (Pelofl/fl), En1-Cre; Upf2cKO
and En1-Cre; PelocKO mice stained with cresyl violet. (B) Sagittal cerebellar sections of P21
control (Pelofl/fl), Atoh1-Cre; Upf2cKO and Atoh1-Cre; PelocKO mice stained with cresyl violet.
Higher magnification images of lobule VI are shown below for each genotype. Cerebellar
lobules are indicated by Roman numerals. (C) Immunofluorescence with antibodies to BrdU
(green) and Ki67 (red) on sections of P6 control (Atoh1-Cre; Upf2fl/+), Atoh1-Cre; Upf2cKO and
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Atoh1-Cre; PelocKO cerebellum. Mice were injected with BrdU 24 hours prior to harvest to
determine the fraction of granule cell precursors in the EGL that exited the cell cycle. Images are
shown for anterior (IV/V) and posterior (IX) lobules. (D) Quantification of the fraction of
granule cell precursors in the EGL (lobules IV/V and IX) that exited the cell cycle (BrdU+, Ki67cells) of control (Atoh1-Cre; Upf2fl/+), Atoh1-Cre; Upf2cKO, Atoh1-Cre; PelocKO and Atoh1-Cre;
Hbs1lcKO mice. Data represent mean + SD. (E) Quantification of terminally differentiated
granule cells (NeuN+ cells) in the IGL in lobules IV/V and IX of control (Atoh1-Cre; Upf2fl/+),
Atoh1-Cre; Upf2cKO, Atoh1-Cre; PelocKO and Atoh1-Cre; Hbs1lcKO mice. Data represent mean +
SD. Scale bars: 200μm (E13.5) and 500μm (P0) (A); 500μm and 20μm (higher magnification)
(B); 50μm (C). VZ, ventricular zone, EGL, external granule cell layer; NTZ, nuclear transitory
zone; SC, superior colliculus; IC, inferior colliculus; ML, molecular cell layer; PL, Purkinje cell
layer; GCL, granule cell layer; oEGL, outer external granule cell layer; iEGL, inner external
granule cell layer; IGL, internal granule cell layer. Two-way ANOVA was corrected for multiple
comparisons using Tukey method (D, E). ns, not significant; *** P ≤ 0.001; **** P ≤ 0.0001.

4.4. Discussion
Translation-dependent quality control pathways govern protein synthesis and proteostasis by
degrading aberrant mRNAs that result in potentially toxic peptide products. However, little is
known about the in vivo defects that arise in the absence of these pathways and how translation is
altered in the absence of these pathways. To interrogate these questions, we investigated the
translational and phenotypic alterations from different translation-dependent quality control
pathways including the NSD/NGD (Pelo/Hbs1l) and the NMD (Upf2) pathways.
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Here we show that Pelo/Hbs1l are both critical for embryonic and cerebellar development but
dispensable after cerebellar development of granule cells in mice. In addition, loss of Pelo or
Hbs1l locally increases the ribosome occupancy (‘ribosome pauses’) of genes. Interestingly, the
number and strength of these pauses were higher in E8.5 Hbs1l-/- embryos, just prior to the time
when these embryos cease developing, compared to the postnatal cerebellum, where loss of
Hbs1l had no effect on cerebellar granule cells. Together these data suggest that this translationdependent quality control pathway may be needed in cell- and/or tissue-specific manner.
In agreement with the differential severity between Pelo-/-- and Hbs1l-/--mediated defects during
embryonic and cerebellar development, pauses were higher and more frequent in Pelo-/- MEFs
and coincided with greater changes in gene expression than in Hbs1l-/- MEFs. Loss of Pelo
induced greater translation elongation defects compared to its binding partner Hbs1l, which may
be in part be influenced by differences in gene expression and translational efficiency between
Pelo and Hbs1l deficient cells. However, additional factors may also play a role. For example,
deletion of either Pelo or Hbs1l led to a reduction of their respective binding partners, the
kinetics of this decrease upon deletion of Pelo or Hbs1l is unknown and may not be equal. In
addition, Dom34 (Pelo) promotes dissociation of ribosomes by Rli1 (Abce1) and this activity
increased in the presence of Hbs1 (Hbs1l) (Pisareva et al., 2011; Shoemaker and Green, 2011).
Hence, we cannot rule out a scenario in which the remaining levels of PELO in Hbs1l-/- cells
might be able to mitigate and/or delay elongation defects even in the absence of Hbs1l.
Most of the ribosome pauses in Pelo- and Hbs1l-deficient tissues or cells were located in the
coding sequence. Although these pauses with a footprint length 27-34 nucleotides could indicate
ribosomes that paused during translation, phenotypes in Hbs1l and Pelo mutant mice were not
dependent on the B6J-associated mutation in n-Tr20 that introduces genome-wide AGA pausing
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within mRNAs. Instead, these pauses may reflect pausing of the ‘trailing’ ribosomes upstream of
the ‘lead’ ribosome that reached the 3’end of truncated mRNAs (Guydosh et al., 2017; Guydosh
and Green, 2014). Footprints of the ‘lead’ ribosome have been analyzed on an exosome-deficient
background (Arribere and Fire, 2018; D’Orazio et al., 2019; Glover et al., 2020; Guydosh and
Green, 2014), and its short length of 15-18 nucleotides makes it difficult to uniquely map these
footprints in mammals with their larger genomes. Regardless, recent biochemical studies have
demonstrated that the Pelo/Hbs1l complex rescues trapped ribosomes near the 3’end of truncated
mRNAs but is not necessary for the resolution of internally stalled ribosomes within the mRNA
(Juszkiewicz et al., 2020a), which is consistent with early biochemical and structural studies
demonstrating that Dom34:Hbs1 preferentially rescues ribosomes arrested at sites of truncation
(Hilal et al., 2016; Pisareva et al., 2011; Shoemaker and Green, 2011).
RNA intermediates that converge on Pelo/Hbs1l may derive from endonucleolytic cleavage for
example during NMD, RNAi or NGD (Arribere and Fire, 2018; D’Orazio et al., 2019; Doma and
Parker, 2006; Eberle et al., 2009; Hashimoto et al., 2017). However, most of the Pelo-/-- and
Hbs1l-/--pausing transcripts were not NMD sensitive, suggesting that if pausing occurred on
truncated mRNAs, many of the RNA intermediates likely derived from additional mechanisms.
Endonucleolytic cleavage of mRNAs may occur upon persistent ribosome collision during NGD
(D’Orazio et al., 2019; Doma and Parker, 2006; Shoemaker and Green, 2012). Intriguingly,
widespread ribosome collision has been observed under normal conditions and may present 10%
of the pool of translating ribosomes (Arpat et al., 2020; Diament et al., 2018; Han et al., 2020;
Meydan and Guydosh, 2020). Numerous human mRNAs are subject to repeated, co-translational
endonucleolytic cleavages and this process is similar to NGD, but independent of NMDassociated nucleases (Ibrahim et al., 2018). Because translation changes during development and
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varies between cell types (Blair et al., 2017; Buszczak et al., 2014; Castelo-Szekely et al., 2017;
Gonzalez et al., 2014; Sudmant et al., 2018), RNA intermediates that are generated during
translation may also vary and thereby, could introduce a need for quality control pathways in a
tissue- and/or cell type-specific manner.
We also observed that loss of Pelo/Hbs1l was associated with the activation of mTORC1
signaling. mTORC1 activation was previously observed in Hbs1l patient derived fibroblasts
(O’Connell et al., 2019) and upon deletion of Pelo during epidermal development (Liakath-Ali et
al., 2018b). Interestingly, inhibition of translation/mTORC1 partially prevented Pelo-/--mediated
epidermal defects (Liakath-Ali et al., 2018b). How mTORC1 responds to loss of Pelo/Hbs1l is
unknown. Multiple mTOR-dependent phosphorylation sites on the surface of the ribosome have
been observed, suggesting that mTORC1 and/or mTORC1-associated kinases interact with the
ribosomes and might provide a mechanism to detect changes in translation elongation (Jiang et
al., 2016). However, changes in levels of ribosomal genes and/or impaired ribosomal biogenesis
also activate mTORC1 signaling (R. Liu et al., 2014). Indeed, deletion of Pelo/Hbs1l led to
decreased transcript levels but increased translation of ribosomal genes. Thus, mTORC1 may be
activated to compensate for decreases in expression of these genes rather than directly sensing
defects in translation elongation. To test whether mTORC1 activation was specific to Pelo/Hbs1l
deficiency or was generally associated with defects in translation-dependent quality control
pathways, we examined MEFs deficient for Upf2, an essential component of the NMD pathway.
Loss of Upf2 also led to decreased expression and increased translation of ribosomal genes and
mTORC1 activation, supporting that changes in mTORC1 signaling are not a direct consequence
of the elongation defects, but likely occurs as a compensatory response.
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In general, impairment of either translation-dependent quality control pathway led to strikingly
similar alterations in gene expression with Pelo and Upf2 showing the most changes compared to
Hbs1l. Reminiscent of these changes, loss of Pelo or Upf2 had remarkably similar effects on
multiple cerebellar neuronal populations during early embryonic and late postnatal neurogenesis,
causing comparable morphological defects in the cerebellum (e.g. inhibition of differentiation
and increase in cell death). Growing evidence highlights the role of mTOR in the decision of
stem cells to self-renew or differentiate (Meng et al., 2018; Xiang et al., 2011). However,
increased mTOR activity generally reduces self-renewal and promotes differentiation of neuronal
stem/progenitor cells (Hartman et al., 2013; Licausi and Hartman, 2018; Magri et al., 2011; Way
et al., 2009), suggesting that likely other molecular changes contributed to the observed defects
in neurogenesis.
The similarities in gene expression and developmental alterations in mice deficient for these
translation-dependent quality control pathways suggest a convergence of molecular and cellular
pathology. In fact, several changes in gene expression and signaling pathways were altered in the
same direction in mutant cells. Thus, phenotypic changes could be due to either a change in a
single molecular pathway or interactions of multiple pathways. For example, Myc activation was
predicted as an upstream regulator of gene expression in both Pelo-/- and Upf2-/- but less in
Hbs1l-/- MEFs. Myc functions as a switch between proliferation and differentiation during
cerebellar development (Knoepfler et al., 2002; Ma et al., 2015; Wey et al., 2010), in which loss
of Myc allows precursors to exit the cell cycle and to undergo differentiation, while maintained
Myc expression retains cells in the proliferation cycle. Intriguingly, previous studies revealed that
depletion of NMD factors inhibited differentiation of embryonic stem cells, which coincided

96

with sustained Myc expression and its downregulation released the differentiation blockage in
NMD deficient cells (Li et al., 2015).
How different translation-dependent quality control pathways can lead to similar changes in
translation and cellular defects is unclear. Recent studies in yeast demonstrated that impairment
of these quality control mechanisms (Hbs1, Dom34, Upf1, Upf2, Ski7 and Ski8) caused protein
aggregation (Jamar et al., 2018). Protein misfolding occurred co-translationally on highly
translated genes and the aggregated proteins overlapped between the different mutant strains.
These data suggest that increased translation and protein aggregation may be common properties
among different quality control mutants (Jamar et al., 2018). Perhaps, regardless of specific
targets of various quality control pathways, defects in protein folding, clearance of defective
peptide products, and/or defects in mRNA decay may trigger similar cellular responses leading
to similar phenotypes.
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CHAPTER 5
CONCLUSIONS AND PERSPECTIVES
Aberrant translation has emerged as a common feature of neurodevelopmental and
neurodegenerative diseases (Bosco, 2018; Chen et al., 2019; Kapur et al., 2017). Impairment of
translation is generally considered an attractive disease mechanism because of the growing list of
disease-linked mutations that affect translation and translational fidelity. However, similar to
mutations in humans, we show that while defects in translation are deleterious for neuronal
homeostasis, these defects may occur in a cell-type specific manner or are critical either during
or post neurodevelopment. As a consequence, it raises the question to what extent aberrant
translatomes have specific changes to evoke such distinctive phenotypes. This question is further
accentuated when defects in translation are associated with specific pathologies outside of the
nervous system.
This apparent paradox of translational defects to evoke seemingly specific pathologies, has often
led to the suggestion that cellular impairment maybe inflicted by mechanisms other than
translation. This notion is supported by the discovery that components of the translation
machinery have evolved non-canonical functions mediated by alternative splicing, posttranslational modifications, changes of subcellular localization (e.g. extracellular or nuclear
localization) or the addition of appended domains. However, an alternate possibility is that celltype and tissue specific defects caused by disruption of ubiquitously expressed genes may reflect
a mechanism of differential cell-type susceptibility. In this scenario, the crosstalk between the
disease-associated gene (e.g. impact of mutation) and other factors (e.g. linear or parallel
pathways) will dictate which cells are able to tolerate the burden of translational defects and in
turn, gives rise to tissue-specific pathologies. In this last chapter, we will discuss mechanisms
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that may influence cell-type and tissue vulnerability for aaRS-mediated diseases and
ribosomopathies.

Over the past two decades, numerous mutations in 37 human aaRSs have been identified of
which dominant mutations (mono-allelic, gain-of-function) in 6 ct-aaRSs (cytoplasmic aaRSs)
are linked to peripheral neuropathy (Charcot-Marie-Tooth disease, CMT), while autosomal
recessive mutations (bi-allelic, loss-of-function) causing multisystem disorders are linked to 14
ct-aaRS and 17 mt-aaRS (mitochondrial aaRS) (Boczonadi et al., 2018; Meyer-Schuman and
Antonellis, 2017; Wei et al., 2019). Mutations in human aaRSs impede yeast growth in
complementation tests, which supported early on an impairment of gene function and/or
translation as a plausible disease mechanism (Meyer-Schuman and Antonellis, 2017).
While mutations in aaRSs generally cause a wide range of disorders (e.g. affecting heart, muscle,
liver and lung tissue), with the increasing discovery of aaRS associated mutations a more
compressive picture emerges in which mutations in different aaRS genes can cause overlapping
phenotypes. Virtually all mutations affect the nervous system, suggesting that tissue
susceptibility may in part be influenced by the metabolic and energy demand of these cells
(Boczonadi et al., 2018; Meyer-Schuman and Antonellis, 2017; Sissler et al., 2017). Autosomal
dominant mutations in aaRSs are specifically associated with peripheral neuropathy and
recessive mutations are commonly linked to leukoencephalopathy (hypo- or demyelination),
epilepsy, neuronal hearing loss and intellectual disability (Boczonadi et al., 2018). While the
precise disease mechanism may be different between the two modes of inheritance, perhaps
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within each the group or at least in the case of recessive mutations an impairment of translation
might be the underlying disease mechanism.
Patients with recessive mutations in aaRSs are homozygous for missense mutations, compound
heterozygous for two different missense mutations or for one missense mutation and one null
allele. Because of the essential function of aaRSs, it is likely that recessive mutations only reduce
their function as opposed to causing a complete loss of activity. Indeed, recessive mutations in
aaRSs often exhibit compromised aminoacylation activity (e.g. impaired binding of ATP, amino
acid or tRNA), affect protein folding, stability, dimerization and/or editing activity (MeyerSchuman and Antonellis, 2017; Sissler et al., 2004).
Multiple synthetases utilize editing mechanisms including post-transfer editing. However, posttransfer editing can occur in cis or trans, depending on whether hydrolysis of the
misaminoacylated tRNA is mediated before it is released from the synthetase or after the release
via resampling of the misaminoacylated tRNA by the aaRS (Ling et al., 2009b; Mohler and Ibba,
2017; Tawfik and Gruic-Sovulj, 2020). In addition, cross-editing may also occur in which
misaminoacylated tRNAs are corrected by a completely different tRNA synthetase (e.g. between
AlaRS and ThrRS) (Chen et al., 2020). Whether disease-associated mutations in aaRSs affect
these editing mechanisms is in many cases unclear. In general, what exact aspect of translation
and the degree to which mutations in aaRSs impair translation is often unknown (MeyerSchuman and Antonellis, 2017). Impairment of translation maybe the consequence of
aminoacylation deficiency, which could directly affect translation elongation and/or editing
deficiency that causes mistranslation.
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A homozygous mutation in mice, referred to as sticky mutant mice because of their unkempt
coat, was identified in the editing domain of ct-AlaRSA734E. This mutation specifically impairs
pre-transfer editing and causes a moderate increase (~2-fold) in mischarging of tRNAAla with
serine, resulting in mistranslation, protein aggregation and cerebellar Purkinje cell degeneration
(Lee et al., 2006). In contrast, mice homozygous for the mutation in ct-AlaRSC723A, which
increases mischarging by ~15-fold, die during embryonic development (Y. Liu et al., 2014).
Compound heterozygous mice with the sticky mutation and either the severe AlaRSC723A
mutation or a loss of function allele displayed cardiac fibrosis in addition to Purkinje cell loss (Y.
Liu et al., 2014). These experiments in mice highlight that loss-of-function mutations in ct-aaRSs
can evoke pathologies outside of the brain including the heart that coincide with the severity of
editing defects. The editing efficacy can be modulated through trans-editing either by specific
missense mutations or by lowering levels of mutant aaRS. Nevertheless, the interplay and
expressivity of the bi-allelic mutations, which seems particularly relevant for the function of
aaRSs is often neglected in human pathologies. However, a trans-acting mechanism could apply
to mutations in human aaRSs. For example, recessive mutations in human mt-AlaRS are linked
to two different phenotypic diseases: (1) severe fatale infantile cardiomyopathy that is associated
with recurrent mutations in mt-AlaRSR592W or mt-AlaRSR580W, which drastically impairs protein
stability of mt-AlaRS and (2) late-onset leukoencephalopathy with varying mutations in mtAlaRS (Euro et al., 2015; Fine et al., 2019; Meyer-Schuman and Antonellis, 2017; Sommerville
et al., 2019). In contrast, recessive mutations in ct-AlaRS are only linked to leukoencephalopathy
(Meyer-Schuman and Antonellis, 2017; Szpisjak et al., 2017).
The severity of translational defects that influence cell-type vulnerability may not only be
regulated by the mutations in aaRSs but also by additional mechanisms (e.g. linear or parallel
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pathways). For example, ANKRD16 binds directly to the catalytic domain of AlaRSA734E,
preventing misaminoacylation of Ser-tRNAAla and thereby, mistranslation, protein aggregation
and Purkinje cell degeneration in sticky mutant (AlaRSA734E) mice. Interestingly, ANKRD16 by
itself or when together with a completely editing deficient AlaRS1-455, is unable to prevent
misaminoacylation of Ser-tRNAAla, highlighting that ANKRD16 can stimulate editing but this
effect may depend on the intrinsic editing activity of AlaRS. A similar interplay is observed on
the phenotypic level, mice homozygous with a severe editing mutation (ct-AlaRSC723A) die
embryonically (Y. Liu et al., 2014), while the sticky mutation (ct-AlaRSA734E) causing mild
editing defects only leads to embryonic lethality upon deletion of ANKRD16.
Interestingly, introducing the equivalent mutations in the mt-AlaRS causes embryonic lethality
regardless of the editing mutation (Hilander et al., 2018). ANKRD16 is not localized in
mitochondria, which has been similarly observed in cell lines (SubCellBarcode (Orre et al.,
2019) and thereby, supplies an editing mechanism that is only available for the cytoplasmic
system. Thus, expressivity and perhaps even the subcellular localization of editing factors may
provide new mechanisms to decipher cell-type and tissue specific vulnerabilities.
Similar to AlaRS, expression of ANKRD16 is not restricted to neurons (brain RNA database
(Zhang et al., 2014)) or even the nervous system. Although conditional deletion of ANKRD16
caused cell death of neurons that usually do not degenerate in the sticky brain, disease
progression differed between the various ANKRD16-deleted sticky neuron populations. For
example, deletion of ANKRD16 in embryonic progenitor cells of the ventricular zone, which
give rise to ANKRD16-deficient Purkinje cells and interneurons of the molecular layer, led to
death of both cell types in the sticky cerebellum. However, loss of Purkinje cells occurred more
rapidly compared to the loss of neurons in the molecular layers. In addition, even though the
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deletion of ANKRD16 occurred during cerebellar development of sticky mice, defects were only
observed after cerebellar development in postmitotic, terminally differentiated neurons,
indicating that likely additional factors contribute to the disease specific pathologies.
ANKRD16 is vertebrate specific protein and therefore, this editing pathway has only been
recently added to the repertoire of editing mechanisms for AlaRS. In contrast, the autonomous
trans-editing factors DTD (D-aminoacyl-tRNA deacylase 1 and 2) and AlaXp (Alanyl-tRNA
synthetase domain containing 1) are found in all eukaryotes. Eukaryotic DTD and AlaXp have
been shown to edit misaminoacylated Gly-tRNAAla and Ser-tRNAAla, respectively (Ahel et al.,
2003; Nawaz et al., 2011; Pawar et al., 2017). Glycine mischarging by AlaRS occurs more
frequently because of its smaller size compared to serine. Surprisingly, DTD hydrolyzes GlytRNAAla about four times more efficiently than AlaRS does (Pawar et al., 2017), highlighting the
potency of autonomous trans-editing factors. In addition to misaminoacylation of non-cognate
amino acids (glycine and serine) onto tRNAAla, AlaRS may also aminoacylate non-cognate
tRNAThr with alanine (Ala-tRNAThr) a mechanism that is specific to the eukaryotic AlaRS (Sun
et al., 2016a). Although, ThrRS is able to hydrolyze Ala-tRNAThr via cross-editing (Chen et al.,
2020), metazoans have an additional trans-editing factor known as ATD (Animalia-specific
tRNA deacylase) that is also able to edit mistakes of incorrect tRNAThr selection by AlaRS
(Kuncha et al., 2018). However, in which cell types or tissues these trans-editing factors act and
how these various editing pathways interact together in vivo is still unclear. Similar questions
remain open for trans-editing factors that have been discovered for other aaRSs including ThrRS
and ProRS (An and Musier-Forsyth, 2005; Korencic et al., 2004; Wong et al., 2003).
Thus, mutations may have varying impacts on aminoacylation activity, editing activity (e.g. preand post-transfer editing) and with that may differentially impact other editing mechanisms (e.g.
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trans- and cross-editing). In addition, parallel pathways that respond to translational defects may
also influence disease pathologies. For example, comparable mt-AspRS deficiency in heart and
skeletal muscle tissues of mice, led specifically to the activation of stress responses in the heart
that included increased expression of mitochondrial proteases (e.g. CLPP) and targets of the
mitochondrial unfolded protein response (UPRMT) (Dogan et al., 2014). The lack of stress
response activation in skeletal muscle tissue was owed to a higher proteostatic capacity (Dogan
et al., 2014), indicating that tissues use different mechanisms to cope with mt-AspRS mediated
defects. CLPP had been initially linked to the activation of the UPRMT (Haynes et al., 2007).
However, genetic inhibition of CLPP in the mt-AspRS deficient heart did not impair activation
of UPRMT (Seiferling et al., 2016). Nevertheless, it led to a strong reduction of faulty peptides
caused by the mt-AspRS deficiency and mitigated mitochondrial respiratory defects and
cardiomyopathy in the mt-AspRS deficient heart (Seiferling et al., 2016). Although the role of
CLPP in protein quality control is still under investigation (Nouri et al., 2020), these experiments
highlight that pathways that respond to translational defects may occur in a cell-type specific
fashion and “activation” of these responses (e.g. increased expression of CLPP in the mt-AspRS
deficient heart) may increase vulnerability of specific cell types. This observation is reminiscent
of our studies with the ribosome rescue factors GTPBP1 and GTPBP2. Although, tRNA-induced
ribosome stalling affected both hippocampal dentate gyrus and cerebellar granule cell neurons,
inhibition of mTOR signaling occurred specifically in DG neurons and this inhibition impaired
neuronal survival. Thus, interrogating pathways that respond to translational insults in
differentially affected cells may also shed light on cell-type susceptibility and disease specific
pathologies.

105

Along with aaRS-mediated diseases, ribosomopathies are another group of disorders in which a
cohort of related translational components causes tissue-specific pathologies in humans.
Ribosomopathies are caused by loss-of-function mutations or haploinsufficiency of genes
involved in ribosomal biogenesis that can be classified based on the affected step of ribosome
production such as (1) pre-rRNA transcription/modification for Treacher-Collins Syndrome (e.g.
mutations in Treacle ribosome biogenesis factor 1, RNA polymerase I subunit C and D, RNA
polymerase I complex selectivity Factor I), (2) pre-rRNA processing for North American Indian
childhood cirrhosis and Labrune Syndrome (e.g. mutations in small nucleolar ribonucleoprotein
complexes), and (3) ribosome assembly for Diamond Blackfan anemia (e.g. mutations in 18
Ribosomal proteins) and Shwachman Diamond syndrome (e.g. mutations in Ribosome
maturation protein SBDS) (Farley-Barnes et al., 2019; Kampen et al., 2020; Lee et al., 2014;
Warren, 2018). Although, ribosome function is essential for all cells, disrupting the process of
ribosome biogenesis and assembly causes diverse developmental disorders with tissue-specific
pathologies (Armistead and Triggs-Raine, 2014). Generally, ribosomopathies can affect both
neural crest and non-neural crest derived tissues, and defects include cardiomyopathy,
craniofacial

and

pigmentation

defects,

neuronal

hearing

loss,

microcephaly,

leukoencephalopathy, bone marrow failure and/or anemia (Farley-Barnes et al., 2019; Kampen et
al., 2020; Tahmasebi et al., 2019b).
Signaling pathways that are activated in response to ribosomal defects have been considered
early on as factors for disease pathologies (Kampen et al., 2020). Impairment of ribosome
biogenesis increases P53 activity and impedes cellular function (Ferreira-Cerca and Hurt, 2009;
Fumagalli et al., 2012; Lindström and Nistér, 2010; Yong Liu et al., 2016; Serrano, 2012).
Interestingly, deletion of P53 rescues ribosomopathy associated phenotypes in experimental
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models (Fumagalli et al., 2009; Griffin et al., 2015; Watt et al., 2018; Zhao et al., 2014). Whether
P53 activation occurs in a cell type specific manner and thereby, increases susceptibility of
specific cell types is still under investigation but this seems plausible as P53 deletion cannot
rescue all disease associated phenotypes (Aspesi et al., 2014; Provost et al., 2012; Tourlakis et
al., 2015; Wan et al., 2016).
The general agreement for ribosomopathies is that mutations in ribosomal proteins (RPs) or
genes that regulate ribosomal biogenesis impair ribosome assembly and mostly lead to moderate
reductions in ribosomal protein levels and global protein synthesis. How moderate changes in
ribosomal protein levels could be the initial driver for impaired cellular homeostasis is still
puzzling. In this regard, the concepts of either specialized ribosomes or ribosome concentration
have recently been re-proposed as possible mechanisms but these two models may not be
mutually exclusive (Farley-Barnes et al., 2019). However, in the model of specialized ribosomes,
ribosome composition is thought to differ within individual cells and different tissues and
thereby, ‘specialized’ ribosomes due to their cell and tissue specific composition would only
translate certain mRNAs. Consequently, loss of a ‘specialized’ ribosome would not affect all
tissues nor global translation but instead impair translation of specific genes and cause tissue
specific pathologies (Farley-Barnes et al., 2019; Kondrashov et al., 2011; Shi et al., 2017; Sulima
and Dinman, 2019). Ribosome heterogeneity, which has been observed in bacteria, yeast and
mammalian cells, could in principle occur through changes in rRNA sequence, ribosomal protein
composition, rRNA modifications, post-translational modifications of ribosomal proteins and/or
by binding of additional proteins (Komili et al., 2007; Mills and Green, 2017; Simsek et al.,
2017; Spence et al., 2000; Werner et al., 2015; Yu et al., 2009). Although this concept is
intriguing, the mammalian ribosome is composed of 80 ribosomal proteins (Anger et al., 2013)
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and mutations in ~25% of RPs have been identified over the last ten years and all are linked to
Diamond Blackfan anemia (Yong Liu et al., 2016), bolstering a more general disease
mechanism.
Thus, an additional model was proposed and is commonly referred to as the ribosomal protein
concentration model. Multiple studies revealed that levels of ribosomal protein vary by three- to
ten-fold among different tissues (Gupta and Warner, 2014; Kim et al., 2014). Thus, some cell
types or tissues may be more vulnerable to changes in the levels of ribosomal proteins than
others. In addition, moderate reductions in ribosome concentration could differentially affect
protein synthesis of genes based on their intrinsic rate of translation initiation, which has been
modeled by using ribosome footprint profiling and proteomics data (Mills and Green, 2017).
Lowering the cellular ribosome concentration would have little impact on genes with high rates
of translation initiation (e.g. housekeeping genes, ribosomal genes, metabolism genes) since
maintaining protein levels is strongly driven by re-loading ribosomes. Other the other hand, it
will be more challenging for genes (e.g. transcription factors) with intrinsically lower initiation
rates to compete for available ribosomes and maintain protein levels when levels of ribosomal
proteins are lower. This idea is exemplified in heterozygous mutations in RPs of Diamond
Blackfan anemia patient cells which show reduced translation of GATA1, a key erythroid
transcription factor (Khajuria et al., 2018; Ludwig et al., 2014). Increasing protein levels of
GATA1 reduced erythroid defects in these patient cells (Khajuria et al., 2018; Ludwig et al.,
2014). Thus, cell types or tissues with intrinsically lower translational activity of either specific
genes or perhaps in general, maybe more susceptible to small changes in the levels of ribosomes.
Interestingly, overexpression of DOM34 (Pelo) rescued growth defects in yeast strains with
mutations in ribosomal genes (Bhattacharya et al., 2010). Similarly, exogenous expression of
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PELO/HBS1L rescued impaired protein expression of hemoglobin as a result of RPS19 depletion
in mammalian cells (Mills et al., 2016). These experiments not only suggest a link between
ribosomal defects and ribosome recycling but also shift the ribosome concentration model
towards a scenario in which the fraction of translationally available ribosomes might be more
relevant than the actual ‘total’ concentration of ribosomes (Mills and Green, 2017). Thus,
mechanisms that aim to liberate ribosomes and increase the proportion of available ribosomes for
translation could provide an additional basis for cell type susceptibility when levels of ribosomal
proteins are reduced.

The model of ribosome protein concentration particularly at the level of translationally active
ribosomes may also apply, at least in part, to phenotypes observed in mutants of ribosome rescue
factors. In ribosome recycling deficient mouse models such GTPBP2, GTPBP1 and
PELO/HBS1L, pausing was observed on hundreds of genes, but had generally little or no impact
on their overall translation levels, suggesting that ribosome pausing on these specific genes is
likely not the major driver for cellular defects. For example, loss of HBS1L dramatically
increased ribosome pausing during embryonic development but only ~9% of pausing genes
showed changes in translation. Interestingly, transcription factors and genes involved in heart
development were translationally downregulated. Perhaps, embryonic lethality may similarly be
influenced by defects of genes with low translational activity, in which the failure of liberating
ribosomes elsewhere to maintain a circulating pool of ribosomes impairs translation of more
vulnerable genes (e.g. transcription factors for heart development). Moreover, inducing
elongation defects in cell types that are linked to ribosomopathies by genetically deleting
ribosome rescue factors, could provide a strategy to interrogate the molecular changes in
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translation and to decipher the impact of possible disease mechanisms (e.g. ‘specialized’
ribosomes and ribosomal protein concentration).

The cellular consequences and cell-type specific pathologies surrounding components of the
translational machinery may not be broadly explainable by the loss of a specific function, or
simply by a specific change in translation and protein synthesis but perhaps by cell-type specific
differences in compensatory mechanism that fail to restore homeostasis. These compensatory
mechanisms might include allelic interactions, the activity of translational control pathways and
stress response pathways that arise upon defects in translation. In the future, the systematic
examination of translational alterations and their response pathways in various affected and
unaffected tissues might untangle questions about cell-type susceptibility and cell-type specific
pathologies in human disease.
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Figure S1: Identification of Ankrd16 as a genetic modifier of the B6J.Aarssti/sti mutation. (A)
Three- to four-month-old Aarssti/sti mice from crosses to inbred strains, and the numbers affected
with ataxia and Purkinje cell degeneration. (B) Location of Msti relative to microsatellite
markers. cM, centimorgan. (C) Nonsynonymous SNPs in Msti candidate genes. The amino acids
and position are shown at the top of the table with the B6 residue listed first. (D) RT-PCR
analysis of Ankrd16 transcripts from cerebellar cDNA prepared from C57BL/6J and CAST/Ei
mice. Note, the alternative Ankrd16 transcript containing exon 5’ (see Figure 2C) amplified by
primers to exon4/6 or exon 5/7 was present in cDNA from C57BL/6J but not CAST/Ei mice,
whereas the alternative transcript detected by exon1/3 primers was present in cDNA from both
strains. (E) RT-PCR analysis of Ankrd16 transcripts from cerebellar cDNA prepared from
C57BL/6J, CAST/Ei, Aarssti/sti, and MstiCAST/CAST; Aarssti/sti mice. Note, the alternative Ankrd16
transcript containing exon 5’ (see Figure 2C) amplified by exon 5/7 or 3/5’ primers was present
in cDNA from C57BL/6J and Aarssti/sti, but absent in the presence of CAST/Ei derived Msti
(CAST/Ei and MstiCAST/CAST; Aarssti/sti mice). (F) Sequence of the SNP-containing region in
intron 5 of Ankrd16. Capital letters indicate novel exon 5’ and lower-case letters indicate intron
5. The SNP in non-rescuing strains is shown in red. (G) Western blotting analysis of ANKRD16
from cerebellar lysates. Note that the expression of ANKRD16 is reduced in C57BL/6J and
Aarssti/sti mice relative to mice with CAST/Ei derived Msti (CAST/Ei and MstiCAST/CAST; Aarssti/sti
mice) (mean ± SD, One-way ANOVA (Tukey correction), **** p ≤ 0.0001). (H) Protein levels
of AlaRS and ANKRD16 were determined by western blotting using various mouse tissues from
C57BL/6J and B6 congenic mice heterozygous for the Msti region (MstiCAST/B6). GAPDH is
included as a loading control. Note the increase in ANKRD16 levels in MstiCAST/B6 tissues,
whereas AlaRS levels do not change between genotypes. (I) PCR results of genomic DNA from
B6 transgenic mouse lines Tg25L9-19 and Tg25L9-46, which carry the CAST/Ei BAC.
Polymorphic markers, which differentiate between C57BL/6J and CAST/Ei were used as shown.
(J) Amino acid sequence comparison of ANKRD16 from various species with the C57BL/6J
strain shown. Non-synonymous SNPs distinguishing CAST/Ei and C57BL/6J are shown in
yellow and serinylated lysines are shown in red.
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Figure S2: Verification of interaction between ANKRD16 and AlaRS in vitro. (A) Peptide
and spectral counts of all proteins co-immunoprecipitated (Co-IP) in Ankrd16-myc mice but not
detected in non-transgenic control tissue. (B) HEK293T cells were transiently co-transfected
with Myc-tagged constructs for mouse Aars, AarsA734E, the Aars aminoacylation domain (AAD),
and FLAG-tagged Ankrd16. Co-IP experiments were performed with ANKRD16-FLAG as the
bait protein. (C) Reciprocal Co-IP experiments were performed by transiently co-transfecting
HEK293T cells with HA-tagged constructs for mouse Aars or AarsA734E and the FLAG-tagged
Ankrd16. HA-AlaRS proteins were used as bait for pull down. (D) Domain structure of mouse
ANKRD16 and ANKRD29. HEK293T cells were transiently transfected with FLAG-tagged
constructs for mouse Ankrd16, Ankrd29, and the HA-epitope tagged Aars. Co-IP experiments
were performed with HA-AlaRS as bait protein. (E) Various domain protein products of AlaRS
(human) as indicated were bacterially expressed, purified, and incubated with GST-ANKRD16.
GST-pull down products and input were immunoblotted with anti-His or anti-GST antibodies.
Asterisks indicate protein degradation products. (F) Binding dynamics were determined between
mouse wild type or mutant AlaRS and mouse wild type or mutant ANKRD16 using
SwitchSENSE (mean ± SD).
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Figure S3. Analysis of the effects of ANKRD16 on steps of translation. (A) Preassembled
ternary complex containing either Ser-tRNAAla or Ala-tRNAAla was mixed with 70S initiation
complex (IC) programmed with codon GCU in the A site, aliquots were transferred at various
times to quench solution (0.5 M KOH), and products were resolved by eTLC. (B) Incubation of
full-length AlaRS with preassembled EF-Tu•GTP•Ser-tRNAAla prevents fMet-Ser formation.
EF-Tu•GTP•Ser-tRNAAla ternary complex and 70S IC were each preassembled. In reaction
scheme 1, AlaRS was incubated with EF-Tu•GTP•Ser-tRNAAla for 15 min, 70S IC was added,
and aliquots were removed at various times for eTLC analysis. In contrast (reaction scheme 2),
AlaRS was incubated with the 70S IC for 15 min, followed by addition of EF-Tu•GTP•SertRNAAla, and aliquots were removed at various times for eTLC analysis. (C) Deacylated tRNAAla
was mixed with AlaRS, serine, ATP, and all other components to form ternary complex, aliquots
were transferred at various time points to the 70S IC, and dipeptide products were resolved by
eTLC. t = 0 (control reactions in the absence of AlaRS); * (oxidized fMet). Note, without alanine
supplementation (B and C), trace amounts of fMet-Ala are detected, likely due to AlaRS-bound
alanyl-AMP during protein purification. (D) Deacylation of [3H]Ser-tRNAAla by mouse wildtype AlaRS or AlaRSA734E in the presence or absence of ANKRD16 (mean ± SD, One Phase
Decay model [R2AlaRSWT

= 0.9892; R2AlaRSA734E

= 0.991; R2AlaRSWT/ANKRD16

= 0.9872;

R2AlaRSA734E/ANKRD16 = 0.9902; R2ANKRD163xArg = 0.7992]). (E) Percentage of EF-Tu retained on
filter membrane upon addition of various components as indicated (mean ± SD). (F) ATPpyrophosphate exchange by mouse AlaRSA734E in the presence or absence of ANKRD16 (mean
± SD, Michaelis-Menten model [R2AlaRSA734E = 0.9763; R2AlaRSA734E/ANKRD16 = 0.9874]). (G)
Aminoacylation of tRNAAla with alanine by mouse AlaRSA734E in the presence or absence of
ANKRD16 (mean ± SD, Michaelis-Menten model [R2AlaRSA734E = 0.9879; R2AlaRSA734E/ANKRD16 =
0.9846]).
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Figure S4. Analysis of serinylation of ANKRD16. (A) tRNA-independent ATPase activity of
mouse wild type AlaRS for serine or alanine (mean ± SD, Michaelis-Menten model [R2Ser =
0.9926; R2Ala = 0.8430]). (B) tRNA-independent ATPase activity of mouse AlaRSWT or
AlaRSA734E for serine in the presence of ANKRD16, ANKRD29, or ANKRD163xArg (mean ± SD,
Michaelis-Menten model [R2AlaRSWT = 0.9926, R2AlaRSA734E = 0.9899, R2AlaRSA734E/ANKRD16 =
0.9918, R2AlaRSA734E/ANKRD29 = 0.9939, R2AlaRSA734E/

ANKRD16

3xArg

= 0.9841], [AlaRSWT,

AlaRSA734E, AlaRSA734E/ANKRD29], [AlaRSA734E/ANKRD16, AlaRSA734E/ANKRD163xArg]).
(C) TLC analysis of ATPase activity of AlaRSA734E against serine in the absence and presence of
ANKRD16. (D) Experimental scheme showing how data were generated for panels E, F, G, and
H. (E) Acylation reactions with radioactive alanine were performed as above to determine
alanine transfer (mean ± SD, Michaelis-Menten model [R2AlaRSA734E/tRNA/ANKRD16 = 0.9611,
R2AlaRSA734E/tRNA/buffer = 0.9641]). (F) Misacylation of tRNAAla with radioactive serine by mouse
AlaRSA734E in the presence or absence (buffer) of ANKRD16. After misacylation, reactions were
subjected to TCA precipitation of RNA (Ser-tRNAAla) and protein under acidic conditions to
maintain Ser-tRNA (mean ± SD, Michaelis-Menten model [R2AlaRSA734E/tRNA/ANKRD16 = 0.9577,
R2AlaRSA734E/tRNA/buffer = 0.7841]). (G) Misacylation reactions using radioactive serine and mouse
AlaRSWT or AlaRSA734E were performed in the presence or absence of ANKRD16, ANKRD29,
ANKRD163xArg, or tRNAAla. After TCA precipitation under neutral pH conditions, serine was
measured (mean ± SD). Note, the higher level of TCA-precipitated serine on tRNA or protein in
the presence of ANKRD16. (H) Acylation reactions using radioactive alanine and mouse
AlaRSA734E were performed in the presence or absence of ANKRD16 or tRNAAla. After TCA
precipitation under neutral pH conditions, alanine was measured (mean ± SD). (I) Misacylation
reactions using radioactive serine and mouse AlaRSA734E were performed in the presence of
ANKRD16 either with or without tRNAAla. Reactions were treated with or without Na2CO3 (final
concentration of 0.15 M [alkaline pH]) for 30 minutes, followed by TCA precipitation.
Precipitated [3H]-serine-links were measured and plotted as relative level of serinylation (mean).
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Figure S5. Analysis of serinylation of ANKRD16 by mass spectrometry. (A) MS/MS
spectrum of peptides from ANKRD16. Incorporation of serine onto ANKRD16 was observed
when serine was misactivated by mouse AlaRSA734E (+ATP). Misactivation was not observed in
the absence of ATP. MS/MS spectrum of peptides from ANKRD16 with serine linked to
positions K102 (B), K135 (C) and K165 (D). a ions [a], b ions [b] and y ions [y] are annotated in
green, red, and purple, respectively. The triply charged precursor had a mass of 2153.065 Dalton
and included carbamidomethyl cysteine. (E) Secondary structure analysis of mouse ANKRD16
and ANKRD163xArg(R). Far-UV circular dichroism (CD) spectra of wild type ANKRD16 (blue)
and ANKRD163xArg(R) (red) show highly similar CD spectra (mean ± SD). (F) Thermal shift
analysis of mouse ANKRD16 (blue) and ANKRD163xArg(R) (red) show highly similar thermal
stability. (G) HEK293T cells were transiently co-transfected with Myc-tagged constructs for
mouse AarsA734E and FLAG-tagged Ankrd16, Ankrd163xArg(R), or Ankrd29. Co-IP experiments
were performed with FLAG-tagged proteins as the bait protein. Binding affinity was determined
by normalizing immunoprecipitation (IP) signal of AlaRSA734E to the input signal, in which the
interaction of AlaRSA734E/ANKRD16 was arbitrarily defined as 1 to determine relative binding
affinity of AlaRSA734E/ANKRD163xArg(R) (mean ± SD).
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Figure S6: Serine-induced cell death in Aarssti/sti fibroblasts. B6.Aarssti/sti embryonic
fibroblasts were co-transfected with hrGFP (humanized recombinant GFP, green) and either
Ankrd16-Flag or Ankrd163xArg(R)-Flag. 12-hours post-transfection, serine was added, and cells
were cultured for 24 hours prior to staining with propidium iodide (PI) (red) and Hoechst (blue)
to determine cell death. Arrowheads represent PI-positive GFP+ cells. Scale bars: 100 μm.
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Figure S7: Analysis of ubiquitous deletion of ANKRD16. (A) Protein levels of ANKRD16
were determined by western blotting of tissues from B6 mice homozygous for the Msti region
(MstiCAST/CAST). (B) Subcellular analysis of ANKRD16 and AlaRS via cell fractionation of brains
from B6.MstiCAST/CAST and Ankrd16-/- mice. Cellular fractions were confirmed using antibodies
for histone 3 (nuclear marker), GAPDH (cytosolic marker), COX IV (mitochondrial marker),
GRP78 (ER marker), and Sec61 beta (rough ER marker). (C) To generate a ubiquitous or
conditional loss-of-function allele, loxP sites that flank exon 2 of Ankrd16 were inserted by
homologous recombination. Removal of exon 2 results in a frame shift and premature stop codon
in exon 3. Ankrd16 was ubiquitously deleted by EIIa Cre-mediated removal of exon 2 and the
neo cassette. Flp-mediated excision of the neomycin cassette was utilized to generate a
conditional loss-of-function Ankrd16 allele. (D) Loss of ANKRD16 was verified by western
blotting. Protein extracts from Ankrd16-/-, MstiCAST/CAST and C57BL/6J mice were used for
comparison purposes and GAPDH was used as a loading control. (E) The number of embryos or
mice of various genotypes from intercrosses of Aarssti/+; Ankrd16-/- mice over the total number
observed. Representative images of E9.5 embryos. Note, Aarssti/sti; Ankrd16-/- embryos are
smaller and have failed to turn. Abbreviations: Embryonic day (E), Postnatal day (P). Scale bars:
500 μm (E).
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Figure S8: Conditional deletion of Ankrd16 accelerates Purkinje cell loss and causes
widespread neurodegeneration in the B6.Aarssti/sti cerebellum. (A and B) Calbindin D-28
immunohistochemistry of sagittal cerebellar sections. (C) Cresyl violet-stained sagittal cerebellar
sections. Note, the presence of interneurons in the ML of B6.Aarssti/sti cerebellum despite the
thinning of the ML as a consequence of Purkinje cell degeneration. In contrast, loss of Ankrd16
in the B6.Aarssti/sti cerebellum results in degeneration of ML interneurons. Scale bars: 500 μm (A,
B, C), 50 μm (C, higher magnification). Abbreviations: Postnatal day (P), molecular layer (ML),
Purkinje cell layer (PL), granule cell layer (GL).
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Figure S9: Conditional deletion of Ankrd16 accelerates formation of protein aggregates in
B6.Aarssti/sti

mice. (A) Ubiquitin (red), p62 (green), and Calbindin D-28 (blue)

immunofluorescence on sagittal cerebellar sections. The percentage of aggregate-positive
Purkinje cells and Purkinje cells are shown (mean ± SD, Multiple t-tests (Holm-Sidak method),
*** p = 0.0002466 (Purkinje cells with aggregates, P21), p = 0.0002336 (Purkinje cells with
aggregates, P28), p = 0.0003214 (percent of Purkinje cells, P21), **** p = 7.701787x10-5
(percent of Purkinje cells, P28)). Note, the percent of Purkinje cells is relative to control
C57BL/6J mice. (B) Cell type-specific markers (red), and p62 (green) immunofluorescence on
sagittal cerebellar sections. Parvalbumin (Parv) was utilized to identify Purkinje cells and
interneurons (stellate and basket cells) in the ML. NeuN was utilized to distinguish between
granule and Golgi cells in the GL. (En1-Cre; Ankrd16fl/-; Aarssti/sti: Golgi cell [closed arrowhead,
p62+/NeuN-]; granule cell [arrow, p62+/NeuN+]; basket/stellate cell [open arrowhead,
p62+/Parv+]). (C) Ubiquitin (red) and p62 (green) immunofluorescence on sagittal sections of the
cortex (layer IV). Scale bars: 10 μm (A), 50 μm (B and C, low magnification) and 10 μm (B and
C, higher magnification). Abbreviations: Postnatal day (P), molecular layer (ML), Purkinje cell
layer (PL), granule cell layer (GL).
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APPENDIX B: Chapter 2: Material and Methods
Ethical compliance: All mouse studies were performed under the guidance of the University of
California, San Diego and The Jackson Laboratory Animal Care and Use Committee in
accordance with institutional and regulatory guidelines.
Mouse strains: Genetic mapping of the Msti (Modifier of sticky) was performed on N1 and F2
mice using polymorphic microsatellite and SNP markers (primer sequences are listed below).
Briefly, C57BL/6J (B6), B6.Aarssti/+ mice were intercrossed with CAST/Ei (CAST) mice and the
resulting F1 Aarssti/+ mice were either backcrossed to B6.Aarssti/+ to generate N1 Aarssti/sti mice (n
= 1249) or intercrossed to generate F2 Aarssti/sti mice (n = 766) for phenotypic assessment.
Ataxia and Purkinje cell degeneration of N1 or F2 Aarssti/sti mice were assessed at 3- to 4-months
of age. To generate Ankrd16-/-; Aarssti/sti embryos, timed matings between Ankrd16-/-; Aarssti/+ and
Ankrd16-/-; Aarssti/+ were performed. The day that a vaginal plug was detected was defined as
embryonic day 0.5 (E0.5). To generate heterozygous congenic B6.CAST-Msti mice
(MstiCAST/B6), B6 and CAST mice were intercrossed and mice carrying the CAST allele at the
Msti flanking markers (D2Mit4 and D2Mit427) were backcrossed to B6 mice for seven
generations. All transgenic mice were generated by pronuclear injection of B6 zygotes. Tg25L9
transgenic mice were generated by injection of a CAST-derived BAC clone (CH26-25L9). To
generate transgenic TgPcp2 - Ankrd16 mice, the coding sequence of Ankrd16CAST cDNA was
inserted into the BamHI site of the fourth exon of the L7/Pcp2 minigene (Barski et al., 2000). To
generate Tg-CAG Ankrd16-myc transgenic mice, the stop codon of the Ankrd16CAST cDNA was
replaced with 3 copies of a myc epitope tag and cloned into the EcoRI site of the pCAGGS
vector (Hitoshi et al., 1991). Generation of the targeted Ankrd16 allele was performed by
homologous recombination of the Ankrd16 locus in R1 ES cells. Targeted ES cells were
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confirmed by Southern blotting. Cells were injected into B6J blastocysts to generate Ankrd16neo/+
mice, which were backcrossed 10 generations to B6J mice. Ubiquitous deletion of exon 2 of
Ankrd16 to generate the Ankrd16+/- allele was accomplished by crossing Ankrd16neo/+ mice to
B6.FVB-Tg(EIIa-cre)C5379Lmgd/J (The Jackson Laboratory, stock #003724). In order to
generate a conditional Ankrd16fl/+ allele, the neo cassette was removed by crossing Ankrd16neo/+
mice to B6.129S4-Gt(ROSA)26Sortm1(FLP1)Dym/RainJ (The Jackson Laboratory, stock #009086).
For conditional loss-of-function experiments, the following Cre-lines were used: B6.129Tg(Pcp2-cre)2Mpin/J (The Jackson Laboratory, stock #004146), En1tm2(cre)Wrst/J (The Jackson
Laboratory, stock #007916), B6.Cg-Tg(Camk2a-cre)T29-1Stl/J (The Jackson Laboratory, stock
#005359).

SNP Markers:
D2SlacCA3 F: 5’GCTAGAAAGATGCTGGTAATGGAA3’, D2SlacCA3 R: 5’GGCTGGCTGTGTAAGCACAT3’
D2SlacCA6 F: 5’AACACACCATACCACACACACA3’, D2SlacCA6 R: 5’TGGAGGTTTGCAAAGGAATC3’
D2SlacCA8 F: 5’ATACCCACCCACATGTGACG3’, D2SlacCA8 R: 5’GTACAAGATACTGAGAGTTGGT3’
D2SlacCA10 F: 5’AGGCTGGAGGACTGTGGGTT3’, D2SlacCA10 R: 5’GCGATTGTCCATGGTGGCTT3’
D2SlacCA11 F: 5’CATCTGGTTTATGTGAATGCC3’, D2SlacCA11 R: 5’CAGAGTGCTTTACCTTTCTC3’
D2SlacCA12 F: 5’AATGGTCAGCCCTGGAAAC3’, D2SlacCA12 R: 5’ACATTCAGCCTGCTTGGTCT3’
D2SlacTAGA1 F: 5’TGGATGAAGATTTTACAGAT3’, D2SlacTAGA1 R: 5’ATCTATCTGTCTGTCTATCC3’
Intr. 5 Ank16 F: 5’GTAGGGTTGGAGAGATAGCC3’, Intr. 5 Ank16 R: 5’TGTGAACACAGTAATACAGGTGC3’
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Rotorod assay: Mice were placed on a rotorod linearly accelerating from 4 to 40 rpm (type
7650, Ugo Basile, Milan Italy). The latency to fall was averaged from four trials and repeated
over the course of 4 consecutive test days. A test was considered over when animals fell, 360
seconds expired, or the mouse used gripping behavior to remain on the rod. Rotorod experiments
were performed with mice of both sexes and at least 15 mice per genotype (MstiB6/B6; Aars+/+, n
= 15); (MstiB6/B6; Aarssti/sti, n = 16); (MstiCAST/B6; Aarssti/sti, n = 15). Data represent mean ± SD
and were analyzed by two-way ANOVA using Tukey’s multiple comparison tests.

Histology and immunohistochemistry: Anesthetized mice were transcardially perfused with
4% paraformaldehyde (PFA, for immunofluorescence and histology) or acetic acid/methanol
(AAM, for calbindin-D28 immunohistochemistry and immunofluorescence, e.g. aggregate
staining). Tissues were post-fixed overnight and embedded in paraffin. For histological analysis,
sections were deparaffinized, rehydrated, and stained with cresyl violet according to standard
procedures. For immunofluorescence (IF), antigen retrieval on PFA-fixed sections was
performed by microwaving sections in 0.01 M sodium citrate buffer (pH 6.0, 0.05% Tween-20)
three times for 3 min each. PFA- or AAM-fixed sections were incubated with the following
primary antibodies: rabbit anti-ubiquitin (DAKO, # Z0458, 1:1,000), mouse anti-ubiquitin (Cell
Signaling, #3936, 1:350), guinea pig anti-p62 (ARP, 03-GP62-C, 1:300), rabbit anti-Calbindin
D28 (Swant, CB38, 1:300), and guinea pig anti-ANKRD16 (1:200). Guinea pig or rabbit antiANKRD16 antibodies were custom-made against recombinant mouse ANKRD16 (1-154 aa) and
affinity purified. Detection of primary antibodies was performed with Alexa Fluor-488, -555 or 350 conjugated goat anti-mouse, -rabbit or -guinea pig secondary antibodies (Invitrogen).
Sections were counterstained with DAPI, and autofluorescence was quenched with Sudan black.
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For aggregate quantification, the total number of Purkinje cells or hippocampal pyramidal
neurons and ubiquitin/p62 positive neurons were quantified using three sections spaced 100 μm
apart per animal. Percent of cells with aggregates ± SD at different time points were compared
between genotypes using multiple t-tests and corrected for multiple comparisons using HolmSidak correction (Figure 1C and Figure S9A). All histological analyses were performed with at
least three mice of each genotype and time point using mice of both sexes.

Constructs: For the generation of the various Aars constructs, a full-length mouse Aars clone
(Open Biosystems/GE Dharmacon) was used as a template. The wild-type mouse Aars sequence
was subcloned and inserted into mammalian expression vector (pCMV3, Agilent Technologies)
via restriction digestion. To generate the mutant AarsA734E construct, the mutant editing domain
of Aars was PCR amplified from total brain cDNA of B6.Aarssti/sti, TOPO subcloned (TOPO TA
cloning kit, ThermoFisher, K450002), and the wild type editing domain of pCMV3-Aars was
replaced with mutant editing domain (pCMV3-AarsA734E) via restriction digestion. In addition,
wild type and mutant Aars (pCMV3) were digested and inserted into pCruz HA © vector (Santa
Cruz, sc-5045). In order to generate AlaRS deletion constructs (pCMV3-AAD Aars, pCMV3ΔAAD Aars, pCMV3-ΔAAD AarsA734E), individual domains of AlaRS were PCR amplified
using either full length wild type or mutant Aars constructs, TOPO subcloned, and inserted into
pCMV3 vector via restriction digestion. The TgCAG Ankrd16-myc construct was used to PCR
amplify Ankrd16, while Ankrd29 was PCR amplified from total brain B6J. cDNA. PCR products
were TOPO subcloned and then inserted into pCMV3 via restriction digestion. QuickChange II
Site-Directed Mutagenesis kit (Agilent, #20052) was used to mutate lysines 102, 135, and 165 in
Ankrd16 to arginines (Ankrd163xArg).
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Cell culture: Mouse embryonic fibroblasts (MEFs) were prepared by standard procedures (Nagy
et al., 2014). HEK293T (ATCC, not authenticated nor tested for mycoplasma contamination) and
MEF cells were maintained in Dulbecco’s modified Eagle’s medium (Sigma) with GlutaMAX
(Gibco) and 10% fetal bovine serum at 37oC in 5% CO2. HEK293T cells were transfected with
various constructs (see listed constructs). Transfections were performed using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s protocol and cultured for 48 hours prior to CoIP and western blot analysis.
For the serine toxicity assay, freshly isolated MEFs were cultured in increasing concentrations of
serine for 24 hours; MEFs were collected and stained with propidium iodide. The percentage of
cell death was measured by fluorescence-activated cell sorting (FACS) (n = 3, see Figure 3D).
Data represent mean ± SD and were analyzed by two-way ANOVA using Tukey’s multiple
comparison tests. For fluorescence microscopy (n = 4, Figure 4G), Aarssti/sti embryonic
fibroblasts were co-transfected with phr-GFP II and either Ankrd16-Flag or Ankrd163xArg-Flag
using the P4 Primary Cell 4D-Nucleofector® X Kit, (Lonza) with ~50% transfection and ~95%
co-transfection efficiency. Twelve hours after transfection/seeding, cells were washed 2X with
PBS and media with either 0.4 mM or 40 mM serine was added for 24 hours. Subsequently, cells
were stained with propidium iodide (Invitrogen, P21493, 250 ng/ml) and Hoechst 33342 (Life
Technologies, H3570, 5 μg/ml) to determine cell death. The number of cells that were PI and
GFP-positive out of the total GFP-positive cells was determined. About 1000 cells were counted
per genotype and condition. Cell death was expressed as the percentage increase in cell death
between low and high serine conditions. Data represent mean ± SEM and were analyzed by oneway ANOVA using Tukey’s multiple comparison tests.
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Cell fractionation: Brains from 6-week-old mice were isolated and immediately processed for
subcellular fractionation as previously described (Song et al., 2006). Briefly, brains were
excised, immersed in ice-cold PBS, and washed three times. After washing, brain tissue was
minced into smaller pieces and homogenized in buffer (0.25 M sucrose, 10 mM HEPES, pH 7.5,
protease inhibitor cocktail [Roche]) using a Potter-Elvehjem Tissue Grinder. The homogenate
was centrifuged at 1000 x g for 10 minutes to generate a crude cytoplasmic fraction and nuclear
fraction for further purification via ultracentrifugation. The supernatant (crude cytoplasmic
fraction) from four brains was pooled to purify the mitochondrial, rough ER and cytoplasmic
fractions, while the pellet (crude nuclear fraction) from two brains was utilized to purify the
nuclear fraction. Eventually, purified pellets (mitochondria, nucleus, rough ER) were lysed (4°C,
30 min.) in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1%
SDS) and proteins from the cytoplasmic fraction were concentrated via ultrafiltration (Millipore,
Amicon Ultra-15, #UFC900308). Equal amounts of total protein from each cellular fraction were
electrophoresed on SDS-PAGE gels.

Reverse transcription, quantitative PCR, and genomic PCR analysis: Cerebella from various
inbred strains were isolated and immediately frozen in liquid nitrogen. Total RNA was extracted
with Trizol reagent (Life Technologies). cDNA synthesis was performed on Dnase-treated
(DNA-free DNA Removal Kit, Life Technologies AM1906) total RNA using oligo(dT) primers
and the SuperScript III First-Strand Synthesis System (Invitrogen/Life Technologies).
Quantitative RT-PCRs (qRT) were performed using iQ SYBR Green Supermix (Bio-Rad) and an
iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad). Reactions were performed with
primers either complementary to the CAST or to the B6 Ankrd16 sequence. Both primer sets
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showed similar results; results using B6 primers are shown in Figure 2D. Expression of Ankrd16
transcript was normalized to 18S rRNA using the 2-ΔΔCT method (Livak and Schmittgen, 2001a),
expressed as fold change ± standard error of the mean (SEM) relative to control (C57BL/6J) and
analyzed by multiple t-tests using Holm Sidak comparison tests (n = 3). Ankrd16 quantitative
and conventional RT-PCR analysis was performed on 50 ng of cerebellar cDNA generated from
1- or 2-month-old mice, respectively.
To confirm non-synonymous SNPs of candidate genes, PCRs were performed on genomic DNA
from various inbred strains. Eventually, PCR products were purified (Agencourt AMPure XP –
PCR Purification, Beckman Coulter) and subjected to sequencing.

RT-PCR Primers:
5’UTR Ankrd16 F: 5’GTCTTCCTCCTACTTTTGTCCA3’, Exon2 Ankrd16 R: 5’CAAGGTTCTTCCTTGTGCAC3’,
Exon1 Ankrd16 F: 5’TCGTGGACTCCTTGAAGAAG3’, Exon3 Ankrd16 R: 5’TTCCAAACAGCCGTGCATTG3’,
Exon2 Ankrd16 F: 5’TGATCCTCCGGTACTTGCT3’, Exon5 Ankrd16 R: 5’ATCTACATCGATGCCAAGACC3’,
Exon4 Ankrd16 F: 5’GCTGCTCCTTGAACAGCATAA3’, Exon6 Ankrd16 R: 5’CACCCAAGGACAACAGAGTT3’,
Exon5 Ankrd16 F: 5’CAGCACTTCACTATGCAGCA3’, Exon7 Ankrd16 R: 5’CATGGTCAAAGTCCTGAAGGA3’,
Exon6 Ankrd16 F: 5’GTGCCGACATCAACTCTACA3’, 3’UTR Ankrd16 R: 5’TGAACGGCCTTGAACTCCAT3’,
Exon3 Ankrd16 F: 5’GCTGTTTGGAAGCAGTCCA3’, Exon5’ Ankrd16 R: 5’CCAAGGAAGAGCTTACGCTAT3’

qRT-PCR Primers:
Exon 5/6 (B6) F: 5’TGCAGCAAAGGAAGGACAGA3’, or Exon 5/6 (CAST) F: 5’TGCAGCGAAGGAAGGACAGA3’,
Exon7 Ankrd16 R: 5’GTAGGAGGAGCCTGGTGCAA3’, 18S RNA F: 5’ GAGGGAGCCTGAGAAACG G 3’,
18S RNA R: 5’GTCGGGAGTGGGTAATTTGC3’
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Non-synonymous SNP Primers (Msti candidate genes):
Il2ra T101S/Q106H F: 5’TCCCATATTCTCCAGCCCAT3’, Il2ra T101S/Q106H R: 5’CACCTGCCTGTTGAGAACA3’
Il2ra S143R F: 5’TGCTGTGTCTTCCCAAACTT3’, Il2ra S143R R: 5’CCCGTTTTCCCACACTTCAT3’
Il2ra G158S F: 5’CCACCTCCTTGGAAACATGA3’, Il2ra G158S R: 5’TCGGTGGTGTTCTCTTTCATC3’
Il2ra M225T F: 5’GCAGTCCTATGCTAGCCATAA3’, Il2ra M225T R: 5’CGTCTTTGCATGCTTCACC3’
Il2ra K236Q/M233V F: 5’TTAGTGGCCGTTTCAACCAG3’, Il2ra K236Q/M233V R: 5’CTTGTGCAGTCCTATGCTAGC3’
Fbxo18 H15G F: 5’CCCTATTCCGTCCTTTTGTTC3’, Fbxo18 H15Q R: 5’ATGAGACGGTTTAAGCGGAA3’
Fbxo18 P369/376A F: 5’ATTAACGTCTGGGCCTTGGT3’, Fbxo18P369/376AR: 5’TGCTGATGTTAATCCCCTTCTC3’
Ank16 E335A/T346M F: 5’ATCTGGCCTGCGCAGGTCA3’, Ank16 E335A/T346M R: 5’CTTGAACTCCATCGCCTC3'

Co-Immunoprecipitation (Co-IP) experiments: Brain or liver tissue from 4-week-old Tg-CAG
Ankrd16-myc or non-transgenic mice were isolated and immediately used or frozen in liquid
nitrogen. Whole protein lysate from either tissue samples or HEK293T cells was extracted with
solubilization buffer (20 mM Tris-HCl (pH 7.4), 137 mM NaCl, 0.1% Triton X-100, Protease
Inhibitor Cocktail [Roche]) using a Potter-Elvehjem Tissue Grinder (for tissue samples). Protein
extraction was performed at 4°C for either 45 minutes (tissue samples) or 30 minutes (cell
culture samples) under gentle agitation. The lysate was centrifuged at 16,000 x g at 4°C (tissue
samples: 30 min.; cell culture samples: 20 min). The lysate was pre-cleared in two steps at 4°C
under

gentle

agitation:

first

with

Dynabeads

Protein

G

(Dynabeads

Protein

G

Immunoprecipitation Kit, Invitrogen, 10007D) for 90 minutes followed by clearing with normal
IgG complex for 90 minutes (corresponding to the species of IP antibody, Santa Cruz, mouse
IgG [sc-2025], or goat IgG [sc-2028]) that was pre-immobilized on Dynabeads Protein G.
Subsequently, pre-cleared lysates were incubated with pre-immobilized Dynabeads Protein G
with antibody (mouse anti-Myc, abcam, ab18185; mouse anti-FLAG, Sigma, clone M2, F1804;
or goat anti-HA, Santa Cruz, HA probe Y-11, sc-805-G) for 3 to 5h at 4°C under gentle
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agitation. After washing with wash buffer (20 mM Tris-HCl (pH 7.4), 137 mM NaCl, 0.5%
Triton X-100 [tissue samples] or 20 mM Tris-HCl (pH 7.4), 300 mM NaCl, 0.1% Triton X-100
[cell culture samples]), proteins were eluted by incubation with SDS-PAGE sample buffer for
western blotting.

Mass spectrometry: Tissue lysates were prepared as described for co-immunoprecipitation and
proteins were eluted twice by incubation with 2% SDS for 5 minutes at 90°C. After elution,
proteins were recovered in 100 mM Tris buffer (pH 7.4) and purified using chloroform/methanol
precipitation. Protein pellets were dried using a speed vac and dissolved in 30 μl of 20 mM Tris
buffer (137 mM NaCl, pH 7.4). The two elutions for each sample were combined (total volume
60 μl), then mixed with 33.5 μl of 50 mM NH4HCO3 and 1 μl of 0.5 M TCEP-HCl
(ThermoScientific, #20490). Samples were incubated for 20 minutes, occasionally vortexed,
mixed with 2.7 μl of 0.55 M iodoacetamide, incubated for 15 minutes in the dark, and mixed
with 1 μl of 1% ProteaseMax (Promega, V2071) to enhance the subsequent digestion. Trypsin
digests were performed at 37°C overnight following the instructions for “Solution Digestion”
using Trypsin Singles (2 μg of trypsin per sample, Proteomics Grade, Sigma, T7575), mixed
with 5% formic acid (final concentration 0.5%), centrifuged for 30 minutes at 13000 x g, and the
supernatant was collected for mass spectrometry (MS) analysis.
For MS analysis, a four-step MudPIT analysis was performed using an Accela pump and a
Thermo LTQ-XL (ThermoFisher Scientific) using an in-house built electrospray stage (Wolters
et al., 2001). Tandem mass spectra were extracted from raw files using RawExtract 1.9.9
(McDonald et al., 2004) and were searched against a Uniprot Mus musculus database with
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reversed sequences using ProLuCID (Peng et al., 2003). The search space included all fully
tryptic and half tryptic peptide candidates with a fixed modification of 57.02146 C. Proteins were
considered putative interaction candidates if they were detected with at least 5 peptides (total
number of peptides). Proteins detected in both transgenic (experimental sample) and nontransgenic (negative sample) tissue were considered non-specific and excluded as putative
interaction candidates.

Western blotting: Proteins were extracted with RIPA buffer (including Proteinase Inhibitor
cocktail, Roche) or solubilization buffer (see above) when used for Co-IP experiments, and were
resolved on SDS-PAGE gels prior to transfer to PVDF membranes (GE Healthcare Life
Sciences, #10600023) using a tank blotting apparatus (BioRad). After blocking in 5% nonfat dry
milk (Cell Signaling, #9999S), blots were probed with primary antibodies at 4°C overnight:
mouse anti-Myc (Abcam, ab18185, 1:1000), goat anti-Myc (Abcam, ab9132, 1:1000), rabbit
anti-Myc (Abcam, ab9106, 1:2000), guinea pig anti-ANKRD16 (1:150), rabbit anti-ANKRD16
(1:400), mouse anti-AlaRS (A-6, Santa Cruz, sc-165990, 1:100), rabbit anti-AlaRS (Sigma,
HPA040870, 1:500), rabbit anti-GAPDH (Cell Signaling, #2118, 1:6500), mouse anti-FLAG
(Sigma, M2 clone, #F1804, 1:5000), rabbit ant-Flag (Sigma, F-7425, 1:5000), mouse anti-HA.11
(Covance, MMS-101P, 1:2000), rabbit anti-Histone 3-HRP (2 hour incubation at RT, Cell
Signaling, #5192, 1:500), rabbit anti-COX IV (Cell Signaling, #4850, 1:5000), rabbit anti-Grp78
(StressGen, SPA-826, 1:500), goat anti-Sec61β (Santa Cruz, sc-27694, 1:500) and followed by
incubation with HRP-conjugated secondary antibodies for 2 hours at room temperature: goat
anti-rabbit IgG (BioRad, #170-6515), goat anti-mouse IgG (BioRad, #170-6516), bovine antigoat IgG (Santa Cruz, sc-2384), donkey anti-goat IgG (Santa Cruz, sc-2056), goat anti-guinea
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pig IgG (Santa Cruz, sc-2903), or donkey anti-guinea pig IgG (Millipore, AP193P). Signals were
detected with SuperSignal West Pico Chemiluminescent substrate (ThermoScientific, #34080).
Quantification of protein expression (cerebellum, C57BL/6J, CAST/Ei, Aarssti/sti, Aarssti/sti;
MstiCAST/CAST and MstiCAST/B6, 3- to 4-week-old mice, n = 3) and tissue expression (C57BL/6J,
MstiCAST/B6, and MstiCAST/CAST, 6-week-old mice) of ANKRD16 was determined, normalized to
GAPDH, and expressed as a fold change ± SD relative to Aarssti/sti and analyzed by ordinary oneway ANOVA (Tukey-test). Quantification of binding affinity was determined by normalizing
immunoprecipitation (IP) signal to the input signal of AlaRS.

Protein expression and purification: Histidine-tagged human or mouse AlaRS (full length and
truncations [AlaRS-ΔAAD has an N-terminal SUMO tag]), E.coli AlaRS, human TyrRS, human
TrpRS, mouse ANKRD16, and mouse ANKRD29 were expressed in E. coli and purified by NiNTA resin (Qiagen), followed by HiLoad 16/60 Superdex 200 prep grade column (GE
Healthcare). GST-tagged mouse ANKRD16 was expressed in E. coli and purified by
glutathione-sepharose 4B beads (GE Healthcare), followed by HiLoad 16/60 Superdex 200 prep
grade column. The final purified proteins were stored in the 20 mM HEPES (pH 7.5), 200 mM
NaCl, and 1 mM DTT.

In vitro transcription of tRNAAla: The DNA template containing a T7 promoter and a tRNAAla
gene was synthesized by PCR of overlapping oligonucleotides. The transcription reaction was
performed in 40 mM Tris-HCl (pH 8.0), 25 mM NaCl, 20 mM MgCl2, 2 µg/ml pyrophosphatase,
0.1 mg/ml bovine serum albumin (BSA), 5 mM DTT, 20 mM NTPs with T7 polymerase and the
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DNA template at 37 °C for 2 h. The tRNA transcript was purified by phenol-chloroform
extraction. The purified tRNA was annealed by heating to 95°C for 3 minutes and then slowly
cooled down to room temperature, with addition of 1 mM MgCl2 at 55°C.

Dipeptide translation experiments: Ribosomal subunits (from E. coli MRE600) and EF-Tu
were purified as described (Boon et al., 1992; Qin et al., 2007). The model mRNA used is
identical to m291 (Shoji et al., 2006), except with GCU as codon 2, and was made by in vitro
transcription followed by PAGE purification. Native E. coli tRNAfMet was purchased (Chemical
Block Ltd, Moscow) and charged and formylated as described (Walker and Fredrick, 2008). A
transcript corresponding to human tRNAAla (AGC) was generated in vitro, PAGE purified, and
charged with alanine and serine (Walker and Fredrick, 2008) using AlaRS and AlaRS1-455,
respectively.
70S initiation complex (IC) was formed by incubating heat-activated 30S subunits (0.2 μM),
mRNA (1 μM), formyl-[35S]-Met-tRNAfMet (0.2 μM), 50S subunits (0.6 μM), and 1 mM GTP in
buffer A (50 mM K-HEPES pH 7.6, 10 mM KCl, 100 mM NH4Cl, 10 mM MgCl2, 1 mM DTT)
at 37°C for 30 min. Charged tRNA was used to form ternary complex (TC) by incubating either
Ser-tRNAAla or Ala-tRNAAla (1 μM) in buffer A with EF-Tu (4 μM), GTP (1 mM), PEP (2 mM),
and pyruvate kinase (Sigma; 50 μg/mL) at 37°C for 15 min. TC was used in reactions at 1 µM.
ANKRD16 was purified as above and used in reactions at 4 µM.
For experiments that begin with deacylated tRNA, tRNAAla (5 μM) was pre-equilibrated at 37°C
with EF-Tu (8 μM), amino acid (e.g., 100 μM alanine [Figure 4A], 500 μM serine and 1 μM
alanine [Figure 4B], or 500 μM serine [Figure S3C]), GTP (1 mM), ATP (10 mM), PEP (2 mM),
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pyruvate kinase (50 μg/mL), pyrophosphatase (Roche; 8 ng/μL), and BSA (4 μM) in buffer A,
and AlaRS (4 μM) was added to initiate the reaction. Peptide products formed upon reaction of
70S IC and TC were resolved by electrophoretic thin layer chromatography (eTLC) (Merryman
and Green, 2004) and quantified using a Typhoon FLA9000 phosphoimager (GE Healthcare).
Apparent rates were obtained by fitting the kinetic data to a single exponential equation.

E. coli strain construction and halo assay: Editing-defective AlaRS (C666A/Q584H) E. coli
was prepared and the halo assay performed as described (Chong et al., 2008). Briefly, E. coli
were transformed with empty pBAD33/21 vector or pBAD33/21 containing either mouse wildtype Ankrd16, Ankrd163xArg, or mouse Ankrd29. The resulting strains were grown overnight in
M9 minimal media with 0.4% glycerol, 0.002% L-arabinose, 0.01 mg/ml thiamine and the
following antibiotics: kanamycin (50 µg/ml), ampicillin (100 µg/ml), and chloramphenicol (30
µg/ml). Five microliters of an overnight culture were diluted (1:100) and spread on M9Kan/Amp/Cm plates. One hundred microliters of 1 M L-serine were added to a well cut into the
center of the plate and allowed to diffuse into the agar, creating a radial gradient. Plates were
incubated at 37°C and imaged after 48 hours.

SwitchSENSE Measurements: AlaRSWT, AlaRSA734E and AlaRS1-455 were coupled to the 5’ end
of a 48mer ssDNA complementary nanolever sequence (cNL-B48) using the Amine Coupling
Kit 1 (Dynamic Biosensors GmbH, Munich, Germany), and the products were purified using an
ÄKTA start system (GE Life Sciences, Chicago) equipped with an Anion Exchange Column
(Dynamic Biosensors). The cNL-B48 conjugates were then hybridized to a 3’ red-fluorescent
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labeled 48mer ssDNA nanolever tethered to a biochip electrode. The analyte wild-type or mutant
ANKRD16 was injected onto the electrode in three different concentrations (0.63, 1.25, and 2.50
or 5.00 µM) at a constant flow rate of 50 µL/min for 3.5 min and dissociation was observed at a
buffer flow rate of 200 µL/min for 6 min. Measurements were performed on a DRX2 instrument
(Dynamic Biosensors) and switchSENSE technology was employed as previously described
(Langer et al., 2015). Molecular interactions were recorded at constant negative potential (-0.1
V) based on the changes in the red fluorescence signal upon analyte binding. Kinetics curves
were referenced to the corresponding buffer control and kinetics values were determined by
global monophasic fitting using switchANALYSIS software (Dynamic Biosensors).

Aminoacylation and misacylation assays: Aminoacylation assays were performed as described
(Beebe et al., 2003). Briefly, assays were carried out at room temperature using either mouse
AlaRSA734E alone (50 nM [Figure S3G] or 2 µM [Figure S4E]) or a mixture of AlaRSA734E and 10
µM ANKRD16 with 50 mM HEPES (pH 7.5), 20 mM KCl, 4 mM ATP, 5 mM MgCl2, 2 mM
DTT, 4 µg/ml of inorganic pyrophosphatase (Roche), 20 µM 3H-L-alanine, 2 µM BSA, and 10
µM in vitro transcript corresponding to human tRNAAla.
Misacylation assays were performed at 25°C in reactions with 5 µM AlaRSA734E alone or a
mixture of 5 µM AlaRSA734E and 10 µM ANKRD16 with 50 mM Hepes (pH 7.5), 50 mM KCl, 4
mM ATP, 10 mM MgCl2, 5 mM DTT, 4 µg/ml of inorganic pyrophosphatase (Roche), 50 µM
3

H-L-serine, 2 µM BSA and 10 µM in vitro transcript corresponding to human tRNAAla.

Serine- or alanine-linked ANKRD16 (aa-linked ANKRD16) and aminoacylated-tRNAAla (aalinked tRNAAla ) were determined based on aminoacylation reactions with [3H]-alanine or [3H]189

serine using 5 µM AlaRSA734E in the presence of 10 µM tRNAAla and 10 µM ANKRD16. The
reaction was incubated for 1 hour, then half of the reaction was treated with alkaline pH
(Na2CO3) for 20 minutes to hydrolyze acylated tRNAAla (leaving aa-linked ANKRD16),
followed by TCA precipitation. Aminoacylated tRNAAla was the difference of total
aminoacylated tRNA (no alkaline hydrolysis) and aa-linked ANKRD16 (after alkaline
hydrolysis). Data represent mean ± SD and were analyzed by two-tailed Student’s t-test.

ATP hydrolysis assays: ATPase assays were performed as previously described (Splan et al.,
2008). Assays measuring the hydrolysis of misactivated serine (Ser-AMP) were carried out at
room temperature in a reaction with either 500 nM mouse AlaRS alone, or a mixture of 500 nM
AlaRS and 10 µM wild type ANKRD16, mutant ANKRD16, or ANKRD29 proteins. Reactions
also contained 100 mM HEPES (pH 7.5), 40 mM KCl, 10 mM MgCl2, 0.5 mM ATP, 0.5 μM α32

P-ATP, 10 units/ml inorganic pyrophosphatase, 2 mM DTT and 200 mM serine. Two

microliter aliquots of the editing reaction were taken at appropriate time points and quenched in
8 μl 200 mM sodium acetate (pH 5.0), and then 1 μl was spotted on a polyethyleneimine (PEI)
TLC cellulose plate (EMD Millipore) and run in a solution containing 0.1 M ammonium acetate
and 5% glacial acetic acid. α-32P-ATP, 32P-AMP, and Ser-32P-AMP. Results were imaged using a
phosphoimager. The percent of hydrolyzed AMP (ATPase activity) was quantified with the
Molecular Dynamics Image Quant software. Data represent mean ± SD and were analyzed by
one-way ANOVA using Tukey’s multiple comparison tests.
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Far-UV circular dichroism: Circular dichroism (CD) spectra were obtained with a CD
Spectrometer 400 (Aviv Biomedical, Inc.). Protein samples were prepared at 10 µM in
phosphate-buffered saline and measurements were scanned from 190 to 260 nm in increments of
0.5 nm at 20°C. Three independent scans were acquired and averaged for each protein sample.

Thermal shift assays: Thermal shift assays were performed using the Protein Thermal ShiftÔ
Dye Kit (ThermoFisher Scientific) according to the manufacturer’s instructions and run on a
StepOnePlus 96 Real Time Cycler (Applied Biosystems). Briefly, a reaction of 20 µl containing
5.0 µl Thermal Shift Buffer, 12.5 µl of 10 µM wild type ANKRD16 or ANKRD163xArg, and 2.5
µl of 8xThermal Shift Dye were mixed in a 96-well Optical Reaction Plate (Applied
Biosystems). The plate was sealed and heated in the StepOnePlus Real-Time PCR from 25 to
90°C in increments of 0.15°C. The measurements were done in four replicates and analyzed
using the Protein Thermal ShiftÔ Software (ThermoFisher Scientific).

Deacylation assay: The aminoacylation assays were performed at room temperature with 50
mM HEPES pH 7.5, 20 mM KCl, 5 mM MgCl2, 4 mM ATP, 2 mM DTT, 4 µg/ml
pyrophosphatase, 20 µM cold L-Serine, 2.68 µM [3H]-Serine (1 mCi/ml) as the assay solution.
20 µM tRNAAla transcript was mixed with the assay solution and the reaction was initiated by
adding 5 µM AlaRS protein into the mixture. After 30 minutes, phenol/chloroform (pH 5.0)
extraction was performed, and the product [3H]-Serine -tRNAAla product was used as the
substrate of the deacylation assay. [3H]-Serine -tRNAAla was incubated at room temperature with
191

100 nM AlaRS (AlaRSWT and AlaRSA734E) and ANKRD16 protein in assay buffer (50 mM
HEPES [pH 7.5], 20 mM KCl, 10 mM MgCl2, 5 mM DTT). At varying time intervals, 5 µl
aliquots were applied to a MultiScreen 96-well filter plate (0.45 µm pore size hydrophobic, low
protein binding membrane, Merck Millipore Ltd.), which was pre-wetted with a quenching
solution containing 0.5 mg/ml DNA and 100 mM EDTA in 300 mM NaOAc (pH 3.0). After all
time points were collected, 100 µl of 20% trichloroacetic acid (TCA) was added to precipitate
the nucleic acids. The plate was then washed four times with 200 µl of 5% TCA containing 100
mM cold serine, followed once with 95% ethanol. On drying after completion of the washing
steps, 70 µl of 100 mM NaOH was added to elute the tRNA, which was then centrifuged into a
96-well flexible PET microplate (PerkinElmer) with 150 µl of Supermix scintillation cocktail
(PerkinElmer). After mixing, the radioactivity in each well of the plate was counted in the 1450
LSC & Luminescence Counter (PerkinElmer).

ATP-Pyrophosphate exchange assays: The ATP-pyrophosphate exchange assays were
performed as previously described (Beebe et al., 2007). Briefly, a reaction mixture of either 250
nM mouse AlaRSA734E alone or a mixture of 250 nM AlaRSA734E and 10 µM ANKRD16 was
incubated at room temperature with 100 mM Tris-HCl (pH 7.5), 10 mM KF, 10 mM MgCl2, 1
mM ATP, 2 mM DTT, 0.1 mg/ml BSA, 20 mM L-serine, and 0.5 mM Na-32PPPi.

Filter binding of EF-Tu with aminoacyl-tRNAAla: The nitrocellulose filter binding assays were
performed as described (Moon and Weissbach, 1972), with some modifications. AminoacyltRNAAla was generated in 200 µl aminoacylation reactions containing either 500 nM AlaRSA734E
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alone or a mixture of 500 nM AlaRSA734E and 10 µM ANKRD16, in reaction buffer with 50 mM
HEPES (pH 7.5), 50 mM KCl, 4 mM ATP, 10 mM MgCl2, 5 mM DTT, 4 µg/ml of inorganic
pyrophosphatase (Roche), 50 µM 3H-L-alanine or 3H-L-serine, 2 µM BSA, and 10 µM in vitro
transcript corresponding to human tRNAAla. Reactions were incubated for 30 minutes at room
temperature. EF-Tu was loaded with GTP in a 200 µl reaction of 2 µM EF-Tu, 3 µM 3H-GTP, 50
mM Tris-HCl (pH 7.4), 50 mM NH4Cl, 10 mM MgCl2, 3.75 mM phosphoenolpyruvate, 0.05
µg/µl pyruvate kinase, which was incubated for 2 minutes at 37 °C, and then placed on ice. An
equal volume (200 µl) of the aminoacylation reaction mixture or non-acylated tRNAAla was
added to the 3H-GTP-EF-Tu reaction mixture, incubated for 2 minutes on ice, and terminated by
the addition of 2 ml of a cold wash buffer containing 10 mM Tris-HCl (pH 7.4), 50 mM NH4Cl
and 10 mM MgCl2. The reaction mixture was filtered through a nitrocellulose filter, and the filter
was washed with 15 ml of cold wash buffer. The filter was dissolved in a scintillation fluid and
counted for radioactivity. The percentage of EF-Tu retained in the membrane was normalized to
that retained in the non-acylated tRNAAla reaction.

GST pull-down assay: GST pull-down experiments were performed in buffer containing 20 mM
of HEPES (pH 7.5), 200 mM NaCl, 0.5 mM EDTA, 1 mM DTT, 10% glycerol, and 0.1% Triton
X-100. Equal amounts of GST-ANKRD16 proteins were incubated with histidine-tagged mouse
or human AlaRS (full length and truncations), E.coli AlaRS, or human TyrRS or TrpRS proteins
for 2 h in 4°C and pulled down by Glutathione-Sepharose 4B beads (GE Healthcare). After SDSPAGE, the proteins were transferred to PVDF membranes using the iBlot Dry Blotting System
(Invitrogen). The membranes were blocked for 1 h with 5% nonfat dry milk in Tris-buffered
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saline with Tween-20 (TBST). Anti-GST and Anti-His-Tag antibodies were purchased from Cell
Signaling. After incubation with primary antibodies, the membranes were washed and incubated
with HRP-conjugated anti-mouse or anti-rabbit secondary antibodies (Cell Signaling), followed
by detection using ECL Western blotting substrate (Thermo Scientific).

Molecular modeling: The mouse ANKRD16 and human AlaRS complex model was obtained
through the Patchdock server and was optimized by manual adjustments. The mouse ANKRD16
and human AlaRS models were generated by the Swiss model server. The human full-length
AlaRS model was built based on the templates of human AlaRS structure (PDB 5KNN) (Sun et
al., 2016b), A. fulgidus AlaRS and tRNAAla complex (PDB 3WQY) (Naganuma et al., 2014).
AlaRS was assigned as the receptor, and ANKRD16 was assigned as the ligand. Molecular
visualization and analysis were performed with PyMOL.

Mass spectrometry for serinylation of ANKRD16: To identify amino acid residues that were
serinylated, misacylation assays were performed at 25°C for 1 h in a reaction mixture of 5 µM
AlaRSA734E and 10 µM ANKRD16 in 50 mM HEPES (pH 7.5), 50 mM KCl, 10 mM MgCl2, 5
mM TCEP, 4 µg/ml inorganic pyrophosphatase (Roche), 10 mM L-serine, 2 µM BSA and 10
µM human tRNAAla in the presence or absence of 4 mM ATP. Proteins were reduced with 5 mM
Tris-(2-carboxyethyl)-phosphine hydrochloride (Sigma, C4706) and alkylated with 55 mM 2chloroacetamide (Fluka Analytical, #22790). Proteins were digested for 18 h at 37°C in 2 M
urea, 100 mM Tris (pH 8.5), and 1 mM CaCl2 with 2 μg trypsin (Promega, V5111). Five-step
MudPIT analysis was performed using an Easy-nLC (ThermoFisher Scientific) and a Q Exactive
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(ThermoFisher Scientific) using an in-house built electrospray stage (Wolters et al., 2001).
Tandem mass spectra were extracted from raw files using RawConverter (He et al., 2015) and
were searched against a Uniprot Mus musculus database with reversed sequences using
ProLuCID (Peng et al., 2003; Xu et al., 2015). The search space included all fully tryptic peptide
candidates with a fixed modification of 57.02146 C and differential modification of serine
(87.03203) or alanine (71.03711) on lysine.

Statistics: P values were computed in GraphPad Prism using either Students t-test (two-tailed),
one-way or two-way ANOVA and corrected for multiple comparisons when applicable as
indicated in the figure legends.
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APPENDIX C: Chapter 3: Supplemental Figures

Figure S10. Expression of Gtpbp1 and Gtpbp2 in the mouse cortex. (A and B) In situ
hybridization was performed on P28 B6J mice demonstrating ubiquitous expression of Gtpbp1
(yellow) and Gtpbp2 (red) throughout the cortex (A) and specifically in layer IV (B). Sections
were counterstained with DAPI (blue). Cortical layers are indicated by Roman numerals. Scale
bar: 20μm (A, B).
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Figure S11. Extensive neurodegeneration in B6J.Gtpbp1-/- mice. (A) Immunofluorescence of
hippocampal sections of the dentate gyrus (DG) with antibodies against cleaved caspase 3 (cas3,
green; arrowheads indicate positive cells). Sections were counterstained with DAPI. (B)
Hematoxylin and eosin-stained sagittal sections of the dentate gyrus (DG). Higher magnification
images of the region indicated by the rectangle are shown for each genotype. Arrowheads
indicate pyknotic cells. Note the similarity in neurodegeneration between mutant genotypes. (C)
Immunofluorescence on cortical sections with antibodies against cleaved caspase 3 (cas3, green)
and CTIP2 (red) to identify layer V neurons. Sections were counterstained with DAPI. Cortical
layers are indicated by Roman numerals. Note the cas3-positive neurons in layer IV (above layer
V CTIP2+ neurons). (D) Hematoxylin and eosin-stained sagittal sections of the cortex from 6week-old mice. Cortical layers are indicated by Roman numerals and higher magnifications
(dashed line rectangle) of layer IV of the cortex are shown. (E) Hematoxylin and eosin-stained
retina sections. Note the similarity in neurodegeneration between mutant genotypes. Scale bars:
50μm (A, E); 25μm (C); 50μm and 20μm (higher magnification) (B, D). OS, outer segment; IS,
inner segment; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer;
IPL, inner plexiform layer; GCL, ganglion cell layer.
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Figure S12. Gtpbp1 and Gtpbp2 resolve AGA pauses. (A) Heatmap of ribosome occupancy
(observed/expected reads) at AGA codons relative to nucleotide (nts) length of ribosome
protected fragments. Note the increase in ribosome occupancy at the A-site AGA codon in P21
B6J.Gtpbp1-/- and B6J-Gtpbp2-/- mice. (B) Venn diagram of all genes with increased AGA
ribosome occupancy (z-score ≥ 10) observed in P21 B6J.Gtpbp1-/- and B6J-Gtpbp2-/- mice. (C)
Gene Ontology (GO) analysis using all AGA pausing genes (z-score ≥10) from P21
B6J.Gtpbp1-/- and B6J-Gtpbp2-/- mice. Top 24 enriched categories (Benjamini-Hochberg adjusted
p-value ≤ 0.05) are shown. The inner circle and outer circle represent GO categories that are
shared between mutant genotypes or unique to each genotype, respectively.
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Figure S13. Loss of GCN2 enhances hippocampal degeneration in B6J.Gtpbp1-/- mice.
Hippocampal sagittal sections of the dentate gyrus (DG) stained with hematoxylin and eosin.
Higher magnification images of the dentate gyrus region defined by the rectangle are shown.
Arrowheads indicate pyknotic cells. Scale bars: 50μm and 20μm (higher magnification).
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Figure S14. Analysis of mTOR signaling in trGTPase-deficient mice. (A) Analysis of
differential translation efficiency (TE) in the cerebellum of P21 B6J and B6J.Gtpbp1-/- (TE
Gtpbp1) or B6J and B6J-Gtpbp2-/- (TE Gtpbp2) mice. The TE of genes was determined by
normalizing the abundance of ribosomal footprints to that of RNA sequencing reads. 5’TOP
genes regulated by mTOR are shown in magenta. The red dashed line marks significant changes
in TE (adjusted p-value ≤ 0.05). (B) Immunofluorescence of P21 cortical sections with
antibodies against p-S6S240/244 (orange). Cortical layers are indicated by Roman numerals. (C)
Immunofluorescence of P21 hippocampal (CA3) sections with antibodies against p-S6S240/244
(orange) and counterstained with DAPI (blue). (D) Western blotting analysis of p-S6S240/244 in
cerebellar tissue extracts from P21 B6J and B6J.Gtpbp1-/- mice untreated or injected with
rapamycin for 7 days. Vinculin was used as an input control. (E) Relative abundance of pS6S240/244 in the cerebellum of P21 B6J and BP1 (B6J.Gtpbp1-/-) mice treated with rapamycin
(R). Levels of p-S6S240/244 were normalized to total levels of S6 and phosphorylation levels are
relative to those of untreated B6J mice. Data represent mean + SD. (F) Relative abundance of pS6S240/244 in the cerebellum of P21 B6J and BP2 (B6J-Gtpbp2-/-) mice treated with rapamycin
(R). Levels of p-S6S240/244 were normalized to total levels of S6 and phosphorylation levels are
relative to those of untreated B6J mice. Data represent mean + SD. (G) Quantitative RT-PCR
analysis of ATF4 targets using cerebellar cDNA from P21 B6J, B6J.Gtpbp1-/-, and B6J-Gtpbp2-/mice injected with rapamycin for 7 days or untreated. Data were normalized to beta-actin and
fold change in gene expression is relative to that of B6J. Magenta colored genes were previously
shown to be sensitive to mTOR inhibition (Park et al., 2017). Data represent mean + SD. Scale
bar: 50μm (B, C). Two-way ANOVA was corrected for multiple comparisons using Tukey
method (E, F, G). ns, not significant, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.
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Figure S15. Inhibition of mTOR signaling accelerates cell death in B6J.Gtpbp1-/- and B6JGtpbp2-/- mice. (A) Sagittal sections of the cortex of P28 mice injected with vehicle or
rapamycin for two weeks stained with hematoxylin and eosin. Higher magnification images of
layer IV (rectangle) are shown for each genotype. Cortical layers are indicated by Roman
numerals and arrowheads indicate pyknotic cells. (B) Number of pyknotic cells in layer IV of the
cortex in (B6J), BP1 (B6J.Gtpbp1-/-), and BP2 (B6J-Gtpbp2-/-) mice injected with vehicle (V) or
rapamycin (R). Data represent mean + SD. (C) Hematoxylin and eosin-stained sagittal sections
of the hippocampus of P28 mice injected with vehicle or rapamycin for 14 days. Arrowheads
indicate pyknotic cells. Note: Due to the large number of pyknotic cells in rapamycin-treated
B6J.Gtpbp1-/- mice, arrowheads to indicate pyknotic cells were not included. (D) Percent of
neurons with pyknotic nuclei in the dentate gyrus (DG) in vehicle (V) or rapamycin (R) treated
control (B6J), BP1 (B6J.Gtpbp1-/-), and BP2 (B6J-Gtpbp2-/-) mice. Data represent mean + SD.
(E) Total number of neurons of the dentate gyrus (DG) in vehicle (V) or rapamycin (R) treated
control (B6J), BP1 (B6J.Gtpbp1-/-), and BP2 (B6J-Gtpbp2-/-) mice. Data represent mean + SD.
(F) Sagittal sections of the hippocampus of P42 mice injected with vehicle or rapamycin for two
weeks stained with hematoxylin and eosin. Arrowheads indicate pyknotic cells. Scale bars: 50μm
and 20μm (higher magnification) (A); 50μm (C, F). Two-way ANOVA, corrected for multiple
comparisons using Tukey method (B, D, E). *** P ≤ 0.001, **** P ≤ 0.0001.
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APPENDIX D: Chapter 3: Material and Methods
Ethical compliance: All mouse studies were performed under the guidance of the University of
California, San Diego and The Jackson Laboratory Animal Care and Use Committee in
accordance with institutional and regulatory guidelines.
Mouse strains: Gtpbp1-/+ mice were generated previously on a mixed genetic background with a
portion of exon 3 and all of exon 4 replaced with a PGK-Neo cassette (Senju et al., 2000). These
mice were backcrossed to C57BL/6J mice for more than 10 generations to generate congenic
B6J.Gtpbp1-/- mice and genotyped with the following primers (wild-type forward primer:
5’GAGTACGGGCTGAGTGAAGC3’, wild type reverse primer: 5’TGGACAGGAACCTGATGTGA3’,

mutant

forward

primer:

5’TACGCCACCGTGAAGAGCAT3’,

mutant

reverse

primer:

5’AGGGGAGGAGTGGAAGGTGG3’). Homozygosity for the tRNA (n-Tr20J/J) mutation was

confirmed by genotyping (Ishimura et al., 2014). For transgene rescue experiments, B6J.Tg(nTr20wt); Gtpbp1-/- mice were generated by crossing B6J.Gtpbp1+/- mice to B6J-Tg(n-Tr20wt)
mice that transgenically express wild-type levels of wild type n-Tr20 (Ishimura et al., 2014) and
then backcrossing to B6J.Gtpbp1-/+ mice. C57BL/6J (B6J) and B6J.Gcn2-/- (Eif2ak4tm1.2Dron)
mice were obtained from The Jackson Laboratory. Neurological defects were observed in
B6J.Gtpbp1-/- and B6J-Gtpbp2-/ males and females; therefore, mice of both sexes were used for
experiments.

Rapamycin treatment: Rapamycin (LC laboratories) stock solution (50mg/ml) was prepared in
ethanol and diluted on the day of injection in equal volumes of a 10% PEG-400/8% ethanol
solution and 10% Tween-80. Mice were injected intraperitoneally with 5mg/kg rapamycin or
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vehicle daily; injections were performed from P14-P21 for tissue collection (RNA isolation or
western blotting) or from P14-P28 or P28-P42 for histological analysis.

Histology and immunohistochemistry: Anesthetized mice were transcardially perfused with
4% paraformaldehyde (PFA) for immunofluorescence, 10% neutral buffered formalin (NBF) for
in situ hybridization or immunofluorescence, or Bouin’s fixative for histology. Tissues were
post-fixed overnight and embedded in paraffin. For histological analysis, sections were
deparaffinized, rehydrated, and were stained with hematoxylin and eosin according to standard
procedures. Histological slides were imaged using a digital slide scanner (Hamamatsu).
For quantification of cerebellar granule cells, the total number of granule cells (viable and
pyknotic cells) were counted in a 0.025mm2 area from lobule VI or IX and averaged from three
sections per brain spaced 100μm apart at midline. For quantification of hippocampal neurons, the
number of neurons with, and without, pyknotic nuclei were counted in the CA1 or dentate gyrus
of the hippocampus and averaged from three sections, spaced 50-70μm apart and about 1.5mm
off midline, per brain. For quantification of pyknotic nuclei in the cortex, the total number of
pyknotic nuclei were counted across the entire section and averaged from three sections per
animal spaced 50-70μm apart and about 2-2.5mm off midline. All histological quantifications
were performed with three mice of each genotype and time point using mice of both sexes.
For immunofluorescence, antigen retrieval on deparaffinized PFA-fixed sections was performed
by microwaving sections in 0.01M sodium citrate buffer (pH 6.0, 0.05% Tween-20), three times
for three minutes each. NBF-fixed sections were microwaved three times for three minutes,
followed by two times for nine minutes. PFA- or NBF-fixed sections were incubated with the
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following primary antibodies: rabbit anti-cleaved caspase 3-D175 (Cell Signaling, #9661, 1:100,
PFA-fixed tissue), CTIP2/BCL11B (Abcam, ab18465, 1:500, PFA-fixed tissue), p-S6240/244 (Cell
Signaling, #5364, 1:1000, NBF-fixed tissue), and RPS6 (Santa Cruz Biotechnology, sc-74459,
1:500, NBF-fixed tissue). Detection of primary antibodies was performed with goat anti-mouse
Alexa Fluor-488, goat anti-rabbit Alexa Fluor-488, goat anti-rat Alexa Fluor-555, and goat antirabbit Alexa Fluor-555 secondary antibodies (Invitrogen). Sections were counterstained with
DAPI and treated with Sudan black to quench autofluorescence.

RNAscope (in situ hybridization): In situ hybridization of Gtpbp1, Gtpbp2, Sesn2, Slc7a1,
Ddr2 and Chac1 probes was performed as per the manufacturer’s protocol (RNAscope®
Multiplex Fluorescent Reagent Kit v2; Advanced Cell Diagnostics). Briefly, deparaffinized
NBF-fixed sections were treated for 15 minutes with Target Retrieval Reagent at 100˚C and
subsequently treated with Protease Plus for 30 minutes at 40˚C. RNAscope probes were
hybridized for 2 hours. TSA® Plus Cyanine 5 (PerkinElmer, 1:1,000) was used as a secondary
fluorophore for C1 probes (Gtpbp2, Slc7a1, Chac1) and TSA® Plus Cyanine 3 (PerkinElmer,
1:2,000) was used as a secondary fluorophore for C2 probes (Gtpbp1, Sesn2, Ddr2).

Reverse transcription, quantitative PCR, and genomic PCR analysis: Cerebella or
hippocampi were isolated and immediately frozen in liquid nitrogen. Total RNA was extracted
with Trizol reagent (Life Technologies). cDNA synthesis was performed on DNase-treated
(DNA-free DNA Removal Kit, Life Technologies AM1906) total RNA using oligo(dT) primers
and the SuperScript III First-Strand Synthesis System (Life Technologies). Quantitative RT-PCR
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(qRT) reactions were performed using iQ SYBR Green Supermix (Bio-Rad) and a CFX96 RealTime PCR Detection System (Bio-Rad). Reactions were performed with primers previously
published (Ishimura et al., 2016). Expression levels of the genes of interest were normalized to βactin

(Actb)

(forward

primer:

5’GGCTGTATTCCCCTCCATCG3’,

reverse

primer:

5’

CCAGTTGGTAACAATGCCATGT3’) using the 2-ΔΔCT method (Livak and Schmittgen, 2001b) and

expressed as fold change + standard error of the mean (SEM) relative to control (B6J).

RNA-Sequencing library preparation: Cerebella from various strains were isolated from 3week-old mice (P21, n=3 mice for each genotype) and immediately frozen in liquid nitrogen.
RNA-Seq libraries were prepared using the TruSeq v2 mRNA kit (Illumina). Briefly, total
cerebellar RNA was isolated and RNA quality was assessed on an Agilent TapeStation. mRNA
was purified using biotin-tagged poly(dT) oligonucleotides and streptavidin-coated magnetic
beads. After fragmentation of mRNA, libraries were prepared according to the manufacturer’s
instructions. Paired end reads (2x100bp) were obtained using the HiSeq 4000 (Illumina).

Ribosome profiling library construction: Ribosome profiling libraries were generated as
previously described (Ingolia et al., 2012; Ishimura et al., 2014) with some minor modifications.
Briefly, dissected cerebella were immediately frozen in liquid nitrogen. One cerebellum from
P21 mice was used for each biological replicate, and three biological replicates were prepared for
each genotype. Tissue homogenization was performed with a mixer mill (Retsch MM400) in
350µl lysis buffer (20mM Tris-Cl, pH 8.0, 150 mM NaCl, 5mM MgCl2, 1mM DTT, 100µg/ml
CHX, 1% (v/v) TritonX-100, 25units/ml Turbo DNaseI). Lysates were treated with RNase I and
overlaid on top of a sucrose cushion in 5ml Beckman Ultraclear tubes and centrifuged in an
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SW55Ti rotor for 4 hours at 4ºC at 46,700 rpm. Pellets were resuspended and RNA was
extracted using the miRNeasy kit (QIAGEN) according to the manufacturer’s instructions. 26-34
nucleotide RNA fragments were purified by electrophoresis on a 15% denaturing polyacrylamide
gel. Linker addition, cDNA generation (first-strand synthesis was performed at 50°C for 1h),
circularization, rRNA depletion, and amplification of cDNAs with indexing primers were
performed. Library quality and concentration were assessed using High Sensitivity D1000
ScreenTapes on the Agilent TapeStation, Qubit 2.0 Fluorometer, and qPCR. Libraries were run
on a HiSeq4000 (SR75).

RNA-Sequencing data analysis: Reads were quantified using kallisto version 0.42.4 (Bray et
al., 2016) and pseudo-aligned to a Gencode M20 transcriptome reference with parameters –bias
and -b 100. Differential expression was performed using sleuth version 0.30.0 (Pimentel et al.,
2017). To identify differentially expressed genes the following pairwise comparisons were
performed: B6J vs. B6J.Gtpbp1-/-, B6J vs. B6J-Gtpbp2-/-, and B6J.Gtpbp1-/- vs. B6J-Gtpbp2-/-.
Using functions within sleuth, we aggregated transcript expression at the gene level (by Ensembl
gene identifier), fit null models and models corresponding to the genotype of the samples for
each gene and performed Wald tests on the models for each gene to identify differentially
expressed genes. Multiple hypothesis testing correction was done using a Benjamini-Hochberg
correction, which is the default method in sleuth and referred to as q-value. For downstream TE
analysis, mapping to mm10 using a Gencode M20 transcript annotation was performed using
hisat2 version 2.1.0 (Kim et al., 2019) using default parameters.
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Ribosome profiling data analysis: Reads were clipped to remove adaptor sequences
(CTGTAGGCACCATCAAT) using fastx_clipper and trimmed so that reads start on the second base
using fastx_trimmer (http://hannonlab.cshl.edu/fastx_toolkit/). Reads containing ribosomal RNA
were then filtered out by mapping to a ribosomal RNA reference using bowtie2 version 2.2.3
using parameters -L 13 (Langmead and Salzberg, 2012). Remaining reads were mapped to a
mm10 mouse reference using a Gencode M20 annotation, or a Gencode M20 transcript reference
using hisat2 version 2.1.0 (Kim et al., 2019). Ribosomal A-sites were identified using RiboWaltz
version 1.0.1 (Lauria et al., 2018), and read lengths 29-33 were retained for further analysis.
Observed/expected reads were calculated with the expected reads being the read density
expected at a given site with a given codon, assuming that reads are uniformly distributed across
the coding part of the transcript. Pauses were identified using previous methodology (Ishimura et
al., 2014) using a 0.5 reads/codon in all samples to threshold transcripts to analyze. Correlation
between gene pauses and gene expression was calculated by taking the average pause scores of
transcripts associated with a gene for transcripts with ≥ 0.5 reads/codon across the B6J.Gtpbp1-/samples. The sum of these pause scores across all replicates was then correlated with the sleuth
beta values (in the B6J.Gtpbp1-/- vs. B6J comparison) for genes that passed the reads/codon
thresholding in the ribosome profiling datasets.

Read counts for translational efficiency (TE) analysis were quantified using featureCounts (Liao
et al., 2014) with footprints overlapping CDS features and RNA read pairs overlapping gene
exon features. Histone mRNAs were removed from the analysis by removing gene names with
the prefix “Hist” and filtering out genes in HistoneDB 2.0 (Draizen et al., 2016). Differential TE
analysis was performed using riborex version 2.3.4 using the DESeq2 engine (Li et al., 2017).
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TE analysis of AGA A-site filtered datasets was performed by identifying AGA codons in the
transcriptome and transferring the coordinates to the genome using ensembldb v.2.6.8 (Rainer et
al., 2019). Then reads with AGAs in the A-site (±1 codon based on riboWaltz A-site offset for
each read length) were removed and the above TE analysis was performed. A list of mouse genes
with known TOP motifs were identified in (Yamashita et al., 2008).

Gene ontology (GO) and pathway analysis: RNA-sequencing data were analyzed using
Ingenuity

Pathway

Analysis

(QIAGEN

Inc.,

https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis). Gene Ontology
(GO) pathway analysis was performed using the DAVID bioinformatics web server
(http://david.abcc.ncifcrf.gov) by uploading the gene lists from our ribosome profiling analysis

(AGA pausing genes, z ≥ 10, stalls detected in any biological replicates). The functional
annotation chart and clustering analysis modules were utilized for gene-term enrichment
analysis, and terms with a Benjamini-Hochberg adjusted p-value ≤ 0.05 were considered
enriched.

Western blotting: Cerebella or hippocampi were isolated and immediately frozen in liquid
nitrogen. Proteins were extracted by homogenizing tissue in 5 volumes of RIPA buffer with
cOmplete Mini, EDTA-free Protease Inhibitor Cocktail (Roche), sonicated two times for 10
seconds (Branson, 35% amplitude), incubated for 30 minutes at 4°C, centrifuged at 16,000xg for
25 minutes, and 25µg of whole protein lysate were resolved on SDS-PAGE gels prior to transfer
to PVDF membranes (GE Healthcare Life Sciences, #10600023) using a tank blotting apparatus
(BioRad).
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For detection of phosphoproteins, frozen tissue samples were homogenized in 5 volumes of
homogenization buffer (50mM HEPES/KOH, pH 7.5, 140mM potassium acetate, 4mM
magnesium acetate, 2.5mM dithiothreitol, 0.32M sucrose, 1mM EDTA, 2mM EGTA)
(Carnevalli et al., 2004), supplemented with phosphatase and protease inhibitors (PhosStop and
cOmplete Mini, EDTA-free Protease Inhibitor Cocktail, Roche). Lysate samples were
centrifuged at 12,000xg for 7 minutes, and either 30µg (detection of ribosomal protein S6) or
70µg (detection of eIF2alpha) of whole protein lysate were resolved on SDS-PAGE gels prior to
transfer to PVDF membranes. After blocking in 5% nonfat dry milk (Cell Signaling, #9999S),
blots were probed with primary antibodies at 4°C overnight: rabbit anti-phospho-S6240/244 (Cell
Signaling, #5364, 1:4000), mouse anti-RPS6 (Santa Cruz Biotechnology, sc-74459, 1:2000),
rabbit anti-phospho-eIF2alphaS51 (Cell Signaling, #9721, 1:1000), rabbit anti-eIF2alpha (Cell
Signaling, #9722, 1:2000), mouse anti-vinculin (Sigma, V-9131, 1:20,000). Followed by
incubation with HRP-conjugated secondary antibodies for 2 hours at room temperature: goat
anti-rabbit IgG (BioRad, #170-6515) or goat anti-mouse IgG (BioRad, #170-6516). Signals were
detected with SuperSignal West Pico Chemiluminescent Substrate (ThermoScientific, #34080).

Statistics: For quantification of protein expression, RNA expression, or histological
quantifications, p-values were computed in GraphPad Prism using either multiple t-tests, oneway ANOVA, or two-way ANOVA, and corrected for multiple comparisons as indicated in the
figure legends. All quantifications were performed with at least three mice of each genotype and
time point. Neurological defects were observed in B6J.Gtpbp1-/- and B6J-Gtpbp2-/- male and
female mice. Therefore, mice of both sexes were used for experiments.
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Data availability: The RNA sequencing and ribosome footprint data have been made available
(GSE157902).
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APPENDIX E: Chapter 4: Supplemental Figures
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Figure S16: Hbs1l is required for the development of multiple cerebellar linages. (A)
Western blot analysis using brain lysates from B6J mice. Vinculin was used an input control. (B)
Immunofluorescence using antibodies to BrdU (green) and Ki67 (red) from cerebellar sections of
E13.5 control (Hbs1lfl/+) and En1-Cre; Hbs1lcKO embryos to determine the fraction of cells in Sphase. Embryos were injected with BrdU 30 minutes prior to harvest. Sections were
counterstained with DAPI. (C) Percentage of cerebellar VZ-progenitors in S-phase (BrdU+,
Ki67+ cells). Data represent mean + SD. (D) Percentage of cerebellar VZ-progenitors in M-phase
(pH3+, PCNA+ cells). Data represent mean + SD. (E) Immunofluorescence using antibodies to
Pax2 (red) on cerebellar sections from E13.5 control (Hbs1lfl/+) and En1-Cre; Hbs1lcKO embryos.
Sections were counterstained with DAPI. (F) Number of cerebellar VZ-derived interneuron
precursors (Pax2+ cells). Data represent mean + SD. (G) Immunofluorescence using antibodies to
Tbr1 (green) on cerebellar sections from E14.5 control (Hbs1lfl/+) and En1-Cre; Hbs1lcKO
embryos. Sections were counterstained with DAPI. (H) Immunofluorescence using antibodies to
Ki67 (green) on cerebellar sections from E14.5 control (Hbs1lfl/+) and En1-Cre; Hbs1lcKO
embryos to identify granule cell precursors in the EGL. Sections were counterstained with DAPI.
(I) Number of RL-derived granule cell precursors in the EGL (Ki67+ cells). Data represent mean
+ SD. (J) Immunofluorescence using antibodies to BrdU (green) and Ki67 (red) on cerebellar
sections from E14.5 control (Hbs1lfl/+) and En1-Cre; Hbs1lcKO embryos. Embryos were injected
with BrdU 24 hours prior to harvest. (J) Number of RL-derived granule cell precursors (BrdU+
cells). Data represent mean + SD. (L) Percentage of RL-derived granule cell precursors that
exited the cell cycle (BrdU+, Ki67- cells). Data represent mean + SD. (M) Percentage of RLderived granule cell precursors in S-phase (BrdU+, Ki67+ cells). Embryos were injected with
BrdU 30 minutes prior to harvest. Data represent mean + SD. (N) Percentage of RL-derived
granule cell precursors in M-phase (pH3+, PCNA+ cells). Data represent mean + SD. (O) Number
of oligodendroglial progenitors (Olig2+ cells) from E14.5 control (Hbs1lfl/+) and En1-Cre;
Hbs1lcKO cerebella. Scale bars: 20μm (C); 50μm (E, G, H, J). VZ, ventricular zone; NTZ; nuclear
transitory zone; EGL, external granule cell layer; RL, rhombic lip. t-tests were corrected for
multiple comparisons using Holm-Sidak method (C, D, F, I, K, L, M, N); Student’s t-test (O). ns,
not significant; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001.
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Figure S17: Hbs1l-/--mediated cerebellar defects are independent of the B6J-associated
mutation in n-Tr20. (A) Cresyl violet staining of sagittal sections of En1-Cre; Hbs1lcKO
cerebellum expressing wild type levels of n-Tr20 (n-Tr20B6N/B6N) or reduced levels of n-Tr20 (nTr20B6J/B6J) and Atoh1-Cre; Hbs1lcKO cerebella with reduced levels of n-Tr20 (n-Tr20B6J/B6J) or
that completely lack n-Tr20 (n-Tr20-/-). Cerebellar lobules are indicated by Roman numerals. (B)
Sagittal sections from 35-week-old control (Gabra6-Cre; Pelofl/+; n-Tr20B6J/B6J), Gabra6-Cre;
PelocKO; n-Tr20B6J/B6J and Gabra6-Cre; Hbs1lcKO; n-Tr20B6J/B6J cerebella stained with
hematoxylin and eosin. Higher magnification images of lobule IX are shown below. Cerebellar
lobules are indicated by Roman numerals. (C) Number of cerebellar granule cells in lobule IX
shown in B. Data represent mean + SD. (D) Western blot analysis using cerebellar lysates from
P28 control (Hbs1lfl/fl; n-Tr20B6J/B6J or Pelofl/fl; n-Tr20B6J/B6J), Gabra6-Cre; PelocKO; n-Tr20B6J/B6J
and Gabra6-Cre; Hbs1lcKO; n-Tr20B6J/B6J mice. GAPDH was used an input control. (E)
Quantification of HBS1L and PELO protein levels shown in D and were normalized to levels of
vinculin. Protein levels are relative to those of controls (Hbs1lfl/fl or Pelofl/fl) from each cross.
Scale bars: 500μm (A); 500μm and 50μm (higher magnification) (B). One-way ANOVA (C) and
two-way ANOVA (E) were corrected for multiple comparisons using Tukey method. ns, not
significant; ** P ≤ 0.01; *** P ≤ 0.001.
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Figure S18: Hbs1l deficiency in embryos alters translation of pathways associated with
heart function. (A) Analysis of differentially translated genes (DE RPF Hbs1l-/-, adj. P ≤ 0.05)
of E8.5 Hbs1l-/- embryos (421 genes, grey). Genes that have ribosome pauses specific to Hbs1l-/embryos with significant (adj. P ≤ 0.05) changes in translation are shown in green (47 genes).
(B) Comparison of z-scores of Hbs1l-/--specific pause sites detected in E8.5 Hbs1l-/- embryos and
P14 Atoh1-Cre; Hbs1lcKO cerebella. Downward direction of arrow indicates significant lower zscores of these pauses in P14 Atoh1-Cre; Hbs1lcKO cerebella. (C) Comparison of differentially
translated genes (DE RPF Hbs1l-/-, adj. P ≤ 0.05) of E8.5 Hbs1l-/- embryos and P14 Atoh1-Cre;
Hbs1lcKO cerebella. Downward direction of arrow indicates significant lower fold changes in
translation in P14 Atoh1-Cre; Hbs1lcKO cerebella. (D) KEGG pathway analysis of differentially
translated genes (DE RPF Hbs1l-/-, adj. P ≤ 0.05) of E8.5 Hbs1l-/- embryos. Top five significantly
(P ≤ 0.05) enriched pathways are shown and the heatmap indicates relative changes in genes
associated with the respective pathway. (E) Ingenuity Pathway Analysis (IPA) of differentially
translated genes (DE RPF Hbs1l-/-) from E8.5 Hbs1l-/- embryos. Pathways that are involved in
heart, muscle contraction, cardiomyocyte and cytoskeleton function are in italics. The red dashed
line indicates the significance threshold (P = 0.05). Up- or downward direction of arrow
indicates predicated up- or downregulated activity of the pathway, respectively. RPF, ribosome
protected fragments. Wilcoxon rank-sum test was used to determine statistical significance (B,
C).
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Figure S19: Loss of Hbs1l and Pelo control protein levels of their respective binding
partner. (A) Quantitative RT-PCR analysis of Hbs1l and Pelo transcripts using cDNA from
MEFs of tamoxifen-treated control (Hbs1lfl/+ or Pelofl/+), Hbs1l-/- and Pelo-/- cells at Day 2
(Passage P1). Data were normalized to Gapdh and fold change in expression is relative to those
of control (Hbs1lfl/+ or Pelofl/+) cells. Data represent mean + SEM. (B) Western blot analysis of
HBS1L and PELO using MEF lysates of tamoxifen-treated control (Hbs1lfl/+ or Pelofl/fl), Hbs1l-/or Pelo-/- cells at Day 2 and 4 (Passage P1). Vinculin was used as an input control. (C)
Quantification of HBS1L and PELO protein levels shown in B and were normalized to levels of
vinculin. Protein levels are relative to those of control (Hbs1lfl/+ or Pelofl/fl) cells at Day 2
(Passage P1). Data represent mean + SD. (D) Location of pause sites. (E) Histogram of A count
on the 3’end of ribosome footprints that mapped after removal of the 3’end A’s. (F) Fraction of
3’end A ribosome footprints that mapped after removal of the 3’end A’s relative to the total
number of ribosome footprints from tamoxifen treated control (CAG-CreER) and Hbs1l-/-, or
control (CAG-CreER) and Pelo-/- cells. (G) Percent of unique pausing transcripts that are proteincoding or NMD transcripts. P1, Passage 1; MEFs, primary mouse embryonic fibroblasts; 4-OHT,
4-hyrdoxytamoxifin; PTC, premature termination codon; nd, not detected; A, adenosines; nts,
nucleotides; CDS, coding sequence; UTR, untranslated region; NMD, nonsense-mediated decay.
Two-way ANOVA was corrected for multiple comparisons using Tukey method (A, C); Fisher’s
exact test (D, G); Student’s t-test (F). ns, not significant; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤
0.0001.
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Figure S20: Pelo/Hbs1l deficiency alters translational gene expression of multiple
pathways. (A) Translational efficiency (TE) of Pelo-/-- and Hbs1l-/--pausing genes was compared
to the TE of the remaining (‘other’) genes from Pelo-/- (blue) and Hbs1l-/- (red) MEFs. Upward
direction of arrows indicates significant increase in translational efficiency of Pelo-/-- and Hbs1l-/-pausing genes. (B) Analysis of differentially translated genes in Pelo-/- (DE RPF Pelo-/-, adj. P ≤
0.05, left) and Hbs1l-/- (DE RPF Hbs1l-/-, adj. P ≤ 0.05, right) MEFs are shown in grey. Pelo-/-and Hbs1l-/--specific pausing genes (z-score ≥ 10, detected in all 3 biological replicates) that are
differentially translated are highlighted. Two-fold changes in expression are indicated by the
black dashed lines. (C) Differentially translated genes in Hbs1l-/- MEFs (DE RPF Hbs1l-/-, adj. P
≤ 0.05, x-axis, red) were plotted against genes that are differentially translated in Pelo-/- MEFs
(DE RPF Pelo-/-, adj. P ≤ 0.05, y-axis, blue). Genes those translation was significantly different
in both Hbs1l-/- and Pelo-/- MEFs are shown in purple. (D) Differential translation of genes in
Pelo (DE RPF Pelo-/-, adj. P ≤ 0.05) and Hbs1l (DE RPF Hbs1l-/-, adj. P ≤ 0.05) was compared to
that of Pelo-/-- and Hbs1l-/--specific pausing genes. Downward direction of arrows indicates
significantly reduced changes in RPFs from the pausing genes compared to non-pausing (‘other’)
genes. (E) KEGG pathway analysis of differentially translated (up- and downregulated) genes
(DE RPF Pelo-/-, adj. P ≤ 0.05) in Pelo-/- MEFs. Top nine of the significantly enriched pathways
are shown. The red dashed line indicates the significance threshold (P = 0.05). Pathways that are
positively (ribosome, ribosome biogenesis) and negatively (lysosome, autophagy) regulated by
mTORC1 are in italics. (F) Ingenuity pathway analysis (IPA) of differentially transcribed genes
in Pelo (DE mRNA Pelo-/-) and Hbs1l (DE mRNA Hbs1l-/-). EIF2 and mTOR/p70S6K signaling
are highlighted in yellow and magenta, respectively. The red dashed line indicates the
significance threshold (P = 0.05). RPF, ribosome protected fragments. Wilcoxon rank-sum test
was used to determine statistical significance (A, D); Pearson coefficient (r) was determined to
analyze linearity of gene expression changes (C).
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Figure S21: Loss of Upf2 leads to an increase of NMD targets. (A) Ensembl-annotated
transcript biotypes of differentially transcribed mRNAs in Upf2-/- (DE mRNA Upf2-/-, q-value ≤
0.05) and Pelo-/- (DE mRNA Pelo-/-, q-value ≤ 0.05) MEFs. (B) Transcriptional expression of
NMD transcripts with significant (q-value ≤ 0.05) changes in expression in Upf2-/- (DE mRNA
Upf2-/-) and Pelo-/- (DE mRNA Pelo-/-) was compared to expression of the remaining (‘other’)
transcripts. The effect size (beta) is analogous to the natural log fold change in expression. Upor downward direction of arrows indicates significant increase or decrease in expression of NMD
transcripts in Upf2-/- or Pelo-/- MEFs. (C) Ingenuity pathway analysis (IPA) of genes with
differential translational efficiency (TE) in Upf2-/- MEFs (TE Upf2-/-). EIF2 and mTOR signaling
are in italics. The red dashed line indicates the significance threshold (P = 0.05). (D) Comparison
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of z-scores (‘pause score’) of specific pauses observed in Pelo-/- (blue) and Upf2-/- (green) MEFs.
Downward direction of arrow indicates significantly lower pause scores specific to Upf2-/compared to Pelo-/- MEFs. (E) Transcriptional expression of either Pelo- or Hbs1l-specific
pausing transcripts (unique protein-coding pausing transcripts) was compared to the remaining
(‘other’) transcripts in Upf2-/- (DE mRNA Upf2-/-) MEFs. The effect size (beta) is analogous to
the natural log fold change in expression. Downward direction of arrows indicates a significant
decrease in expression of Pelo- or Hbs1l-specific pausing transcripts in Upf2-/- MEFs. NMD,
nonsense-mediated transcript; lncRNA, long noncoding RNA. Wilcoxon rank-sum test was used
to determine statistical significance (B, D, E).
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Figure S22: Upf2 and Pelo are required for the development of multiple cerebellar linages.
(A) Immunofluorescence using antibodies to BrdU (green) and Ki67 (red) on cerebellar sections
from E13.5 control (Upf2fl/fl), En1-Cre; Upf2cKO and En1-Cre; PelocKO embryos to determine the
fraction of cells in VZ that exited the cell cycle. Embryos were injected with BrdU 24 hours prior
to harvest. (B) Percentage of cerebellar VZ-progenitors that exited the cell cycle (BrdU+, Ki67cells). Data represent mean + SD. (C) Number of cerebellar Purkinje cell precursors (Lhx1/5+
cells). Data represent mean + SD. (D) Immunofluorescence using antibodies to Lhx1/5 on
cerebellar sections from E13.5 control (Upf2fl/fl), En1-Cre; Upf2cKO and En1-Cre; PelocKO
embryos. Sections were counterstained with DAPI and higher magnification images of boxed
areas are shown. (E) Immunofluorescence using antibodies to Pax2 (red) on cerebellar sections
from E13.5 control (Upf2fl/fl), En1-Cre; Upf2cKO and En1-Cre; PelocKO embryos. Sections were
counterstained with DAPI. Arrowheads denote occasional Pax2+ cells. (F) Number of cerebellar
VZ-derived interneuron precursors (Pax2+ cells). Data represent mean + SD. (G)
Immunofluorescence using antibodies to Tbr1 (red) on cerebellar sections from E13.5 control
(Upf2fl/fl), En1-Cre; Upf2cKO and En1-Cre; PelocKO embryos. Sections were counterstained with
DAPI. Arrowheads denote occasional Tbr1+ cells. (H) Number of cerebellar RL-derived Tbr1+
deep neurons. Data represent mean + SD. (I) Quantification of newborn granule cell precursors
(BrdU+ cells) in E13.5 control (Upf2fl/fl), En1-Cre; Upf2cKO and En1-Cre; PelocKO EGL. Data
represent mean + SD. Embryos were injected with BrdU 24 hours prior to harvest. (K)
Immunofluorescence using antibodies to cleaved caspase 3 (Casp3, red) on cerebellar sections
from E13.5 control (Upf2fl/fl), En1-Cre; Upf2cKO, En1-Cre; PelocKO and En1-Cre; Hbs1lcKO
embryos. Sections were counterstained with DAPI. Note: Because the number of apoptotic cells
was noticeably higher in En1-Cre; Upf2cKO and En1-Cre; PelocKO cerebella, arrowheads
(magenta) to indicate these cells were not included. (J) Number of Casp3+ cells. Data represent
mean + SD. (L) Immunofluorescence on sections of E13.5 control (Upf2fl/fl), En1-Cre; Upf2cKO
and En1-Cre; PelocKO cerebellum with antibodies to p-S6S240/244 (red) and PCNA (green). (M)
Relative fluorescence intensity (FI) of p-S6S240/244 of control (Upf2fl/fl), En1-Cre; Upf2cKO and
En1-Cre; PelocKO embryos. Levels of p-S6S240/244 are relative to those of control (Upf2fl/fl). Data
represent mean + SD. Scale bars: 100μm and 20μm (higher magnification) (A); 100μm and
50μm (higher magnification) (D); 50μm (E, G); 20μm (J); 25μm (L). VZ, ventricular zone; RL,
rhombic lip; NTZ; nuclear transitory zone; EGL, external granule cell layer. One-way ANOVA
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was corrected for multiple comparisons using Tukey method (B, C, F, H, I, K, M). ns, not
significant; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001.
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APPENDIX F: Chapter 4: Material and Methods
Ethical compliance: All mouse studies were performed under the guidance of the University of
California, San Diego and The Jackson Laboratory Animal Care and Use Committee in
accordance with institutional and regulatory guidelines.
Mice strains: Generation of Hbs1lGTC mice was performed by injection of targeted ES cells
(International Gene Trap Consortium, IGTC, cell line ID: XE494) into C57BL/6J (B6J)
blastocysts. B6N-Hbs1ltm1a (C57BL/6N-Atm1BrdHbs1ltm1a(KOMP)Wtsi, MMRRC:048037) mice were
produced at the Wellcome Trust Sanger Institute Mouse Genetics Project as part of the
International Mouse Phenotype Consortium (IMPC). In order to generate the conditional Hbs1l
knock out allele, heterozygous B6N-Hbs1ltm1a/+ mice were crossed to B6N.129S4Gt(ROSA)26Sortm1(FLP1)Dym/J (The Jackson Laboratory, #016226, MGI:5425632) to remove the
gene trap cassette and generate B6N-Hbs1lfl/+ mice. Generation of the constitutive B6N-Hbs1l+/knock out allele was accomplished by crossing homozygous B6N-Hbs1lfl/fl mice to B6N.CgEdil3Tg(Sox2-Cre)1Amc/J mice (The Jackson Laboratory, #014094, MGI:4943744). The B6NHbs1l+/- or B6N-Hbs1lfl/fl mice were backcrossed to congenic B6N.B6Jn-Tr20 mice (n = 2
backcross generations) to introduce the B6J-associated n-Tr20 mutation. The conditional knock
out Pelo allele was generated by placing the 5’loxP site 117bp upstream of exon 2 and the 3’loxP
site 302bp downstream of exon2. Targeted B6J ES cells were injected into B6J blastocysts to
generate heterozygous B6J-Pelofl/+. Generation of the ubiquitous B6J-Pelo+/- knock out allele
was accomplished by crossing homozygous B6J-Pelofl/fl mice to B6.FVB-Tg(EIIacre)C5379Lmgd/J mice (The Jackson Laboratory, #003724, MGI:2174520). The conditional
Upf2 knock out allele (Upf2fl/fl mice) was kindly provided from Drs. Bo Torben Porse and Miles
Wilkinson. Genotyping primers are listed below and for the conditional knock out alleles of
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Hbs1l and Pelo, genotyping primers were multiplexed to simultaneously detect the wild type,
flox (fl) and delta allele. Genotyping for the conditional knock out allele of Upf2, was performed
as previously described (Weischenfeldt et al., 2008).
Hbs1l common Forward: 5’AGTCCAGGTGTTTCCTCACG’3
Hbs1l wild type Reverse: 5’CCCTGGCCTATTTTTGGTTT’3
Hbs1l GTC Reverse: 5’TGTCCTCCAGTCTCCTCCAC’3

Hbs1l cKO Forward I: 5’CATGGCCTCCTATGGGTTGA’3
Hbs1l cKO Forward II: 5’GCCTACAGTGAGCACAGAGT’3
Hbs1l cKO Reverse: 5’TAGGTGCTGGGATTTGAACC’3

Pelo cKO Forward: 5’TGTAACTGAACCCTGCAGTATCT’3
Pelo cKO Reverse I: 5’GTGGAGCATGAAATGAAATTCGG’3
Pelo cKO Reverse II: 5’ATCCAAGGCTTTTACTTCGCC’3

For conditional knock out experiments, the following Cre-lines were used and the Cre allele was
maternally inherited to generate mutant mice (F2 generation): En1tm2(cre)Wrst/J (En1-Cre, The
Jackson Laboratory, #007916, MGI:3815003), B6.Cg-Tg(Atoh1-cre)1Bfri/J (Atoh1-Cre, The
Jackson Laboratory, #011104, MGI:4415810) and B6.Tg(Gabra6-cre)B1Lfr (Gabra6-Cre,
MGI:4358481, Fünfschilling and Reichardt, 2002). In order to avoid the introduction of the B6Jassociated n-Tr20 mutation in En1-Cre; Hbs1lcKO mice, En1tm2(cre)Wrst/J mice were backcrossed to
congenic B6J.B6Nn-Tr20 mice (Ishimura et al., 2016) to generate En1tm2(cre)Wrst/J mice that no
longer carry the B6J-assciated mutation in n-Tr20. Subsequently, B6J.B6Nn-Tr20; En1cre mice
were intercrossed with B6N-Hbs1l+/- to produce F1 mice, then these mice were crossed to B6NHbs1lfl/fl mice to generate En1-Cre; Hbs1lcKO; n-Tr20B6N/B6N without the B6J-associated tRNA
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mutation. To generate Atoh1-Cre; Hbs1lcKO mice lacking n-Tr20, B6.Cg-Tg(Atoh1-cre)1Bfri/J,
B6N-Hbs1l+/-, and B6N-Hbs1lfl/fl mice were crossed to B6J-nTr20-/- mice. Subsequently, these
strains were intercrossed to generate Atoh1-Cre; Hbs1l

cKO

; n-Tr20

-/-

mice. For BrdU

experiments, pregnant females or pups were injected with BrdU (0.05mg/g, Sigma-Aldrich,
B9285) and collected 30 minutes (S-phase analysis) or 24 hours (cell cycle exit analysis) post
injection. For the isolation of MEFs or embryos, the day that a vaginal plug was detected was
defined as embryonic day 0.5 (E0.5).
For conditional knock out experiments in primary mouse embryonic fibroblasts (MEFs), we
crossed mice to the tamoxifen inducible Cre-line B6.Cg-Tg(CAG-cre/Esr1*)5Amc/J (CAGCreER, The Jackson Laboratory, #004682, MGI:2680708). The Cre allele was paternally
inherited to generate embryos (F2 generation) because Cre-mediated recombination (“leaky Cre
expression”) was occasionally observed even in the absence of tamoxifen (4-OHT) treatment of
MEFs when the Cre allele was maternally inherited (F2 generation).
All experiments and quantifications were performed with at least three mice/embryos of each
genotype and time point using mice of either sex (embryos were not sexed). The Jackson
Laboratory Animal Care and Use Committee and The University of California San Diego
Animal Care and Use Committee approved all mouse protocols.

Strain abbreviation: For conditional knock out (cKO) experiments, animals were given a
simplified abbreviation throughout the article. The complete genotype is shown below.
Abbreviation

Genotype
cKO

En1-Cre, Hbs1l

En1cre/+; Hbs1lfl/-; n-Tr20B6J/B6J
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En1-Cre, PelocKO

En1cre/+; Pelofl/fl; n-Tr20B6J/B6J

En1-Cre, Upf2cKO

En1cre/+; Upf2fl/fl; n-Tr20B6J/B6J

Atoh1-Cre, Hbs1lcKO

Tg(Atoh1-cre); Hbs1lfl/-; n-Tr20B6J/B6J

Atoh1-Cre, PelocKO

Tg(Atoh1-cre); Pelofl/fl; n-Tr20B6J/B6J

Atoh1-Cre, Upf2cKO

Tg(Atoh1-cre); Upf2fl/fl; n-Tr20B6J/B6J

Gabra6-Cre, Hbs1lcKO

Tg(Gabra6-cre); Hbs1lfl/-; n-Tr20B6J/B6J

Gabra6-Cre, PelocKO

Tg(Gabra6-cre); Pelofl/-; n-Tr20B6J/B6J

CAG-CreER (control MEFs)

Tg(CAG-cre/Esr1); n-Tr20B6J/B6J

CAG-CreER, Hbs1lcKO (Hbs1l-/- MEFs)

Tg(CAG-cre/Esr1); Hbs1lfl/-; n-Tr20B6J/B6J

CAG-CreER, PelocKO (Pelo-/- MEFs)

Tg(CAG-cre/Esr1); Pelofl/fl; n-Tr20B6J/B6J

CAG-CreER, Upf2cKO (Upf2-/- MEFs)

Tg(CAG-cre/Esr1); Upf2fl/fl; n-Tr20B6J/B6J

Cell culture: Primary mouse embryonic fibroblasts (MEFs) were isolated on embryonic day
E13.0 and prepared by standard procedures (Nagy et al., 2014). MEFs were maintained in
Dulbecco’s modified Eagle’s medium (Gibco, #41965039) with GlutaMAX (Gibco, #35050061),
PSN (Gibco, # 15640055), and 10% embryonic stem cell fetal bovine serum (Gibco, #10439024)
at 37oC in 5% CO2. Two days post-isolation (Passage P0), the cell culture media was replaced
with fresh media and supplemented with 1μM 4-OHT (4-hydroxytamoxifen, Sigma, H7904) for
both control and mutant cells. After 48 hours, cells were washed, trypsinized, and seeded on a
10-cm dish (Passage P1). For RNA sequencing and ribosome footprint profiling experiments,
cells were collected 48 hours (Passage P1, Day 2) later when cells reached ~80% confluency. For
western blotting experiments, cells of Passage P1 were collected 48 hours (Day 2) and 96 hours
(Day 4) post-seeding.
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Histology and immunohistochemistry: Anesthetized mice were transcardially perfused with
4% paraformaldehyde (PFA, for immunofluorescence and histology), bouins (for histology) or
10% neutral buffered formalin (NBF, for in situ hybridization). Tissues were post-fixed
overnight and embedded in paraffin. For histological analysis, sections were deparaffinized,
rehydrated, and were stained with cresyl violet according to standard procedures. Histological
slides were imaged using a digital slide scanner (Hamamatsu).
All quantifications were performed with three mice or embryos of each genotype and time point
using animals of either sex (embryos were not sexed). For cell quantification in embryos at
E12.5 to E16.5 and pups at P5 (Olig2+ cells), cells were counted from the entire section and
values were averaged from three parasagittal (embryos) or sagittal (pups) sections (spaced 35μm
apart) per mouse. For the analysis of granule cell precursors or granule cells in P5 or P6 pups, the
total number of cells was determined within lobule IV/V or IX, and values were averaged from
three sagittal sections (spaced 50μm apart) per mouse. For the analysis of granule cells in adult
mice (35 weeks of age), granule cells were counted in a 0.025 mm2 area of lobule IX and values
were averaged from three midline sections per mouse spaced 100μm apart.
For immunofluorescence, antigen retrieval on deparaffinized PFA-fixed sections was performed
by microwaving sections in 0.01M sodium citrate buffer (pH 6.0, 0.05% Tween-20) for three
times with three minutes each or three times for three minutes, followed by two times for nine
minutes. PFA-fixed sections were incubated with the following primary antibodies overnight at
4ºC: rabbit anti-cleaved caspase 3 (Cell signaling, #9661, 1:100), mouse anti-BrdU (Dako,
M0744, 1:50), rabbit anti-Ki67 (Abcam, ab15580, 1:100), mouse anti-Lhx1/5 (DSHB, 4F2-c,
1:100), mouse anti-NeuN (Millipore, MAB377, 1:500), mouse anti-PCNA (Invitrogen, MA511358, 1:100), rabbit anti-p-S6240/244 (Cell Signaling, #5364, 1:1000), rabbit anti-Pax2
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(ThermoFisher, 71-6000, 1:50), rabbit anti-Olig2 (Abcam, ab109186, 1:200), rabbit anti-Tbr1
(Chemicon,

AB9616,

1:1000),

and

rabbit

anti-pH3

(Upstate,

06-570,

1:1000).

Immunofluorescence with antibodies to BrdU was performed on sections treated with DNase I
(5mU/µl, Worthington, LS002139) for 45 minutes at 37ºC after antigen retrieval. Detection of
primary antibodies was performed with goat anti-mouse Alexa Fluor-488 or -555, goat antirabbit Alexa Fluor-488 or -555, and donkey anti-rabbit Alexa Fluor-555 secondary antibodies
(Invitrogen). Sections were counterstained with DAPI and Sudan Black to quench
autofluorescence.
For immunofluorescence quantification, the fluorescence intensity was measured in an area of
60x125μm using ImageJ, averaged from three sections (spaced 35μm apart) per embryo and
expressed as the fold change relative to control.

RNAscope (in situ hybridization): In situ hybridization of Hbs1l-C2 probes (ACD, #527471C2) was performed with the ACD RNAscope Multiplex Fluorescent Reagent Kit v2 (ACD,
#323100) using the manufacturer’s protocol. Briefly, deparaffinized NBF-fixed sections were
treated for 15 minutes with Target Retrieval Reagent at 100˚C and subsequently, treated with
Protease Plus for 20 minutes (E13.5 embryos) or 30 minutes (P28 mice) at 40˚C. RNAScope
probes were hybridized for 2 hours, TSA® Plus Cyanine 3 (PerkinElmer, 1:1,500) was used as a
secondary fluorophore for Hbs1l-C2 probes.
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Reverse transcription and quantitative PCR (qPCR) analysis: Whole mouse embryos,
primary mouse embryonic fibroblasts, or adult mouse tissues were isolated and immediately
frozen in liquid nitrogen. Total RNA was extracted with Trizol reagent (Life Technologies).
cDNA synthesis was performed on DNase-treated (DNA-free DNA Removal Kit, Life
Technologies AM1906) total RNA using oligo(dT) primers and SuperScript III First-Strand
Synthesis System (Life Technologies). Quantitative RT-PCR reactions were performed using iQ
SYBR Green Supermix (Bio-Rad) and an CFX96 Real-Time PCR Detection System (Bio-Rad).
Expression levels of β-actin were used as input control for semi-quantitative RT-PCR. For
quantitative RT-PCR (qPCR) analysis, expression levels of the genes of interest were normalized
to Gapdh using the 2-ΔΔCT method (Livak and Schmittgen, 2001b) and expressed as the fold
change + standard error of the mean (SEM) relative to control.

Semi-quantitative RT-PCR Primers (F, Forward; R, Reverse):
Hbs1l Exon 3 F: 5’GAAATTGACCAAGCTCGCCTGTA3’; Hbs1l Exon 6 R: 5’CTCAGAAGTTAAGCCAGGCACT3’
β-actin F: 5’GGCTGTATTCCCCTCCATCG3’; β-actin R: 5’CCAGTTGGTAACAATGCCATGT3’

Quantitative RT-PCR Primers (F, Forward; R, Reverse):
Hbs1l F: 5’AGACCATGGGATTTGAAGTGC3’; Hbs1l R: 5’CCGGTCTCAGGAATGTTAGGA3’
Hbs1l II F: 5’TGAAGTTGAACAAAGTGCCAAG3’; Hbs1l II R: 5’CTGCTTCCTCTGTGTTCCTC3’
Pelo F: 5’CCCCAGGAAACGGAAAGGC3’; Pelo R: 5’ACGCACTTTACAACCTCGAAG3’
Gapdh F: 5’CATTGTCATACCAGGAAATG3’; Gapdh R: 5’GGAGAAACCTGCCAAGTATG3’
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Western blotting: MEFs or tissues were immediately frozen in liquid nitrogen. Proteins were
extracted by homogenizing frozen tissue or cell samples in 5 volumes of RIPA buffer with
cOmplete Mini, EDTA-free Protease inhibitor Cocktail (Roche), sonicating tissues two times for
10 seconds (Branson, 35% amplitude) or triturating cells 10 times using a 26G needle. Lysates
were incubated for 30 minutes at 4°C, centrifuged at 16’000xg for 25 minutes, and 25µg of
whole protein lysate were resolved on SDS-PAGE gels prior to transfer to PVDF membranes
(GE Healthcare Life Sciences, #10600023) using a tank blotting apparatus (BioRad).
For detection of phosphoproteins, frozen tissue samples were homogenized in 5 volumes of
homogenization buffer (50mM Hepes/KOH, pH 7.5, 140mM potassium acetate, 4mM
magnesium acetate, 2.5mM dithiothreitol, 0.32M sucrose, 1mM EDTA, 2mM EGTA)
(Carnevalli et al., 2004), supplemented with phosphatase and protease inhibitors (PhosStop and
cOmplete Mini, EDTA-free Protease inhibitor Cocktail, Roche). Frozen cell samples were
homogenized by using a 26G needle (5 times) in homogenization buffer (see above). Lysate
samples were immediately centrifuged at 12,000xg for 7 minutes and whole protein lysate were
resolved on SDS-PAGE gels prior to transfer to PVDF membranes.
After blocking in 5% nonfat dry milk (Cell Signaling, #9999S), blots were probed with primary
antibodies at 4°C overnight: rabbit anti-phospho-eIF2aS51 (Cell Signaling, #9721, 1:1000), rabbit
anti-eIF2a (Cell Signaling, #9722, 1:2000), rabbit anti-Hbs1l (Proteintech, 10359-1-AP, 1;1000),
rabbit anti-Pelo (Proteintech, 10582-1-AP, 1:2000), rabbit anti-GAPDH (Cell Signaling, #2118,
1:10,000), rabbit anti-phospho-p70S6KT389 (Cell Signaling, #9234, 1:1000), rabbit anti-phosphop70S6K (Cell Signaling, #2708, 1:1000), mouse anti-vinculin (Sigma, V-9131, 1:20,000).
Primary antibodies were detected by incubation with HRP-conjugated secondary antibodies for 2
hours at room temperature: goat anti-rabbit IgG (BioRad, #170-6515) or goat anti-mouse IgG
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(BioRad, #170-6516). Signals were detected with SuperSignal West Pico Chemiluminescent
substrate (ThermoScientific, #34080) or ProSignal Femto ECL Reagent (Genesee Scientific,
#20-302).

RNA sequencing library construction: For RNA sequencing of primary mouse embryonic
fibroblasts (MEFs), one 10-cm dish of tamoxifen (4-OHT) treated MEFs at Day 2 (Passage P1)
from CAG-CreER (control) CAG-CreER; Hbs1lcKO (Hbs1l-/-), CAG-CreER; PelocKO (Pelo-/-) and
CAG-CreER; Upf2cKO (Upf2-/-) were collected. One 10-cm dish from one individual embryo was
used as one biological replicate, and either two (Pelo) or three (control, Hbs1, Upf2) biological
replicates (individual embryos) were used per genotype. Two micrograms of DNase-treated
(DNA-free DNA Removal Kit, Life Technologies AM1906) total RNA were used for the RNA
library construction, performed as per the manufacturer’s protocol (KAPA Stranded mRNA-Seq
Kit, KR0960) and the adapter ligation was performed for 3 hours at room temperature. Library
quality and concentration was assessed using D1000 screen tape on the Agilent TapeStation and
Qubit 2.0 Fluorometer. All libraries were pooled, and the pool of libraries was sequenced on 2
lanes using HiSeq4000 (PE100).

Data analysis of RNA sequencing data: Reads were quantified using kallisto version 0.42.4
(Bray et al., 2016) and pseudo-aligned to a Gencode M24 transcriptome reference with
parameters –bias and -b 100. Differential expression was performed using sleuth version 0.30.0
(Pimentel et al., 2017). Pairwise comparisons were performed to identify differentially expressed
transcripts and genes: CAG-CreER vs. CAG-CreER; PelocKO, CAG-CreER vs. CAG-CreER;
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Hbs1lcKO, and CAG-CreER vs. CAG-CreER; Upf2cKO. We used functions within sleuth to perform
differential transcript and gene expression. Briefly, we fit null models and models corresponding
to the genotype of the samples for each transcript and performed Wald tests on the models for
each transcript to identify differentially expressed transcripts. Differential gene expression was
performed by aggregating transcript expression on Ensembl gene identifiers. Multiple
hypotheses testing was corrected using Benjamini-Hochberg correction, referred to as q-value.
Transcript biotypes were identified using biomaRt version 2.42.1 (Durinck et al., 2005). For
downstream TE analysis, mapping to mm10 using a Gencode M24 transcript annotation was
performed using hisat2 version 2.1.0 (Kim et al., 2019) using default parameters.

Ribosome profiling library construction: Ribosome profiling libraries were generated as
previously described (Ingolia et al., 2012; Ishimura et al., 2014) with some modifications.
Cerebella were dissected and immediately frozen in liquid nitrogen. One cerebellum from P14
mice was used for each biological replicate, and three biological replicates were prepared for
each control (Atoh1-Cre; Hbs1l+/+) and mutant (Atoh1-Cre; Hbs1lcKO) genotype. For profiling of
mouse embryos, embryos from timed mating were dissected at embryonic day E8.5, frozen in a
drop of nuclease free water on dry ice, and then flash frozen in liquid nitrogen. Five embryos
were pooled for each biological replicate, and three biological replicates were prepared for each
control (Hbs1l+/+) and mutant (Hbs1l-/-) genotype. For profiling of primary mouse embryonic
fibroblasts (MEFs), tamoxifen (4-OHT) treated MEFs at Day 2 (Passage P1) from CAG-CreER
(control), CAG-CreER; Hbs1lcKO (Hbs1l-/-), CAG-CreER; PelocKO (Pelo-/-) and CAG-CreER;
Upf2cKO (Upf2-/-) were collected. Two 10-cm dishes from one individual embryo were pooled as
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one biological replicate, and three biological replicates (three individual embryos) were used for
each genotype.
The tissue and embryo homogenization were performed with a mixer mill (Retsch MM400) in
lysis buffer (20mM Tris-Cl, pH 8.0, 150 mM NaCl, 5mM MgCl2, 1mM DTT, 100µg/ml CHX,
1% (v/v) TritonX-100, 25units/ml Turbo DNase I). The cell homogenization was performed by
triturating the cells in lysis buffer (20mM Tris-Cl, pH 8.0, 150 mM NaCl, 5mM MgCl2, 1mM
DTT, 100µg/ml CHX, 1% (v/v) TritonX-100, 25units/ml Turbo DNase I) ten times through a
26G needle. RNase I-treated lysates were overlaid on top of a sucrose cushion in 5ml Beckman
Ultraclear tubes and centrifuged in an SW55Ti rotor for 4 hours at 4ºC at 46,700 rpm. Pellets
were resuspended and RNA was extracted using the miRNeasy kit (Qiagen) according to
manufacturer’s instructions. 26-34 nts (cerebella samples) or 15-34 nts (embryo and MEF
samples) RNA fragments were purified by electrophoresis on a denaturing 15% gel. Linker
addition, cDNA generation (first-strand synthesis was performed at 50°C for 1 hour),
circularization, rRNA depletion, and amplification of cDNAs with indexing primers were
performed. Library quality and concentration was assessed using high sensitivity D1000 screen
tape on the Agilent TapeStation and Qubit 2.0 Fluorometer.
All libraries were pooled as set of six samples consisting of three control and mutant samples.
Libraries were run on HiSeq4000 (SR75) and either 3 lanes (cerebella samples) or 2 lanes
(embryo and MEF samples) per set of samples were sequenced.
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Data analysis of ribosome profiling data: Reads were clipped to remove adaptor sequences
(CTGTAGGCACCATCAAT) using fastx_clipper and trimmed so that reads start on the second
base using fastx_trimmer (http://hannonlab.cshl.edu/fastx_toolkit/). Reads containing ribosomal
RNAs, snoRNAs, and tRNAs were then filtered out by mapping to a ribosomal RNA reference
using bowtie2 version 2.2.3 using parameters -L 13 (Langmead and Salzberg, 2012). Remaining
reads were mapped to an mm10 mouse reference using a Gencode M24 annotation, or a Gencode
M24 protein-coding transcript reference using hisat2 version 2.1.0 (Kim et al., 2019). Ribosomal
A-sites were identified using RiboWaltz version 1.0.1 (Lauria et al., 2018), and reads with
lengths of 27-34 nucleotides were retained for further analysis.
To identify potential codon bias in the A-site, observed/expected reads were calculated for each
transcript with alignments with the expected reads being the read density expected at a given site
with a given codon, assuming that reads are uniformly distributed across the coding part of the
transcript. Differences in codon usage were then tested with a student’s t-test followed by
Benjamini-Hochberg multiple hypothesis testing correction.
Pauses were identified using previous methodology (Ishimura et al., 2014). Reads with lengths of
27-34 nucleotides were analyzed using a 0.5 reads/codon threshold in all samples to analyze
pausing on transcripts. Additionally, pauses with P-sites nearby start and stop codons (P-sites at
the -3, 0,1,2,3, and 4 positions for start codons and P-sites at the -1 and -2 positions for stop
codons) in any isoform of the gene were excluded from the analysis. To identify pauses
overlapping start and stop codons in other isoforms, we used ensembldb v.2.6.8 (Rainer et al.,
2019) to map transcript coordinates back to the genome and analyzed whether pauses with
identical genome coordinates overlapped start/stop codons.
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To extend this approach to identify pauses at the gene level, we removed start/stop overlapping
pauses (in any gene-matched transcript) and collapsed pauses based on the genomic location of
the A-site, which was also identified with ensembldb v.2.6.8. Mean pause score across
transcripts of genomically identical pauses for each sample was the reported pause score
(excluding transcripts without a reported pause in a sample). If genomically identical pauses
were in multiple transcript regions (i.e. 3’UTR or CDS depending on the isoform), all were
reported.
Pauses were further filtered such that the pause locus appeared in all three replicates of the
genotype and thereby, pauses that were only detected in one or two of three replicates of the
genotype were removed from the analysis. Pauses were compared between the 4-OHT treated
knock out (CAG-CreER; Hbs1lcKO, CAG-CreER; PelocKO and CAG-CreER; Upf2cKO) and the
control (CAG-CreER) sample that each mutant sample was pooled with for sequencing.
To identify ribosome footprint reads with 3’end As (untemplated reads), we extracted at first
reads from a genome mapped bam file with six or more As at the 3’end of the read (3’end As
were soft-clipped). Mapped reads were only considered if the 3’end A reads were not matching
the reference sequence, while all unmapped reads with six or more As at the 3’ end were
considered. Afterwards, the 3’end As were then removed from these untemplated reads and they
were mapped back to the transcriptome using parameters described above for ribosome footprint
profiling mapping to the transcriptome. Only the untemplated reads that mapped after the
removal of the 3’end As were considered as ribosome footprints that may derive from ribosomes
translating premature polyadenylated transcripts.
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For differential RPF and differential TE analysis, genome mapped reads were quantified using
featureCounts (Liao et al., 2014) with footprints overlapping CDS features. For TE analysis
specifically, RNA-seq read pairs overlapping gene exon features were also quantified using
featureCounts. Differential RPF analysis was performed using DESeq2 (v1.26.0) (Love et al.,
2014) comparing 4-OHT treated knock out (CAG-CreER; Hbs1lcKO, CAG-CreER; PelocKO and
CAG-CreER; Upf2cKO) to control (CAG-CreER) cells using default parameters. Histone mRNAs
were removed from the analysis by removing gene names with the prefixes “Hist”, “H1f”,
“H2a”, “H2b”, “H3” and “H4”. TE was quantified and tested for using riborex version 2.3.4
using the DESeq2 engine (Li et al., 2017).

Pathway analysis: Data were analyzed using Ingenuity Pathway Analysis (IPA, QIAGEN Inc.,
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis).
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed using the
ShinyGO v0.61 bioinformatics web server (http://bioinformatics.sdstate.edu/go) (Ge et al., 2020)
by uploading the gene lists from our RNA sequencing or ribosome profiling analysis. Pathway
enrichment terms with a P-value cutoff (FDR) ≤ 0.05 were considered enriched.

Statistics: For quantification of protein expression, RNA expression (quantitative RT-PCR),
fluorescence intensity or histological quantifications, P-values were computed in GraphPad
Prism using either student’s t-test, multiple t-tests, one-way ANOVA, or two-way ANOVA and
statistical tests were corrected for multiple comparisons as indicated in the figure legends. All

242

quantifications were performed with at least three mice/embryos of each genotype and time point
using mice of either sex (embryos were not sexed).

Data availability: The RNA sequencing and ribosome footprint data have been made available
(GSE162556).
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